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Abstract 
 
LMO2 is a nuclear LIM-only protein encoded by a gene located on chromosome 11p13 and 
was originally discovered through its activation due to specific chromosomal translocations 
in patients with T-cell acute lymphoblastic leukaemia (T-ALL). The specific chromosomal 
translocations occur with either the T-cell δ receptor gene (14q11) or T-cell β receptor gene 
(7q35) and result in aberrant LMO2 expression in T-cells. Transgenic mouse models of 
LMO2 induced T cell neoplasias showed that enforced LMO2 expression caused 
accumulation of immature thymic T cells, followed by clonal T cell tumours with long 
latency. LMO2 is therefore a specific therapeutic target as not only is it associated with 
chromosomal translocations but is also expressed in approximately 50% of T-ALL. The 
aims of this project were to structurally determine LMO2 for structure based drug 
development of small molecules that will target LMO2 protein-protein interactions.  
 
LMO2 could not be purified alone as removal of the fusion tag resulted in severe 
precipitation of the free LMO2. Consequently, LMO2 was co-expressed with an antibody 
single domain termed VH#576, and purified to a high yield and purity. A final construct of 
LMO2, spanning residues 9 to 147, bound to VH#576 has been crystallised and the structure 
solved, to a medium resolution of 3.3Å, using phase information from single anomalous 
dispersion (SAD) data in combination with molecular replacement. Using a mammalian 
two-hybrid mutagenesis screen, key VH#576 binding residues have been identified. This 
data can be used, in combination with the crystal structure of VH#576/LMO2ΔN7ΔC11, to 
produce a Pharmacophore model for in silico screening and lead drug discovery. In addition 
to the crystallography approach, NMR was also investigated as a means to collect structural 
data on VH#576, in solution. A protocol has been developed to isotopically label and purify 
VH#576 along with unlabeled LMO2, in order to increase the stability of the antibody 
single domain for NMR data acquisition. Solving the structure of VH#576 by NMR requires 
further data collection. Advantageously, NMR solution structures represent more 
physiological environment and comparison of a VH#576 NMR structure and the crystal 
structure would enable the detection of any crystallisation artifacts. 
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Arginine 
Asparagine 
Aspartic acid  
Cysteine 
Glutamic acid 
Glutamine 
Glycine 
Histidine 
Isoleucine 
Leucine 
Lysine 
Methionine 
Phenylalanine 
Proline 
Serine 
Threonine 
Tryptophan 
Tyrosine 
Valine 
 
Three letter code 
Ala 
Arg 
Asn 
Asp 
Cys 
Glu 
Gln 
Gly 
His 
Ile 
Leu 
Lys 
Met 
Phe 
Pro 
Ser 
Thr 
Trp 
Tyr 
Val 
 
One letter code 
A 
R 
N 
D 
C 
E 
Q 
G 
H 
I 
L 
K 
M 
F 
P 
S 
T 
W 
T 
V
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1.1 Human leukaemias 
Some human cancers are associated with chromosomal mutations, either through a change 
in the number of chromosomes through nondisjunction or through a change in chromosome 
structure. Chromosomal aberrations can be described as a variation from the wild type 
chromosome structure. There are four common types of chromosomal mutations: deletions, 
duplications, inversions and translocations (Russell, P.J., 2002). All four are initiated by 
breaks in the chromosome. Reciprocal chromosomal translocations are a hallmark of 
leukaemias and lymphomas and invariably convert proto-oncogenes to oncogenes. This can 
result in the transformation from a differentiating cell to a tumour cell with abnormal 
proliferation.  
 
Leukaemia generally arises from haematopoietic stem cells, which involve the peripheral 
blood and bone marrow. The leukaemias may be myeloid or lymphoid in origin and this can 
be determined by their cellular morphology (microscopy and cell surface markers), 
molecular cytogenetics (e.g. Fluorescent in situ hybridisation) and genomics (e.g. reverse 
transcription PCR). Leukaemia is further subdivided into acute or chronic forms (Harris et 
al., 1997). Chronic leukaemia is characterised by a variable level of terminal differentiation, 
as well as the presence of mature blood cells. In contrast, acute leukaemia is distinguished 
by low levels of differentiation, to mature haematopoietic cells, such as lymphocytes or 
neutrophils. Somatically acquired chromosomal translocations have been found in 65% of 
the acute leukaemias (Look, 1997). These structural chromosomal rearrangements effect 
gene expression and act to disrupt normal cell proliferation and differentiation pathways.  
1.1.1 Chromosomal translocations and transcription factors 
The most frequent targets of chromosomal translocations are genes that encode transcription 
factors emphasising the critical role of these ‘master’ regulatory proteins in the control of 
blood cell development (Rabbitts, 1991). As such, nuclear transcription factors are often 
involved in oncogenic signaling pathways, activating the gene expression patterns that lead 
to malignancy. These balanced chromosome translocations result in the formation of gene 
fusions, which may lead to neoplastic tumour transformation in one of two ways. 
Translocations may activate proto-oncogenes by being juxtaposed with a strong promoter or 
tumour specific fusion proteins may be created. Translocations that inappropriately activate 
transcription factor genes in acute lymphoblastic leukaemia (ALL) and acute myeloid 
leukaemia (AML) frequently result in a blockage of haematopoietic cells in defined stages 
of differentiation (Stegmaier et al., 1995). 
Introduction 
 
 3 
1.1.2 Factors associated with chromosomal translocations 
It has been suggested that DNA double strand breaks are required for chromosomal 
aberrations that result in gene fusions (Mitelman et al., 2007). The risk of developing a 
translocation has been linked to inducing agents such as DNA topoisomerase II poisons. 
DNA topoisomerase II, acts during replication and regulates DNA topology through 
transient DNA cleavage of both strands followed by strand passing and religation (Martin-
Cordero et al., 2003). Chemotherapeutic agents, which poison DNA topoisomerase II, are 
thought to act by aborting the DNA rejoining step and thus inducing apoptosis. However it 
has been found, in for example breast cancer patients, that treatment can predispose patients 
to secondary leukaemias with balanced chromosomal rearrangements (Mistry et al., 2005).  
This suggests a role, for DNA topoisomerase II mediated cleavage of DNA, in forming 
translocations. Radiation has also been implicated in DNA double strand breaks and hence 
chromosome translocations.  
 
Interphase (G1, S, G2) is a stage during the cell cycle in which DNA replicates. The 
chromosomes are not visible and the DNA appears as uncoiled chromatin. Chromosome 
structure during this stage may play a role in the formation of gene fusions (Russell, P.J., 
2002). An example of this is the BCR-ABL1 fusion gene, the product of a translocation, 
which occurs in chronic myelocytic leukaemia, and accounts for 92% of cases. The loci 
involved in the BCR-ABL1 fusion have been found to be close to each other in the 
corresponding normal cell (Neves et al., 1999). Another factor, which enables illegitimate 
recombination, is shared sequence motifs at the chromosome breakpoints (Aplan, 2006). 
However shared sequence motifs account for a minority of gene rearrangements hence, the 
mechanism of gene fusions at a DNA level is a subject of ongoing research.  
The point in time when translocations such as gene fusions occur, in different cell types, is 
also the focus of much research. In haematological malignancies there is evidence, from 
twin studies and PCR analysis, of specific gene fusions in Guthrie spots (sample of neonatal 
blood) (Greaves and Wiemels, 2003). This suggests the gene fusions are formed in utero, 
several years before overt leukaemia. This single genetic event is not sufficient for overt 
leukaemia and this is supported by a concordance rate, for leukaemia in twins, of 10%. 
Second genetic abnormalities may occur post-natally and this results in the onset of 
leukaemia (Riggi et al., 2005). 
1.1.3 Consistent features of leukaemic cells 
The leukaemic cells of any one patient all derive from a single mutant progenitor cell 
(Bonnet and Dick, 1997) whose transformation initiates clonal expansion and subsequent 
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overt, clinical leukaemia. The development of leukaemia is a stepwise process with an early 
initiating event such as a chromosome translocation and an increasing number of somatic 
mutations resulting in an increasingly transformed clonal population of cells. Leukaemic 
cells or blasts have an increased ability to survive conditions such as growth factor 
deprivation or stresses that would cause normal cells to undergo apoptosis. Thus, there are 
general mechanisms underlying leukaemic transformation including increased cell survival, 
increased proliferation capacity, increased self-renewal capacity, genomic instability and 
prevention of differentiation (Passegue et al., 2003).  
1.1.4 Acute myeloid leukaemias 
Myeloid cells are defined as any leukocyte that is not a lymphocyte. AML is characterised 
by a large number of abnormal cells that fail to differentiate into functional granulocytes or 
monocytes (Fialkow et al., 1987). The translocations associated with AML seem to 
aberrantly activate genes in primitive cells that have retained both multilineage and self-
renewal capacity (Bonnet and Dick, 1997). The most common target of associated 
translocation is the acute myeloid leukaemia 1 core binding factor β (AML1-CBFβ), a 
transcription factor which directly binds the enhancer core DNA sequence TGT/cGGT 
(Licht, 2001). AML1 has been found to fuse with ETO (eight-twenty-one); the fusion 
protein retains the ability to bind the enhancer core DNA sequence but not the 
transcriptional activation domain, and contains almost the entire length of ETO. The 
chimeric gene generated greatly enhances self-renewal of the haematopoietic stem cell 
population and blocks differentiation of committed progenitor cells (Okuda et al., 1998, 
Mulloy et al., 2002). Transformation of AML1-ETO may alter the transcriptional regulation 
of normal AML1 target genes.  
 
MLL (mixed lineage leukaemia) is another example of a protein that forms a fusion protein 
and has been found to cause AML. Translocations t(4;11) (q23;p13.3), t(9;11) (q23;p13.3), 
t(11;19)(q23;p13.3), fuse MLL with AF-4 (ALL-1 fused gene from chromosome four), AF-
9 (ALL-1 fused gene from chromosome nine) and ENL (eleven-nineteen-leukaemia) 
respectively (Rubnitz et al., 1999). These fusion partners are all serine/proline rich proteins 
with nuclear localisation signals. The C terminal of ENL has transcriptional regulation 
activity in vitro. MLL-ENL induces myeloid leukaemia when introduced into mice, 
however this was not seen with truncated MLL suggesting MLL-ENL mediates tumorigenic 
activity through a gain of function mechanism (Lavau et al., 1997). This mouse model also 
demonstrates the consistency of the association between these genetic aberrations and 
subtypes of leukaemia.  
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1.1.5 Acute lymphoid leukaemias 
Acute lymphoblastic leukaemia (ALL) is the most common malignant disease of childhood 
and one of the leading causes of childhood death from diseases in developed countries 
(Rubnitz and Crist, 1997). ALL can also affect adults and involves either the T or B-cell 
lineage. T and B-cell genes are constantly rearranging their T-cell receptor and 
immunoglobulin genes respectively and therefore are susceptible to translocations (Zhang 
and Rowley, 2006). These rearrangements are thought to arise from errors in the 
recombination process. Furthermore, such translocations can result in the activation of an 
oncogene in a new transcriptional environment (Klein, 2000). In contrast to AML, the 
initiating translocation often generates an oncoprotein, which transforms committed 
progenitors at a stage of differentiation, which matches the majority of cells in the 
leukaemic clone. The distribution, of translocation generated oncogenes, among the acute 
lymphoblastic leukaemias is shown in Figure 1.1. 
1.1.6 T-cell acute lymphoblastic leukaemia 
Despite an increase in the knowledge of molecular pathways relating to leukaemias, 60% of 
adult patients diagnosed do not survive beyond five years (based on Cancer Research UK 
statistics). This has led to a novel approach to improve the efficacy of therapeutics available 
to treat leukaemia by targeting specific proteins in the disease pathway. LMO2 is 
potentially, one such therapeutic target as it is ectopically expressed in a subset of patients 
with T-cell acute lymphoblastic leukaemia (T-ALL). The LMO2 gene is a consistent target 
of t(11;14)(p13;q11) translocations in T-ALL, as well as t(7;11)(q35;p13). LMO2 over 
expression can also be demonstrated in T-ALL where these translocations are lacking 
(Ferrando et al., 2002). The translocations detailed lead to the juxtaposition of LMO2 
downstream of TCR promoter genes; LMO2 is expressed as a normal protein product but 
with abnormal control of transcription (Larson et al., 1996). Initially the focus of the 
remainder of this chapter will be the normal role of LMO2, in haematopoiesis (Warren et 
al., 1994). This will be followed by an in depth evaluation of the involvement of LMO2 in 
the development of T-ALL. The mechanism of tumorigenesis, initiated by aberrant LMO2 
expression, is not clear however theories will be discussed. The current treatment available 
for patients with T-ALL and options for development will also be reviewed. 
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Figure 1.1: The distribution of translocation generated oncogenes among the acute 
lymphoblastic leukaemias 
In acute lymphoblastic leukaemia (ALL), the gene fusions tend to be specifically associated 
with a specific lymphocyte subset: T-cell, B-cell, pre B-cell and pro B-cell. The T-cell 
leukaemias, account for 7% of ALL. Figure taken from (Look, 1997). 
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1.2 LMO2 forms a DNA binding complex 
Lmo2 has been identified as an essential protein for erythropoiesis since null mutations of 
this gene result in a blockage in erythroid development (Warren et al., 1994). Mouse models 
with null mutations introduced into the genes Gata1, Gata2 and Tal1 (also known as SCL) 
were also found to prevent erythropoiesis, which implies a close functional relationship. 
Yeast two-hybrid experiments indicate a complex of Lmo2, TAL1, E47 and GATA1 forms 
in haematopoietic cells (Osada et al., 1995). It was shown TAL1 and E47 can bind the E-
box motif as a heterodimer and GATA proteins bind to the GATA site however there is no 
evidence to suggest Lmo2 can bind DNA. Murine erythroleukaemia (MEL) cells have been 
used to analyse the LMO2 protein complex using CASTing (cyclic amplification and 
selection of targets) experiments (Wadman et al., 1997); the cellular extracts were mixed 
with a random oligonucleotide pool and specific complexes immunoprecipitated with anti-
Lmo2 antiserum. After several rounds of binding and immunoprecipitation, the 
oligonucleotides were cloned and sequenced. This experiment identified bipartite DNA 
motif of an E-box followed, 9bp downstream, by a GATA site. In erythroid cells the 
complex has been characterised as E2A (E47/E12), Gata1, Ldb1, Lmo2 and Tal1 (Wadman 
et al., 1997). The LMO2 complex may vary throughout haematopoietic differentiation 
controlling various stage specific functions by regulating particular sets of genes.  
 
A recent proteomics study also using MEL cells expanded the number of proteins present in 
the complex (Ldb1/Lmo2/Tal1/E2A/Gata1) to include HEB, Lmo4, and Lyl1 (closely 
related to Tal1) and a number of single stranded DNA binding proteins (Ssbp-1-4) 
important for the stability of the Ldb1 protein. In the proerythroblast-proliferating state, this 
complex was found to interact with another complex consisting of 
Gata1/Tal1/E47/HEB/Mtgr1/Eto2. This complex was also found to interact with the cell 
cycle regulator cdk9 and E2-2, with the equilibrium favouring the interaction of all these 
proteins to form a large multiprotein complex (Meier et al., 2006). Upon induction of 
differentiation of MEL cells, the level of Eto-2 drops whereas the level of Lmo4 rises and 
this may favour dissociation of the two smaller complexes. The repressive role of Eto-2 may 
be a mechanism for the activation of late erythroid genes. These findings highlight the 
dynamics of the LMO2 protein complex and reflect a mechanism for transcriptional control 
according to the differentiation stages of the erythroid cell; this will be discussed further in 
the next section.  
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1.3 The role of LMO2 in development 
1.3.1 Control of LMO2 transcription 
LMO2 is part of a transcriptional network that controls blood and endothelial development, 
it is composed of six exons and transcribed from two promoters, a distal promoter upstream 
of exon one and a proximal promoter upstream of exon three (Royerpokora et al., 1995). 
Eight enhancer elements have been identified (Landry et al., 2009) in mice, which appear to 
control the full pattern of endogenous Lmo2 expression in embryos (midgestation). In silico 
comparative genomics and in vivo CHIP-chip studies were used to analyse the control of 
Lmo2 expression. The extended proximal promoter was found to direct Lmo2 expression in 
endothelial cells when bound by ETS transcription factors (SFPI1, FLI-1). Lmo2/Tal1 and 
Gata-factors bind upstream (distal enhancer) haematopoietic elements and when both the 
distal and proximal promoters are activated, Lmo2 is expressed in erythroid and fetal liver 
cells. Therefore, it is the combination of distal and proximal promoters, which confer the 
expression of Lmo2 in haematopoietic tissues.  
1.3.2 Role of LMO2 in haematopoiesis 
Gastrulation is the period, after the blastocyst stage (inner cell mass from which the embryo 
arises) of embryonic development, in which cell masses become organised into three 
distinct germ layers. The mesoderm is one of three primary germ cell layers along with the 
ectoderm and endoderm. The mesoderm gives rise to blood cells in a process known as 
haematopoiesis (Figure 1.2). Prenatally, haematopoiesis occurs in the yolk sac, then in the 
liver and eventually in the bone marrow. In mouse, the yolk sac is the initial site of blood 
development where large nucleated erythroblasts first arise between embryonic day seven 
and eight. This is defined as primitive haematopoiesis and is followed by definitive 
haematopoiesis at embryonic day seven (Landry et al., 2008). All blood cells are derived 
from haematopoietic stem cells that are thought to originate from the Aorta-gonad-
mesonephros region and then colonise in the fetal liver where definitive haematopoiesis is 
established. As will be discussed, LMO2 is essential for both definitive and primitive 
haematopoiesis (Yamada et al., 1998, Warren et al., 1994). 
 
Lmo2 null mutation in mice leads to failure of yolk sac haematopoiesis and embryonic 
lethality around E10.5 (Warren et al., 1994). In fact, the knock out of transcription factors 
Gata2/Gata1, Lmo2 and Tal1 each result in the absence of primitive haematopoiesis 
(Porcher et al., 1996, Shivdasani et al., 1995, Robb et al., 1995, Fujiwara et al., 2004, 
Warren et al., 1994).  
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The role of Lmo2 in adult mice was studied using chimeric mice made by injecting 
blastocysts with embryonic stem cells carrying the homozygous null mutations (Lmo2-/-) of 
Lmo2. Analysis of these adult mice showed that the Lmo2-/- ES cells made no contribution to 
any haematopoietic lineage, indicating a critical role for Lmo2 in definitive haematopoiesis. 
Furthermore, introduction of an Lmo2 expression vector rescues the Lmo2-/- embryonic stem 
cells and enables them to contribute to all haematopoietic lineages tested (Yamada et al., 
1998). The early phenotype of these knockouts is explained by the observation that Ldb1, 
Cdk9, E2A, Lmo2, Gata1 and Eto2 are expressed around E9.5 in the Aorta-gonad-
mesonephros region of the mouse embryo that gives rise to haematopoietic stem cells 
(Meier et al., 2006). Figure 1.2 shows the expression of LMO2 during haematopoietic stem 
cell development. 
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Figure 1.2: The haematopoietic tree 
This diagram represents the main lineage commitment steps in haematopoiesis. The 
haematopoietic stem cell (HSC) gives rise to the multi-lineage progenitors (MLP), which 
can differentiate, into the haematopoietic lineages. MLPs differentiate into lymphoid and 
myeloid lineages in the common lymphoid progenitor (CLP) and common myeloid 
progenitor (CMP). CLPs can give rise to T and B cells only while CMPs give rise to 
megakaryocyte-erythrocyte progenitors (MEP) and granulocyte-monocyte progenitors 
(GMP). It has also been suggested that the first lineage commitment separates myeloid and 
erythoid potential, in the CMP, from myeloid lymphoid potential in the common myeloid 
lymphoid progenitor (CMLP). CMLPs can then further differentiate into B cells, T cells, 
and GMPs (as shown by the dashed line). Transcription factors relevant for the development 
of specific haematopoietic lineages are indicated. LMO2 has also been found to be 
expressed in erythroid and megakaryocytic cells (Warren et al., 1994). Figure taken from 
(Ferreira et al., 2005). 
Introduction 
 
 11 
1.3.3 Role of LMO2 in haematopoietic and endothelial development 
Tal1 and Lmo2 have been shown to drive haematopoietic and endothelial development 
through conversion of progenitors from early mesoderm to haemangioblasts, the putative 
progenitors contributing to both haematopoietic stem cells and vascular endothelial cells. It 
has also been shown that Tal1 and Lmo2 can synergistically act, during primitive 
haematopoiesis, to differentiate non-axial mesoderm into haemangioblasts in Zebrafish 
embryos (Gering et al., 2003).  
 
Haematopoietic gene expression was analysed in Lmo2 null Zebrafish. Lmo2 morpholinos 
(25-mer antisense oligonucleotide with modified bases containing a morpholine ring, 
making them very stable) were used to knock down gene expression. The effects were loss 
of haematopoiesis and disruption of endothelial development leading to loss of the dorsal 
aorta. In addition, these phenotypes are the same as those found for Tal1 morphants 
(organism that has been genetically modified with a morpholino). This again suggests that 
Tal1 and Lmo2 work together in a multiprotein complex during mesoderm development and 
differentiation to haemangioblast. The only exception to this was a difference in the control 
of Runx1 in the absence of Tal1 or Lmo2. Runx1 is a heterodimeric transcription factor also 
involved in definitive haematopoiesis. The expression of Runx1 was found to differ slightly 
in the posterior lateral plate mesoderm. In the absence of Tal1, Runx1 began to recover at an 
earlier time point than in the absence of Lmo2 (Patterson et al., 2007). It may be that Lmo2 
interacts with unknown genes that rescue expression of Runx1 in the posterior lateral plate 
mesoderm in the absence of Tal1. The expression of glycoprotein draculin (anti-coagulant) 
and haematopoietically expressed homeobox protein Hhex were also analysed in Lmo2 
morphants and were found to be initially independent but after seven somites (mesodermal 
segments that form sequentially), increasingly dependent on Lmo2 expression.  
 
Haematopoiesis rescue studies using Tal1-/- ES cells demonstrated that the phenylalanine 
within the second helix of Tal1 is necessary for interaction with Lmo2 (Patterson et al., 
2007). Lmo2 interaction with Tal1 was shown to be required for erythroid (Gata1 and 
Pu.1), myeloid (Pu.1) and endothelial (Flt4) gene expression. Erythroid differentiation only 
occurs in the pronephric mesoderm when Lmo2 and Tal1 induce Gata1 expression. It was 
found that in the absence of Gata1, Tal1-Lmo2 induced haemangioblasts differentiate into 
endothelial cells (Gering et al., 2003). 
 
Further proteins have been found to interact with the erythroid DNA binding complex (Tal1, 
Gata1, Ldb1 bound to E-box-GATA DNA sequence motif) including single stranded DNA-
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binding proteins, Ssbp2 and Ssbp3. Specifically, Ssbp2 was found to augment the 
transcription of the Protein 4.2 (P4.2) in an Ldb1 dependent manner through interaction 
with the P4.2 proximal promoter (Xu et al., 2007). P4.2 is a major component of the 
erythrocyte cell membrane skeleton. Quantitative reverse transcription PCR experiments 
showed that over expression of Ssbp2, increased β-globin and P4.2 levels in murine 
erythroleukaemia (MEL) cells suggesting Ssbp2 has a role as a positive regulator in 
erythroid progenitors. Finally, Ssbp2 was found to inhibit the interaction of both Ldb1 and 
Lmo2 with E3 ubiquitin ligase, Rlim, and prevent Rlim-mediated Ldb1 ubiquitination and 
thus protect Lmo2 and Ldb1 from proteasomal degradation (Xu et al., 2007). Thus, single 
stranded DNA-binding proteins may play a role in regulating the abundance of LMO2. 
 
The LMO2 complex has been found on the promoter regions of several other essential 
haematopoietic specific genes, such as retinaldehyde dehydrogenase 2, erythroid Kruppel-
like factor, c-kit, α-globin and glycophorin A (GPA) (Wang et al., 2007). The ability of 
Lmo2 to mediate the expression of such a large number of genes is thought to be due to its 
ability to participate in multi-protein complexes. LMO2 is down regulated during the final 
stages of erythroid differentiation to release TAL1 and GATA1. Ectopic expression of 
LMO2 at this stage interferes with this release and inhibits erythropoiesis (Teranoa et al., 
2005).  
1.3.4 Role of LMO2 in the activation of GATA1 
GATA1 is a haematopoietic transcription factor known to be essential for normal 
erythropoiesis (Pevny et al., 1995). LMO2 has been shown to be involved in the activation 
but not the repression of GATA1 target genes. To explore this further, a recent study 
examined the composition of GATA1 associated protein complexes at sites where GATA1 
acts as an activator and at sites where it acts as a repressor using a erythroid cell line (Tripic 
et al., 2009). The TAL1, LMO2, LDB1, E2A complex was found at all sites where GATA1 
activates transcription. In contrast, GATA1 fails to recruit this complex at sites where 
GATA1 acts as a repressor. In the same study, an LMO2 shRNA (short hairpin RNA) was 
introduced in order to knock down LMO2 expression. The mRNA level of genes repressed 
or activated by GATA1 were measured using quantitative reverse transcription PCR (Tripic 
et al., 2009). This showed a decrease in the level of GATA1 activated genes (Hbb-b1 and 
Eraf), whereas the expression of genes usually repressed by GATA1 were unaffected (Kit, 
Gata2, Lyl1). This research indicates, the TAL1, LMO2, LDB1, E2A protein complex 
represents a tissue specific GATA1 co-activation complex but not repression. Alternatively 
the complex may be removed at repression sites by a proteosome mediated turnover of 
LMO2 or LDB1.  
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1.3.5 Role of LMO2 in vascular development 
Development of a vascular system is essential for embryos to grow after they reach a certain 
size to allow blood flow to the rapidly developing embryonic tissues. The vascular system is 
constructed from two distinct processes, vasculogenesis and angiogenesis. Vasculogenesis 
forms the primary capillary network from haemangioblasts (primitive precursors specified 
from mesoderm) while angiogenesis is the process by which mature vascular structures are 
formed by the remodeling of endothelial cells from the existing capillary network. Lmo2-
null ES cells were followed in mouse chimeras and were found to contribute to the capillary 
network normally until embryonic day nine (Yamada et al., 2000). Moreover, these ES cells 
do not contribute to endothelial cells of large vessel walls after day ten. These results 
suggest that Lmo2 is required for angiogenesis but not for capillary formation from the 
mesoderm (vasculogenesis). Hence, the Lmo2 transcription factor mediates specific phases 
of angiogenesis as well as haematopoiesis.  
 
1.4 LIM-only protein family 
LMO2 is one of four proteins in the LIM-only (LMO) family, a group of transcription 
factors that contain two tandem LIM domains. The LIM only protein family consists of 
LMO1, LMO2, LMO3 and LMO4 and all members have the ability to mediate specific 
protein-protein interactions (Foroni et al., 1992). These proteins act as adaptors to mediate 
the assembly of large protein complexes and have vital roles in both normal development 
and tumorigenesis (Table 1.1).  
 
In general, LMO proteins are located in the nucleus but lack a nuclear localisation sequence; 
it is thought that binding of LDB1 maintains these proteins in the nucleus (Kenny et al., 
1998). LMO proteins are made up of a type A LIM domain followed by a type B LIM 
domain. The domains are composed of two zinc binding LIM fingers (Figure 1.3) and are 
generally made up of four β strands followed by a short α helix. The only significant 
difference between type A and type B topologies is that type B contains a 310-helix, rather 
than a short α helix, after the final β hairpin (Dawid et al., 1998).  
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A: 
        10         20         30         40         50       
MSSAIERKSL DPSEEPVDEV LQIPPSLLTC GGCQQNIGDR YFLKAIDQYW  
 
        60         70         80         90        100   
HEDCLSCDLC GCRLGEVGRR LYYKLGRKLC RRDYLRLFGQ DGLCASCDKR 
 
       110        120        130        140        150 
IRAYEMTMRV KDKVYHLECF KCAACQKHFC VGDRYLLINS DIVCEQCIYE  
 
 
WTKINGMI 
 
B:   
 
Figure 1.3: LMO2 protein and sequence  
A: The amino acid sequence (in single letter code) of LMO2 with LIM1 and LIM2 
represented in blue and purple respectively. The 158 amino acid protein has a molecular 
weight of 18.36 KDa and isoelectric point of 6.79.  
B: LIM domains are composed of two zinc-binding LIM fingers. The residues that co-
ordinate with each zinc ion are highlighted in yellow (cysteine, histidine, aspartate) in the 
sequence (A). Figure adapted from (McCormack and Rabbitts, 2004). 
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LMO1 and LMO2 (formerly known as RBTN1 and RBTN2) were originally identified 
through their association with specific chromosomal translocations involved in T-ALL 
(Rabbitts et al., 1999), and have a sequence identity of 58.3%. Recently, LMO3 has been 
identified as a potential translocation partner of T-cell receptor β locus through the use of 
chromatin conformation capture on chip (4C) technology (Simonis et al., 2009). The 
translocation t(7;12)(q35;p12.3) was identified in cell lines and samples from patients with 
T-ALL. Furthermore, LMO3 has recently been implicated in neuroblastomas (Aoyama et 
al., 2005) and associates with HEN2, a basic helix-loop-helix protein. It has been proposed 
that LMO3 may differentially regulate the expression of downstream target genes involved 
in neuronal differentiation or tumour formation. LMO2 and LMO3 have a sequence identity 
of 59.5%.  
 
LMO4 was originally identified as a breast cancer auto antigen and is aberrantly expressed 
in 56% of breast tumours, of which 65% have an amplification of the ERBB2 gene 
(Visvader et al., 2001). LMO4 associates with BRCA1 and represses its transcriptional 
activity (Sum et al., 2002). Loss of LMO4 results in G2/M arrest (Montanez-Wiscovich et 
al., 2009). LMO2 and LMO4 have 46.6% sequence identity. The oncogenic properties of 
the LMO gene family are summarised in Table 1.1. 
 
Table 1.1: The LMO gene family encode oncogenic proteins 
Gene Chromosome Translocation Leukaemia Others 
LMO1 11p15 t(11;14)(p15;q11) T-ALL  
LMO2 11p13 t(11;14)(p13;q11)  
t(7;11)(q35;q11) 
T-ALL Diffuse large B-cell 
lymphoma 
Pancreatic 
Prostate 
LMO3 12p12.13 t(7;12)(q35;p12) 
 
T-ALL Neuroblastoma 
LMO4 1p22.3   Breast cancer 
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1.5 LMO2 expression in T-cells results in Leukaemia 
1.5.1 T-cell acute lymphoblastic leukaemia 
T-cell acute lymphoblastic leukaemia (T-ALL) is a neoplastic disorder of the lymphoblasts 
(immature lymphocyte cells) committed to the T-cell lineage (Graux et al., 2006). Acute 
lymphoblastic leukaemia is the most common malignancy diagnosed in children 
(approximately 2 to 5 years of age) and occurs slightly more frequently in boys than girls. 
T-ALL is associated with an enlarged thymus and early spread to the cerebrospinal fluid. 
“Paediatric T-ALL is an aggressive malignancy of thymocytes that accounts for about 15% 
of ALL cases and for which treatment outcome remains inferior compared to B-lineage 
acute leukaemias” (van Vlierberghe et al., 2008). This neoplastic disorder originates in the 
thymus, due to a block in T-cell development and results in a deficiency in the number of 
mature lymphocytes, which can fight infection. Leukaemic transformation of immature 
thymocytes, is the result of a number of genetic abnormalities that permit uncontrolled cell 
growth (Mansour et al., 2007).  
 
In many cases T-ALL is initialised by a disruption in the rearrangement of T-cell receptor 
(TCR) genes, which results in a chromosomal translocation, and thus activation of an 
oncogene such as HOX11, TAL1 or LMO2. LMO2 is found at the breakpoints of two 
translocation which in total account for 7% of T-ALL cases; t(11;14)(p13;q11) and 
t(7;11)(q35;p13) (Garcia et al., 1991). LMO2 is located on the short arm (p) of human 
chromosome 11 at band 13 (11p13). The chromosome 11p13 breakpoint has been found to 
be paired with either the TCRδ gene on chromosome 14 (band q11) or, the TCRβ gene on 
chromosome 7 (band q35). LMO2 has two transcriptional promoters and the majority of 
known LMO2 translocations occur upstream of one or both of the LMO2 promoters 
(Boehm et al., 1991). Enforced LMO2 expression results from these translocations and 
causes a block in T-cell development.  
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Figure 1.4: LMO2 gene translocations  
Chromosomal translocation between LMO2, chromosome 11, and either TCR δ/α on 
chromosome 14 and TCR β gene on chromosome 7.  
Adapted from (Nam and Rabbitts, 2006) 
 
 
 
Figure 1.5: A distinct LMO2 DNA binding protein complex found in leukaemic T cells 
A distinct complex of LMO2, TAL1, E47 and LDB1 was found in leukaemic T cells from 
Lmo2 transgenic mice. The complex found in normal erythroid cells (top) also contains 
GATA1. Adapted from (McCormack and Rabbitts, 2004). 
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1.5.2 LMO2 DNA binding complex 
The LMO2 complex present in the T-cells of Lmo2 transgenic mice and transgenic tumours 
was studied via electrophoretic mobility shift assay and antibody mediated super shifts 
(Grutz et al., 1998b) and was found to be distinct from the complex found in normal 
erythroid cells. The complex was found to bind two E-boxes with the most common spacer 
being 10bp long. In comparison with the erythroid-specific Lmo2 DNA binding complex, 
the complex was shown to recruit a second basic helix-loop-helix (bHLH) heterodimer in 
place of a GATA factor. The complex was limited to the immature double negative 
thymocyte subpopulation. A putative model (Figure 1.5) of the complex binding to a dual E 
box motif was produced in which LMO2 is represented as a bridging molecule, binding two 
bHLH heterodimers (TAL1, E47).  
1.5.3 LMO2 is not involved in normal T-cell development 
Functional LMO2 is not involved in normal T-cell development. An Lmo2 conditional 
knockout mouse model, was utilised to study the effect of Lmo2 knockout on lymphocyte 
development. In this model a mouse with Lmo2 flanked by loxP sites (Cre recombinase 
recognition sites) was crossed with a mouse expressing Cre recombinase, under the control 
of lymphoid specific promoter (Rag1, CD19 or Lck), thus leading to the lymphoid specific 
deletion of Lmo2. No effect on lymphoid development was observed suggesting LMO2 has 
no role in normal T-cell development (McCormack et al., 2003).  
1.5.4 Effect of LMO2 on T-cell development 
T-cells mature from common lymphocyte progenitors in the thymic cortex, their stage of 
development is classified according to the combination of clusters of differentiation (CD) 
markers expressed. The most immature thymic T-cells do not express CD4 or CD8 and are 
referred to as double negative (DN) cells. Upon differentiation the double negative 
population pass through four stages, from DN1 to DN4 and almost all follow the α:β 
pathway (Janeway et al., 2005). Phase one double negative (DN1) thymocytes express Kit 
and CD44 (Figure 1.6). Genes encoding both chains of the T-cell receptor are in the 
germline configuration however upon transient expression of CD25, expression of CD44 
and Kit are reduced and the T-cell receptor β chain locus undergoes the process of V(D)J 
rearrangement (McCormack and Rabbitts, 2004). Recombinase activating genes (RAG1 and 
RAG2) are switched on in order to rearrange the T-cell receptor genes. The β chain 
expressed is able to pair with pre T-cell receptor α chain to form the pre T-cell receptor 
which is expressed, along with CD3 molecules, on the cell surface (Janeway et al., 2005). 
This prevents further β chain rearrangements and expression of both CD4 and CD8 (double 
Introduction 
 
 19 
positive thymocytes) is followed by cell proliferation (Figure 1.6). Rearrangement of the α 
chain locus occurs once proliferation stops and cells become small double positive cells. 
Positive and negative selection occurs in the thymic cortex and medulla of the thymus, 
respectively. Double positive cells that can recognise self peptides, present on major 
histocompatibility complex molecules, can undergo positive selection and go on to mature 
and express high levels of T-cell receptor. These cells become either CD4 or CD8 single 
positive thymocytes (Janeway et al., 2005). 
 
The effect of Lmo2 expression in T-cells was analysed by the generation of a mouse model. 
Lmo2 transgenic mice express Lmo2 in thymocytes under the CD2 promoter (a lymphocyte 
specific promoter that is usually active at the common lymphoid progenitor stage). FACS 
(fluorescence activated cell sorting) analysis of thymocytes from CD2-Lmo2 transgenic 
mice, with enforced expression of Lmo2, show an increase in the CD4- CD8- double 
negative population at the DN3 stage of development (Larson et al., 1995, McCormack et 
al., 2003) preceding the appearance of clonal T-cell tumours. To allow such clonal selection, 
the cell of origin must have the property of self-renewal, which is normally reserved for 
stem cells (McCormack, M.P., et al., 2010). Lmo2 is normally down regulated at the DN3 
stage and it is this ectopic expression of Lmo2 that results in a block in T-cell development. 
Transgenic mice with enforced Lmo2 expression develop thymic tumours with leukaemic 
blasts at approximately 6 months (Larson et al., 1994). 
 
Tal1 ectopic expression in the thymus results in no tumour growth. However, Lmo2-Tal1 
double transgenic mice display an enhanced onset of T-cell leukaemia (Larson et al., 1996, 
McCormack et al., 2003), with tumour growth occurring at a faster rate of approximately 
three months. This may be due to an abolition of E2A protein function in T-cell 
development. The E2A gene encodes either E47 or E12, which form homodimers in order to 
regulate lymphoid development. Tal1 may form heterodimers with E2A, preventing the 
formation of E2A homodimers, which leads to a block in transcriptional activity. In support 
of this, development of T-ALL in Tal1 transgenic mice was enhanced when E2A was also 
knocked out (O'neil et al., 2004). Furthermore, E2a null mice develop leukaemia of a similar 
phenotype to CD2-Lmo2 transgenic mice (Bain et al., 1997). 
 
Lmo2 transgenic thymocytes have been found to have long term engraftment potential; this 
is restricted to double negative 3 thymocytes (CD44- CD25+). This suggests LMO2 may 
promote the self-renewal of pre-leukaemic thymocytes. Thymocyte self-renewal provides a 
mechanism for committed T-cells to generate secondary mutations in other genes for 
leukaemic transformation. This may occur by reactivation of a haematopoietic stem cell 
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(HSC) transcriptional program as microarray analysis showed up regulation of several HSC 
associated genes and down regulation of T-cell developmental genes (McCormack, M.P., et 
al., 2010).  
 
 
 
Figure 1.6: Effect of LMO2 on T-cell development 
Progenitors from the bone marrow migrate to the outer edge of the cortex, in the sub 
capsular region of the thymus. Activation of LMO2 by chromosomal translocation results in 
a block in T-cell development at the CD44- CD25+ stage (DN3) during a period where RAG 
recombinase is actively expressed. Secondary mutations in other genes result in the onset of 
T-cell leukaemia. When no block in development occurs and positive selection is 
successful, newly mature cells leave the thymus through the medulla. 
 
Introduction 
 
 21 
1.6 T-ALL and associated translocations 
The human immune system is made up of adaptive and innate responses. The adaptive 
immune system has evolved to provide a more extensive means of defense and is made up 
of mainly T and B lymphocytes. The system is highly adaptive due to somatic 
hypermutation and V(D)J recombination (Janeway et al., 2005). T cells develop in the 
thymus and have T cell receptors (TCRs), specially adapted to detect antigens from foreign 
proteins or pathogens that have entered into the host cell and function to activate a T cell 
response. TCRs consist of a disulphide heterodimer of highly variable α and β chains 
expressed at the cell membrane as a complex with CD3. An alternative receptor, expressed 
in a subset of T cells, is made up of γ and δ chains expressed with CD3. Both of these 
receptors are expressed with a disulphide-linked homodimer of ζ chains, which has an 
intracellular signaling function (Janeway et al., 2005). Gene loci encoding α and δ chains 
are located on chromosome 14q11, while those encoding the β and γ chain are located on 
7q35 and 7p15 respectively.  
 
Cytogenetic analysis of lymphoblasts (leukaemic blasts) has found translocations activating 
oncogenes in 25 to 50% of T-ALL cases. Translocations involving TCR loci are found in 
approximately 35% of T-ALL (Graux et al., 2006). V(D)J recombination is a process of 
genetic rearrangement that occurs during the development of all T-cells and results in the 
specificity of antigen receptors (TCR). During V(D)J recombination many other genes are 
in an open chromatin conformation and as such are susceptible to the action of 
recombination enzymes. Illegitimate recombination can result in a juxtaposition of a 
transcription factor gene and a strong promoter of the TCR genes. In the case of LMO2, the 
breakpoint occurs upstream of the natural LMO2 promoter, resulting in ectopic expression 
of LMO2. 
1.6.1 V(D)J recombination 
Variable chains (α, β, γ and δ) are encoded by several gene segments, which are assembled, 
in developing lymphocytes, by somatic DNA recombination. Recombination activating 
genes, RAG-1 and RAG-2, are part of a complex of enzymes that carry out somatic V(D)J 
recombination (Mcblane et al., 1995). This pair of genes are expressed in developing 
lymphocytes only while they are engaged in assembling their antigen receptors. The RAG 
protein complexes specifically recognise recombination signal sequences (Finger et al., 
1986). Recombination signal sequences are found adjacent to the coding sequences of V, D 
or J gene segments and consist of a heptamer-spacer-nonamer motif. The heptamer is a 
conserved block of seven nucleotides, the spacer is a non-conserved region of twelve or 
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twenty-three nucleotides followed by another conserved region of nine nucleotides, the 
nonamer. In general, a gene segment flanked by a recombination signal sequence with a 
twelve base pair spacer can only be joined to one flanked by a twenty-three base pair spacer 
recombination signal sequence (Janeway et al., 2005). 
 
Theoretically, translocations may occur due to the RAG proteins making a cut at one true 
recombination sequence which is at the V(D)J region, and another cryptic recombination 
sequence at the other chromosome involved, resulting in the aberrant rejoining of ends 
(Agarwal et al., 2006). Thus, the chromosomal loci containing such sequences might be 
more likely to participate in translocations. Sequences matching the V(D)J recombinase 
signal were found at the SIL-TAL1 translocation junction, reflecting an illegitimate 
recombinase activity in the TAL1 gene rearrangement in T-ALL. 
 
Chromosomal translocations involving LMO2 t(7;11)(q35;p13) lead to sequences from 
chromosome 11 becoming inadvertently joined to TCRβ (Garcia et al., 1991). An 
alternative translocation, t(11;14)(p13;q11) results in a breakpoint that pairs the LMO2 gene 
with TCRδ (Cheng et al., 1990). About 65% of these translocations are caused by 
illegitimate V(D)J recombination due to RAG mistargeting of many different LMO2 cryptic 
recombination signal sequences (sequences which resemble the TCR/Ig recombination 
signal sequences located next to the LMO2 breakpoint) (Dik et al., 2007). In other cases the 
breakage in TCR/Ig is induced by RAG while the break in the LMO2 locus is initiated by an 
unknown mechanism. Thymocytes from eight T-ALL patients were analysed for LMO2 
expression levels using real-time quantitative PCR. This experiment provides evidence to 
support the theory that LMO2 activation in most t(11;14)(p13;q11) translocations, is due to 
decoupling of the negative regulatory element and not, as currently thought, due to 
juxtaposition of LMO2 to the TCRδ enhancer. However, the TCRδ enhancer was also 
shown, in the same experiment, to have a potent role in high LMO2 expression but this was 
in a less common inversional recombination at Vδ3-Dδ2 signal joints (join between two 
recombination signal sequences) (Dik et al., 2007).  
1.6.2 Alternative genes involved in T-ALL 
Another gene involved in T-ALL translocations is the HOX11 gene located on chromosome 
10. It encodes a homeodomain protein that can bind DNA and activate transcription (Dear et 
al., 1993). Reciprocal translocations occur between HOX11 and either TCR δ or TCR β in 
31% of adult T-ALL cases.  
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Several DNA binding proteins, activated by translocations in T-ALL, have a bHLH domain 
i.e. TAL1. This motif has basic amino acids at the amino terminal region which mediate 
specific DNA recognition of the E box motif (Hsu et al., 1991). LYL1 (lymphoblastic 
leukaemia derived sequence 1) shares 90% sequence identity with TAL1 in the bHLH motif 
and have a largely overlapping pattern of expression (Giroux et al., 2007). Studies indicate 
that LYL1 may be involved in the development of a wide range of blood tumours (Meng et 
al., 2005). In a Lyl1 transgenic mouse model, driven by human elongation factor 1 α 
promoter, 30% of mice developed malignant lymphoma after 12 months and were 
associated with infiltration in multiple organs. Analysis of tumour cells showed they were 
mainly CD4 CD8 double positive or mature B cells (Zhong et al., 2007). 
 
NOTCH1 mutations have also been found to be involved in T-ALL translocations (Lee et 
al., 2005). NOTCH1 encodes a heterodimeric receptor that regulates normal T-cell 
development. The mechanism of T-ALL driven by aberrant NOTCH1 signaling is unclear. 
Proteolytic processing of NOTCH receptors 1-4, mediated by γ-secretase leads to the 
cytoplasmic release of the ICN1 intracellular domain which translocates to the nucleus and 
forms a ternary complex (Pui, 2009). This complex is then able to recruit basal transcription 
machinery and thus activate NOTCH dependent target genes. Therefore NOTCH may 
activate downstream oncogenes such as MYC or the PI3K-AKT signaling pathway, which 
results in the development of T-ALL. NOTCH1 activating mutations have been discovered 
in more than 50% of patients with T-ALL. Interestingly, a recent study revealed that 
NOTCH1 mutations were detected in most molecular subtypes of human T-ALL including 
samples where TAL1 and LMO2 were also activated (Zhu et al., 2006).  
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Table 1.2: Translocation involving TCR genes in T-All  
(adapted from (Graux et al., 2006) and (van Vlierberghe et al., 2008)) 
 
Translocation 
involving TCR genes 
Gene involved Function of fusion gene/expressed oncogene 
t(7;10)(q34;q24) 
t(10;14)(q24;q11) 
 
HOX11 Transcription factor 
t(5;14)(q34;q32) 
 
HOX11L2 Transcription factor 
inv(7)(p15q34), 
t(7;7) (p15;q34) 
HOXA cluster Transcription factor 
t(1;14)(p32;q11) 
t(1;7)(p32;q34) 
 
TAL1 Transcription factor 
t(7;9)(q34;q32) 
 
TAL2 Transcription factor 
t(7;19)(q34;p13) 
 
LYL1 Transcription factor 
t(14;21)(q11.2;q22) 
 
BHLHB1 Transcription factor 
t(11;14)(p15;q11) 
t(7;11)(q34;p15) 
 
LMO1 Protein-protein interaction 
t(11;14)(p13;q11) 
t(7;11)(q35;p13) 
LMO2 Protein-protein interaction 
t(1;7)(p34;q34) LCK Signal transduction 
t(7;9)(q34;q34.3) NOTCH1 Fate determination, differentiation 
t(7;12)(q34;p13) 
t(12;14)(p13;q11) 
CCND2 Cell cycle activator 
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1.6.3 Secondary mutations are required for the onset of T-ALL 
It is thought that the development of T-ALL requires two cytogenetic events such as a 
translocation and secondary mutation. The mechanism, which results in secondary 
mutations and onset of leukaemia, remains unclear. A possible explanation, which has 
already been discussed, is the mechanism of self-renewal to generate secondary mutations. 
Another possibility is that mutations are mediated by RAG V(D)J recombinase. This 
hypothesis has been tested by comparing tumorigenesis, in CD2-Lmo2 transgenic mice, in 
the presence or absence of the Rag1 gene. The proportion of mice, which developed T-ALL 
within 14 months, was the same for both groups. In addition, there was no significant 
difference between the tumour incidence curves for the two groups (Drynan et al., 2001). 
Therefore it can be postulated that Rag1 has no effect on the rate of T-cell tumour 
development and thus does not mediate secondary mutations.  
1.6.4 X-linked severe combined immunodeficiency gene therapy trial 
Boys with X-linked severe combined immunodeficiency (SCID) are deficient in the 
common γ chain of the interleukin-2 receptor, which causes failure of normal lymphocyte 
development. In a French gene trial CD34+ haematopoietic stem cells were transduced with 
a defective retroviral vector (moloney murine leukemia) that carried the human IL2RC gene 
and were then transplanted back into the patients. Five out of the twenty boys treated 
developed T-ALL, three to six years after treatment due to integration of the vector 
upstream of LMO2 (Figure 1.7). As integration was in proximity of the LMO2 promoter, 
aberrant transcription and expression of LMO2 resulted (Hacein-Bey-Abina et al., 2008). 
Gamma retroviral vectors preferentially integrate near the 5’ end of actively transcribed 
genes and as a consequence LMO2 is a good target for insertional mutagenesis due to its 
expression during the early stages of haematopoiesis. A high incidence region of vector 
integration has been located near exon one of the LMO2 locus (Yamada et al., 2009).  
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Figure 1.7: Retroviral insertion results in ectopic LMO2 expression 
Ex vivo autologous bone marrow derived CD34+ cells transduced with a long terminal 
repeat driven MFG vector resulted in the development of a functional adaptive immune 
system in sixteen out of twenty-one patients treated. However five of the boys developed 
leukaemia; four of these cases were due to viral insertion close to the distal promoter of 
LMO2. Insertions were found either just ahead of LMO2 exon one (patient P5) or between 
exons one and two (patient P4). In both circumstances the LMO2 protein product is 
identical before and after the genetic abnormality has occurred, and it is the enforced 
expression of LMO2 that influences T-cell development and the onset of leukaemia. 
Met = methionine protein translation-initiation codon,  
Stop = protein-translation stop codon.  
Figure adapted from (McCormack and Rabbitts, 2004). 
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Two children (patients P4 and P5) that received retrovirus-mediated IL2RC gene transfer, as 
part of the trial, developed clonal proliferation of T lymphocytes thirty to thirty-four months 
after gene therapy. The loci of retroviral insertion in patient P4 and P5 clones were 
characterised by linear amplification mediated PCR sequencing of the 5’ insertion-site 
fusion sequence and showed a 100% match to the 5’ LMO2 genomic DNA locus on 
chromosome 11 (Hacein-Bey-Abina et al., 2003). Clone P4 was mapped to the short arm of 
chromosome 11, close to the distal promoter of LMO2 in the reverse orientation. The 
integration site of P5 was mapped 3Kbp upstream of the first exon of LMO2, in the forward 
orientation. Single nucleotide polymorphism (SNP) analysis supported findings that 
retroviral cis-activation results in monoallelic LMO2 expression. The data suggests that viral 
long terminal repeat (LTR) has an enhancing effect on the activity of the LMO2 distal 
(haematopoietic) promoter (Hacein-Bey-Abina et al., 2003). However, the possibility of 
disruption of a negative regulator of LMO2 has not been excluded experimentally.   
 
A recent study cloned and sequenced the retroviral integrations from five murine 
leukaemias containing insertional mutations (Dave et al., 2009). All the Lmo2 insertions 
were located 5’ upstream of exons four to six. To identify genes that may act together with 
Lmo2 in tumorigenesis insertionally mutated genes were identified by ligation-mediated 
PCR. Microarray data from human leukaemias with up regulated LMO2 expression was 
analysed with respect to the insertional mutations identified in murine leukaemias. 
Transcriptional profiles of these T-ALLs showed high expression of TAL1 and LYL1 
oncogenes as well as GATA1 and GATA2. Down regulation of E2A activated genes and up 
regulation of E2A repressed genes were also found (Dave et al., 2009). This again suggests 
Lmo2 redirects E2A activity by binding through its partners Tal1 or Lyl1. Lmo2 clonal 
tumours show low expression of Notch1 target genes and higher expression of genes that are 
repressed by Notch1 reflecting the insertion in this gene. Despite the sample size of this 
study being very small, the findings are consistent with the theory that leukaemia requires 
many “hits” in addition to activation of LMO2. In the gene therapy trial, leukaemias 
developed three to six years after engraftment suggesting a similar course of events (Dave et 
al., 2009). LMO2 ectopic expression in T-cells results in an accumulation of cells with 
blocked differentiation which are susceptible to further mutations; secondary mutations 
result in leukaemia.  
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1.7 LMO2 expression in other forms of cancer  
1.7.1 Diffuse large B-cell lymphomas 
LMO2 is expressed in normal germinal centre B cells and a subset of germinal centre 
derived B cell lymphomas (Natkunam et al., 2007). The germinal cell provides an 
environment in which naïve B-cells can diversify their antigen receptors. Deregulation of 
this step contributes to germinal centre derived B cell lymphomas. It has been shown that 
the overall survival rate of patients with diffuse large B-cell lymphomas, the most common 
adult non-Hodgkin lymphoma, is longer if the patient has a gene expression profile similar 
to that of germinal centre derived B cell lymphomas (Alizadeh et al., 2000). As a result of 
these findings, a recent study (Natkunam et al., 2008) explored if LMO2 expression is 
similar. The study provided evidence that LMO2 has prognostic significance in germinal 
centre B-cell-like diffuse large B-cell lymphomas, when treated with anthracycline based 
regimens with or without rituximab. No chromosomal translocations or genetic aberrations 
are known to account for the over expression of LMO2 in this cancer. Gene expression 
studies have also shown LMO2 mRNA expression to be the strongest predictor for a 
superior outcome in diffuse large B-cell lymphoma patients (Lossos et al., 2004). It may be 
that, in germinal centre B-cells, LMO2 protein interacts with transcription factors, which 
exert a specific effect on the cell.  
1.7.2 Prostate cancer 
LMO2 expression has been studied in human prostate tissue samples, cell lines and 
xenografts. Prostate cancer is the most common malignancy in men in the USA and UK 
(Rizzo et al., 2005). Analysis of prostate cancer cells revealed LMO2 was predominantly 
localised in the cytoplasm but also found in the nucleus suggesting LMO2 expression is 
tissue-type-specific. LMO2 expression was also shown to be associated with the advanced, 
tumour stage, of prostate cancer as well as the development of distant metastasis (Ma et al., 
2007). LMO2 mRNA and protein were found in the more aggressive, androgen 
independent, cell lines and xenografts but not the androgen dependent. A possible 
mechanism, which promotes prostate invasion, maybe that LMO2 is able to repress E-
cadherin. E-cadherin down regulation decreases the strength of cellular adhesion within a 
tissue, resulting in an increase in cellular motility thus promoting invasion to the 
surrounding tissues (Shapiro et al., 1995). 
 
However, a second study (Gratzinger et al., 2009), using a monoclonal anti-LMO2 instead 
of the polyclonal (as for the previous study) antibody, showed no expression of LMO2 in 
the nucleus of prostate cancer cells and only weak cytoplasmic staining for a small number 
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of cases with uncertain significance. For that reason, the role of LMO2 in prostate cancer is 
unclear and requires further research. 
1.7.3 Pancreatic cancer 
The expression of LMO2 has been analysed in a large cohort of patients with pancreatic 
cancer (Nakata et al., 2009). mRNA levels were analysed in eleven different pancreatic cell 
lines and in cultures of normal pancreatic ductal epithelial cells. All eleven pancreatic 
cancer cell lines expressed LMO2 mRNA, the normal pancreatic ductal epithelial cells did 
not express LMO2 mRNA. In support of this, LMO2 mRNA levels of pancreatic cancer 
tissues were higher than in normal pancreatic tissue. Tissue samples from one-hundred and 
thirteen pancreatic cancer patients were analysed for LMO2 mRNA levels and survival 
curves constructed. Multivariate analysis (statistical analysis method) showed LMO2 
expression was associated with a better prognosis in pancreatic cancer.  
1.7.4 Role of LMO2 in tumour angiogenesis 
A blood supply is vital for tumour growth and metastasis and is created by remodeling 
existing blood vessel endothelium, a process known as angiogenesis. Lmo2 expression, has 
been found to be raised, in tumour endothelium such as mouse thymomas and human lung 
tumours. To investigate this, a mouse model was created to study the possible role of Lmo2 
in tumour angiogenesis (Yamada et al., 2002). Tetracarcinomas (a tumour or group of 
tumours composed of tissue foreign to the site of growth) were induced in nude mice, by 
injecting Lmo2-lacZ targeted embryonic stem cells. β–galactosidase staining revealed 84% 
of tumours had an intrinsic Lmo2+/- embryonic stem cell derived visible vascular system. 
This suggests, Lmo2 is an essential regulator of neo-vascularisation in tumours. 
 
1.8  T-ALL treatment 
The current strategy to treat patients with T-ALL is multi-agent chemotherapy using drugs 
of different classes and modes of action to maximise leukaemic toxicity while keeping 
resistance and side effects to a minimum (Bernard et al., 1998). Treatment for adults 
remains poor with only 30 to 40% of patients being long term survivors. Current treatments 
cure over 70% of children with acute lymphoblastic leukaemia, although many patients 
develop serious acute and late complications due to the side effects (van Vlierberghe et al., 
2008). Some drugs used to treat T-ALL are nonspecific, acting by either blocking protein 
synthesis through hydrolysis of an amino acid essential for leukaemic growth or by 
interfering with the mitotic spindle apparatus. Such drugs often produce adverse cytotoxic 
effects in various normal tissues (Pui and Jeha, 2007, Crazzolara and Bendall, 2009). Drug 
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resistance can also develop through various cellular mechanisms such as an increased ability 
of the cell to repair DNA or decreased permeability of the cell (Aroui et al., 2010). 
1.8.1 Alternative treatment for T-ALL 
The aim now and for the future, is to reduce the toxicity of T-ALL treatment by designing 
new drugs that specifically interfere with leukaemic pathways and overcome chemo-
resistance induced by common treatment regimes (Crazzolara and Bendall, 2009). 
According to microarray analysis, LMO2 is expressed in 45% of T-ALL, even in the 
absence of chromosomal aberrations (Ferrando et al., 2002). Therefore, LMO2 is a potential 
drug target to treat patients with T-ALL (Nam and Rabbitts, 2006). 
 
One possibility to target translocations, such as those that result in aberrant LMO2 
expression, is to design zinc finger proteins to recognise unique chromosomal sites. The 
idea is to create binding elements which bind a region of the LMO2 gene and block its 
transcription (Pabo et al., 2001). Zinc fingers have a ββα structure that fold around a central 
ion. Tandem sets of fingers can contact neighbouring sites along the major groove of the 
DNA with the helix fitting into the groove. Still, a delivery strategy would also have to be 
developed such as retroviral expression vectors.  
 
On an mRNA level, it may be possible to use short interfering double stranded RNA to 
down regulate LMO2 by mRNA degradation. Short interfering RNA is an intermediate in 
the RNA interference pathway (Hannon, 2002) and has been used extensively in genome 
research to target and inactivate certain genes in order to study their function. The double 
stranded regions that are formed through binding of siRNAs are targets for the RNA 
induced silencing complex, which destroys the mRNAs by activation of the enzyme slicer. 
Cationic liposomes have been developed that can be administered safely in vivo. An 
example of an application of this liposome technology is the delivery of anti-bcl2 siRNA 
which was shown to have a strong anti-tumour activity, when administered intravenously, in 
the mouse model of liver metastasis (Yano et al., 2004). One downside to siRNA as a 
therapy is that the effects are transient and there is the possibility of off-target translational 
repression. Delivery of the siRNA is also still in the developmental stages with other 
possibilities including a delivery plasmid (e.g. viral vector) or hydrodynamic injections 
(McCaffrey et al., 2002).  
 
On a protein level, an ideal way to inhibit activity is through the development of a small 
molecule, which specifically interacts with the target protein. This requires pockets on the 
surface of the protein and this may prove problematic, as the interface of protein-protein 
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interactions are often large and flat. Many successful small molecule therapeutics, designed 
to inhibit proteins, have targeted an enzyme. For example, the anti-kinase drug ST1571 
(Gleevec) which targets the ABL portion of the BCR-ABL fusion protein (Druker et al., 
2001). ST1571 causes arrest of growth or apoptosis of haematopoietic cells that express 
BCR-ABL but does not affect normal cells. The drug produced a cytogenetic response in 
54% of patients treated in a phase one clinical trial including seven patients with complete 
cytogenetic remission. Myelosuppression occurred in 25% of patients, which may have 
been due to c-kit inhibition or haematopoiesis may have been compromised in patients with 
leukaemia. The drug binds to the ATP binding site situated within a deep cleft of the fusion 
protein. ST1571 only binds when the activation loop of the kinase is closed, and the drug 
stabilises the protein in this inactive conformation thus contributing to the drugs specificity. 
Resistance to ST1571 is primarily mediated by mutations within the kinase domain of BCR-
ABL (Shah et al., 2004) and to a lesser extent due to the amplification of the BCR-ABL 
genomic locus. This has led to the development of further tyrosine kinase inhibitors. 
 
One major problem posed by LMO2 inhibition is the probable development of anaemia. 
Therefore, it would be desirable to develop a delivery mechanism to specifically target an 
anti-LMO2 small molecule to T-cells.  
1.8.2 Anti-LMO2 intracellular antibody domain as the basis for small molecule drug 
design 
In response to the problem of developing an anti-LMO2 small molecule inhibitor, anti-
LMO2 antibody single domains have been isolated in order to determine sites on LMO2 that 
have potential for small molecule drug design. A whole antibody is comprised of two heavy 
chains and two light chains held together by inter-chain disulphide bonds. Each chain has a 
variable and constant region: The variable regions form the antigen binding site and as such 
are highly variable between different antibodies, they display three external antigenic loops 
termed the complementarity determining regions (CDRs). Variable heavy (VH) and variable 
light (VL) antibody domains can be expressed without the constant region of the antibody; 
this yields the Fv fragment or single chain variable fragment (scFv) when linked together 
with a glycine linker. Initially scFv were thought to be the smallest unit capable of specific 
antigen binding however subsequent studies showed that VH domains can retain a large 
percentage of the initial binding affinity (Jaton et al., 1968). Furthermore, antibodies lacking 
VL domains have been found to exist naturally in Camelids (Camels, dromedaries, llamas 
etc.) (Hamerscasterman et al., 1993).  
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Anti-LMO2 scFv (ALR3) has been isolated and shown to reduce the block in T-cell 
development in CD2-Lmo2 transgenic mice (Nam et al., 2008). An anti-LMO2 peptide 
aptamer has also been identified which binds specifically to Lmo2 and prevents its function 
as a T-cell oncogenic protein in a mouse transplantation assay (Appert et al., 2009). 
Antibody fragments or peptide aptamers can be used as a guide to functionally relevant 
parts of a target protein. Furthermore, the macrodrugs have the capacity to validate LMO2 
as a potential drug target. The remainder of this section will discuss the isolation of an anti-
LMO2 antibody single domain, VH#576. 
 
Isolation of an anti-LMO2 VH antibody domain, termed VH#576, has been successful using 
the third generation intracellular antibody capture method (Tanaka and Rabbitts, 2010). 
Briefly; the antigen LMO2 (amino acids 26-158) was fused to a DNA binding domain 
(DBD) and a library of single domain antibody fragments fused to an activation domain 
(AD). The human, intracellular antibody domain (iDab) libraries screened were generated 
by randomising codons in the CDR three regions. Interaction between bait (DBD) and pray 
(AD) results in a hybrid transcription factor complex that can activate yeast reporter genes. 
Both LexA and GAL4 yeast two-hybrid systems were used; interaction results in the 
reporters activating histidine expression allowing growth in media lacking the amino acid or 
β-galactosidase expression detected using X-gal. Yeast carrying cDNA encoding the 
antibody fragment were isolated and the plasmid extracted from yeast for sub library 
construction. Sub libraries were constructed using assembly PCR with PCR primers 
designed to randomise the amino acids whose side chains are most exposed in CDR one and 
CDR two (in direct contact with the antigen based on single domain crystal structure PDB 
2UZI). The first round positives were used to randomise CDR two and, usually, the second 
round positives used to randomise CDR one however, in this case, CDR one affinity 
maturation was not required. True iDab binders were identified from those that could grow 
in the absence of histidine by extracting the yeast single domain expression plasmids and re-
testing them in Gal4 and LexA baits. The binding affinity of VH#576 for LMO2 was 
shown, by Surface plasmon resonance, to have an equilibrium dissociation constant (Kd) of 
94nM (Tanaka and Rabbitts, 2009).  
 
These antibody single domains can be termed macrodrugs as they have the potential as 
research tools to validate relevant protein interactomes of disease cells using mouse models. 
Macrodrugs also have potential as therapeutics however currently there are no successful 
delivery systems to deliver macrodrugs, such as VH#576, into the cell. An alternative 
strategy currently under development in the THR laboratory, is to solve the crystal structure 
of the macrodrug bound to the target protein. This not only identifies key regions of the 
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target protein to focus on but also provides the information required to screen small 
molecule compound libraries in silico (Goodford, 1985). Information from the crystal 
structure can be utilised for structure-based lead discovery. Drugs on the market which have 
originated from this structure-based design approach include those used to treat Human 
immunodeficiency virus (Agenerase) and were developed using the crystal structure of HIV 
protease (Goodford, 1985, Tie et al., 2004).  
 
1.9 Study aims 
The possibility of eventually specifically targeting the cell-specific LMO2 complex is a 
plausible therapeutic strategy but as yet, no specific drugs or other reagents are available for 
treatment. The aim of this project was to develop small molecules that will target LMO2 
protein-protein interactions. This work required structural information of LMO2 and of 
LMO2 bound to the macrodrug, VH#576.  
 
Previous structural work carried out on LMO2 (Matthews et al., 2001) resulted in an NMR 
solution structure (PDB 1J20) of the N terminal LIM domain (residues 26-87) bound, 
through a C-terminal flexible linker of eleven residues, to the LIM interaction domain (LID) 
of Ldb1 (residues 300-339). The crystal structure of LMO4, a protein that shares 46.6% 
sequence identity with LMO2, has been solved to a high resolution of 1.3Å (Deane et al., 
2004). The construct comprised of near full length LMO4 (residues 16-152 of the 166 
amino acids) linked to LID via a flexible linker (PDB 1RUT). Upon embarking on this 
project no other LMO2 structural information was available and as such the main purpose of 
this project was to crystallise LMO2 and collect X-ray diffraction data in order to solve the 
structure. Initially, attempts were made to purify LMO2 recombinant protein with and 
without the anti-LMO2 macrodrugs. However, as will be discussed, recombinant LMO2 
could not be purified alone except as a fusion protein because removal of the fusion tag 
resulted in precipitation of the free LMO2. 
 
Consequently, a bipartite approach was initiated to obtain structural information on VH#576 
for the development of a pharmacophore model. Both NMR and X-ray crystallography 
techniques were utilised in parallel. NMR analysis was carried out on VH#576 both as a 
free protein and in complex with LMO2. As will be discussed, further NMR data would 
enable the structure of VH#576 to be solved in solution. In this case, X-ray crystallography 
proved more successful resulting in the crystal structure of LMO2 (residues 9-147) bound to 
VH#576. Completion of a VH#576 NMR structure (in the complexed state) would provide a 
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comparison for this crystal structure, which would either verify the structure or identify any 
crystal contacts, which disturb the local structure. 
 
The second aim of this project was to identify a VH#576 hotspot region; amino acid 
residues which make a significant energetic contribution to the interaction with LMO2. This 
aim was fulfilled through the collection of VH#576 mutagenesis data. Vital binding residues 
and important interacting regions of both VH#576 and LMO2 were identified. This 
information may also be used to facilitate drug design as the target area has been 
significantly reduced. Furthermore, these results provide information required for a third 
structural approach; one of homology modeling followed by docking of the VH#576 and 
LMO2 models. This resulted in a structural prediction of how the two proteins might 
interact.  
 
This investigation has led to a crystal structure of LMO2 that provides an insight into the 
mechanism of interaction of LMO2 and reflects the intrinsic flexibility of the protein. The 
structure defines the topography of the VH#576 binding interface. Results of a recent 
erythroid differentiation assay (T. Tanaka, personal communication) has provided evidence 
that VH#576 can interfere with LMO2 within the cell, presumably by blocking its 
interaction with other proteins in the DNA binding complex. The VH#576/LMO2 structure 
appears to represent a conformation of LMO2, which is unable to interact with other 
proteins in the complex, e.g. LDB1. Therefore if a small molecule can be designed to lock 
LMO2 in this conformation its interacting ability will be blocked, preventing its 
downstream tumorigenicity.  
 
Work carried out within this PhD has contributed to a publication (Appendix D): 
Appert, A., Nam, C. H., Lobato, N., Priego, E., Miguel, R. N., Blundell, T., Drynan, L., 
Sewell, H., Tanaka, T. & Rabbitts, T. (2009) Targeting LMO2 with a Peptide Aptamer 
Establishes a Necessary Function in Overt T-Cell Neoplasia. Cancer Research, 69, 4784-
4790. 
 
The contribution of H. Sewell towards this paper is detailed as follows: 
Design and development of an effective strategy for the expression and purification of an 
anti-LMO2 peptide displayed on a thioredoxin scaffold (PA-207). H. Sewell purified the 
recombinant protein, which was then passed onto T. Tanaka for analysis by Surface 
plasmon resonance. 
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2 Methods and theory of structural techniques 
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2.1 DNA analysis 
2.1.1 Agarose gel electrophoresis 
In order to separate and determine the size of DNA, agarose gel electrophoresis was 
performed. 1 to 2 % w/v of electrophoresis grade agarose (Invitrogen, Paisley, UK) was 
dissolved in 100ml final volume of 1 X TBE (Tris/borate/EDTA) by heating the solution in 
the microwave for 2 minutes. 7 µg of ethidium bromide (10 mg/ml solution) was then added 
to the agarose. The solution was then poured into a gel casting tray with an appropriate well 
forming comb and left to set. The DNA was mixed with 6 X DNA loading dye and loaded 
into the wells along side a 1 Kb DNA marker (Invitrogen, Paisley, UK). The gels were run 
at 65 V for 1 hour and photographed using a UV transilluminator (Gel documentation 
system, Bio-Rad). 
2.1.2 Restriction endonuclease digestion 
Typically 1 µg of DNA was digested using 1 unit of the appropriate restriction enzyme 
(New England Biolabs, MA, USA) and buffer in a 20µl reaction. When specified, 0.2 mg/ml 
BSA was added. The digestion was incubated at the temperature recommended, usually 
37°C, for 1 hour. Preparative digests for ligation of DNA fragments contained 30 to 50 µg 
of DNA in a 50 µl reaction and incubated at the appropriate temperature for 3 to 4 hours. 
2.1.3 Quantification of DNA 
Accurate quantification of DNA was obtained by reading the absorbance of purified DNA at 
260nm using the nucleic acid module of the NanoDrop spectrophotometer (Thermo 
scientific, UK). The spectrophotometer was blanked using 2 µl of TE (10mM Tris-HCl pH 
8.0, 1mM EDTA) buffer or water as appropriate. 2 µl of DNA sample was then placed on 
the optical surface and the absorbance at 260 nm measured. A DNA concentration is given 
in ng/µl (as calculated by Beer-Lambert law). The 260/280 ratio of the sample absorbance 
was also noted as this should be 1.8 for “pure” DNA. 
 
2.2 Cloning methods  
2.2.1 Polymerase chain reaction 
The Peltier thermal cycler (Biorad, Hertfordshire, UK) and Platinum Pfx (Invitrogen, 
Paisley, UK), DNA polymerse (proof reading exonuclease activity for higher fidelity DNA 
amplification) were used for PCR amplifications. The following reaction mixture and 
thermo cycling conditions were used (Table 2.1 and Table 2.2). Oligonucleotides were 
ordered from Invitrogen and 100 µM stock solutions were prepared by adding the 
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appropriate volume of sterile water and stored at -20°C. Annealing temperatures were 
calculated by subtracting 5°C from the melting temperature (Tm) of the smallest primer. 
The stock solution was diluted 1 in 10 and the appropriate volume added to the PCR master 
mix.  
 
Table 2.1: PCR master mix for 4 X 50µl reactions 
Component Volume 
(µl) 
10 X Pfx buffer 20 
10mM dNTP 6 
50mM MgSO4 4 
Upstream primer 6 
Downstream primer 6 
Pfx polymerase 1.6 
Sterile water 152.4 
Template DNA or water for the negative control 
(both added after mix had been divided into aliquots) 
1 
 
The master mix was divided into 49 µl reactions (0.2 ml eppendorf tubes used) and either 
DNA template or water (for the negative control) added as appropriate. A DNA engine 
Tetrad 2 peltier thermal cycler (Biorad, Hertfordshire, UK) was programmed with the 
protocol shown in Table 2.2 below. 
 
Table 2.2: General PCR protocol  
Number of 
cycles 
Temperature (°C) Time (Seconds) 
1 95 300 
95 30 
58 (annealing temperature may 
vary) 
30 
35 
68 30 
68 600 1 
4 Forever 
 
The PCR reaction was purified using a QIAquick nucleotide removal kit (Qiagen, Crawley, 
UK), according to the manufacturer’s instructions, and digested with the appropriate 
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restriction enzymes. The PCR product was then loaded onto an agarose gel (up to 2 % w/v 
agarose Tris/Borate/EDTA gel) and the DNA visualised using ethidium bromide and a UV 
trans illuminator (long wave to prevent DNA damage). The appropriate band was extracted, 
using a clean scalpel, and the DNA purified using a QIAquick gel extraction kit (Qiagen, 
Crawley, UK) according to the manufacturer’s instructions. A negative control, with no 
template DNA, was also analysed, by gel electrophoresis, to check for contamination.  
2.2.2 Vector preparation and ligation reaction 
Plasmid DNA was digested, sequentially, with the appropriate enzymes using the QIAquick 
nucleotide removal kit (Qiagen, Crawley, UK) between digests. The final digest reaction 
was run on a 1 % w/v agarose Tris/Borate/EDTA gel (Sigma-Aldrich, Dorset, UK) and the 
appropriate band excised using a scalpel. The plasmid DNA was purified using QIAquick 
gel extraction kit (Qiagen, Crawley, UK). The DNA concentrations of plasmid and insert 
were quantified using a NanoDrop spectrophotometer. If required the DNA concentration of 
the cut vector was increased using a Concentrator 5301 (Eppendorf, UK). The standard 
ligation reaction (3:1 insert:vector molar ratio) used is detailed in Table 2.3. T4 DNA ligase 
and T4 DNA ligase buffer (250 mM Tris-HCl pH 7.6, 50 mM MgCl2, 5 mM ATP, 5 mM 
DTT and 25% PEG-8000) were obtained from Invitrogen. The ligation reactions was set up 
according to Table 2.3 and incubated overnight at 16˚C. 
 
Table 2.3: Ligation reaction 
Component Amount 
5 X ligase buffer 4µl 
Plasmid 200ng 
Insert Calculated from 3:1 molar 
ratio 
T4 DNA Ligase  1µl 
Sterile water Make up to total reaction 
volume of 20 µl  
 
2.2.3 Preparation of Electro-competent Cells 
5 ml of SOB was inoculated with a single DH5α colony and grown up overnight at 37˚C, 
255 rpm. The starter culture was diluted (2ml in 198ml SOB) and grown up until the OD at 
600 nm read 0.4 (6305 Spectrophotometer, Jenway). The culture was kept on ice for 30 
minutes and then centrifuged at 4000 X g for 15 minutes. The cells were resuspended in  
200 ml ice cold milli Q H2O and centrifuged using the same conditions. The cells were then 
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resuspended in 100 ml ice cold milli Q H2O. The cells were again centrifuged and 
resuspended in 10 ml ice cold milli Q H2O with 10 % glycerol (sterile). After a final 
centrifuge step, 1 ml ice cold milli Q H2O with 10 % glycerol was added to the cells. The 
resuspended cells were divided into aliquots (45 µl). Cells were used directly for 
electroporation and those not used were frozen by immersion in liquid nitrogen and stored at 
-80˚C. 
2.2.4 Electroporation 
5 µl of ligation reaction was added to 45 µl competent cells, transferred into an 
electroporation cuvette (0.2 mm electrode, Biorad) and kept on ice for 30 minutes. The same 
was done with the cut vector only (amount added to ligation reaction divided by 4) and 
uncut starting vector to act as negative and positive controls respectively. The cells were 
electroporated using a Biorad Gene Pulser on the following settings: 2.5 KV field strength, 
200 Ω resistance and 25 µF capacitance. The cells were removed from the cuvette and 
placed into an eppendorf by addition of 150 µl LB and incubated at 37˚C, 220 rpm for 1 
hour. The cells were plated onto LB (plus appropriate antibiotic) agar plates and incubated 
overnight. Vector DNA was purified from any resulting colonies by miniprep.  
2.2.5 Plasmid miniprep purification 
5 to 24 colonies were picked from the ligation plate (depending on the number of colonies 
present on the negative control plate) and grown up in 5 mls of LB (plus appropriate 
antibiotic) by overnight incubation at 37˚C, 255 rpm. The cells were harvested by 
centrifugation at 4000 X g for 15 minutes at 4˚C.  The plasmid was purified using Qiagen 
Miniprep plasmid purification kit, according to the manufacturer’s instructions, and eluted 
in 30 µl TE (10 mM Tris pH 8.0, 1 mM EDTA) buffer. A diagnostic restriction enzyme 
digest was performed using the enzyme sites used to ligate the insert. If positive, the digest 
should release a DNA fragment the size of the insert when analysed by 1 % w/v agarose 
Tris/Borate/EDTA gel. 2 of the positive clones were sent for sequencing (The sequencing 
service, The University of Dundee).  
2.2.6 DNA sequencing service 
DNA sequencing was performed by DNA Sequencing & Services (MRCPPU, College of 
Life Sciences, University of Dundee, Scotland) using Applied Biosystems Big-Dye 
chemistry (version 3.1) on an Applied Biosystems model 3730 automated capillary DNA 
sequencer. 
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2.2.7 Large scale plasmid purification 
A single colony of DH5α (transformed with the positive clone) was used to inoculate 1 ml 
2TY (plus appropriate antibiotic) and incubated for approximately 8 hours at 37˚C, 255 
rpm. The starter culture was diluted 100 µl in 50 ml of selective 2TY medium and incubated 
overnight at 37˚C, 255 rpm. The cells were harvested by centrifugation at 4000 X g for 15 
minutes at 4˚C. The plasmid was purified using Qiagen Hispeed plasmid Midi kit, according 
to the manufacturer’s instructions, and eluted in 500 µl TE buffer. 
2.2.8 Plasmid glycerol stock 
5ml of 2TY broth (and appropriate antibiotic) were inoculated with a single colony of 
DH5α transformed with the correct clone (as checked by DNA sequencing) and incubated 
overnight at 37˚C, 255 rpm. The culture was centrifuged for 5 minutes at 4000 X g. The 
cells were resuspended in 2 ml 50% glycerol (sterilised by autoclaving) and incubated on 
ice. The cells were divided into aliquots and snap frozen by immersing in liquid nitrogen. 
The tubes were stored at -80˚C. To obtain single colonies of bacteria containing the plasmid 
DNA of interest, a stab of the glycerol stock was streaked, using aseptic techniques, onto an 
agar plate containing the appropriate selection antibiotics. 
 
2.3 Protein purification screen at Oxford protein production 
facility  
2.3.1 Preparation of vectors for protein expression screen at Oxford protein 
production facility 
The appropriate primer extensions (see Appendix C) were used to enable In-Fusion cloning 
(Clontech, France) into the prepared pOPIN vectors to derive the desired His-tagged protein 
constructs. PCR reactions were performed using KOD Hi-Fi polymerase (Novagen, 
Nottingham, UK) with 30 pmol of each forward and reverse primers, and 1 µl of plasmid 
DNA (100ng/µl) per 50 µl reaction. PCR products were purified using AMPure magnetic 
beads (Beckman-Coulter, UK) according to the manufacturer's instructions and eluted with 
50µl of TE buffer. Approximately 5 µl of purified PCR product (10 to 200 ng in total) and 
100ng of the appropriately linearised pOPIN vector were mixed in the wells of an In-Fusion 
Dry-Down 96-well plate (Clontech, France) and incubated at 42°C for 30 min. All reactions 
were diluted 1:5 with TE buffer and 5 µl used to transform OmniMaxII T1-phage resistant 
cells (Invitrogen, Paisley, UK), in 96 tube format. Transformants were selected by plating 
on 24 well culture plates containing 1ml of LB agar per well, supplemented with the 
appropriate antibiotic, 0.02% w/v X-Gal and 1mM IPTG. Plates were incubated overnight at 
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37°C. For each ligation reaction 4 white colonies were used to inoculate separate aliquots of 
1.5 ml LB supplemented with the appropriate antibiotic in deep well, 96-well plates. The 
cultures were grown overnight (37°C, 200 rpm) before harvesting by centrifugation at 5000 
X g for 10 min at 4°C. Plasmids were prepared from the cell pellets using a QIAgen 
BioRobot 8000 and QIAgen Turboprep kits (Qiagen, Crawley, UK), according to the 
manufacturer's instructions. The resulting plasmids were screened by PCR with a standard 
T7 forward primer and the reverse primer used for the initial insert amplification. PCR 
products were analysed, for the correct size, by agarose gel electrophoresis. 
2.3.2 Protein expression screen at Oxford protein production facility 
Expression constructs were checked by PCR and transformed into Rosetta LysS E. coli in a 
96 tube format. 35 µg/ml Chloramphenicol was added to maintain the pRareLysS plasmid. 
Plates were incubated for 18 hours at 37ºC before individual colonies were used to 
inoculate, 500 µl GS96 broth (QBioGene, Cambridge, UK) supplemented with 0.05% v/v 
glycerol, 1% w/v glucose and 50 µg/ml carbenicillin in 96 well deep well plates. The plates 
were sealed with gas permeable adhesive seals and shaken at 225 rpm at 37ºC for 18 hours. 
Cells were grown up in auto induction media by inoculating, in 24-well deep-well plates, 
2.5 ml of overnight express instant TB media (Novagen, Nottingham, UK) supplemented 
with 50 µg/ml carbenicillin and with 50 µl of each overnight culture. The diluted cultures 
were grown at 37ºC with shaking at 225 rpm, for 3 hours before reducing the temperature to 
25ºC and shaking for a further 24 hours at 25ºC. A 1.5ml aliquot of culture from each well 
was then transferred to a 2ml 96 well deep well plate and harvested by centrifugation at 
6000 X g for 10 min at 4ºC. Cell pellets were frozen at -80ºC for at least 30 minutes prior to 
screening for soluble protein expression using a QIAgen BioRobot 8000 robotic platform 
and a standard Qiagen Ni-NTA magnetic bead protocol (as per manufacturer’s instructions). 
Soluble protein eluted from the Ni-NTA beads was analysed by SDS-PAGE (Invitrogen 
NuPAGE Novex 10% Bis-Tris Midi gels with MES buffer system) and visualised with 
SafeStain (Invitrogen, Paisley, UK).  
 
2.4 Protein purification methods  
2.4.1 Expression of GST-LMO2 
pGEX-His-Tev-LMO2 (Ampicillin resistance) was used to transform Rosetta pLysS 
(Chloramphenicol resistance), C41 or B834, by electroporation. A single E. coli colony 
from the appropriate expression host strain was used to inoculate 5 ml LB containing 
appropriate antibiotics and grown overnight at 37oC, 225 rpm. This culture was used as a 
starter culture to inoculate 1L LB medium containing appropriate antibiotics and allowed to 
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grow, under the same conditions, to OD600nm 0.6 before induction of recombinant protein 
expression by the addition of IPTG to a final concentration of 0.5mM at 16oC. The cells 
were harvested after 12 to 16 hours of cultivation at 16oC. Please note, for the expression of 
LMO2, ZnSO4 was added prior to induction at a final concentration of 0.1mM. Cells were 
collected by centrifugation (Beckman coulter Avanti J-26 XP with rotor JS 4) at 4000 X g 
for 20 minutes and resuspended in 30ml of lysis buffer (10mM Na2HPO4, 1.8mM KH2PO4, 
pH 7.3, 2.7mM KCl 140mM NaCl) containing EDTA-free protease inhibitor cocktail tablets 
(Roche Diagnostics, Mannheim, Germany) and 0.1mM ZnSO4. Cells were lysed using a cell 
disrupter (Constant cell disruption systems, UK) at 27Kpsi and the lysate centrifuged at 
50,000 X g for 50 minutes using a centrifuge (Beckman coulter Avanti J-26 XP), with rotor 
JA 25.50, to remove the cell debris.  
 
Glutathione-sepharose 4B resin was diluted to a 50% slurry and equilibrated in wash buffer. 
The cell lysate was incubated with 4ml of glutathione sepharose (per liter prep) for 2 hours 
at 4˚C. The slurry was transferred into a disposable chromatography column (Biorad, 
Hertfordshire, UK) and the unbound fraction collected for analysis. The column was washed 
with 50 ml of wash buffer (10 mM Na2HPO4, 1.8 mM KH2PO4 pH 7.3, 2.7 mM KCl, 140 
mM NaCl, 0.1 mM ZnSO4) and soluble GST-LMO2 eluted with 10 mM glutathione elution 
buffer (50 mM Tris-HCl, pH 8.0, 10 mM reduced glutathione, 0.1 mM ZnSO4).   
2.4.2 Expression of NusA-LMO2  
pET43a-NusA-LMO2 plasmid was used to transform E. coli C41. Bacterial cells were 
cultured in 1L of LB plus Ampicillin (100µg/ml) at 30˚C, to an OD600nm of 0.4 to 0.5. Again, 
ZnSO4 was added to a final concentration of 0.1 mM and protein expression induced with 
IPTG (final 0.5mM) at 16˚C for 14 hours. Cells were harvested, lysed and cell debris 
removed as in 2.4.1. In this case, the lysis buffer was made up of 50 mM Na2HPO4 pH 8, 
300 mM NaCl, 10 mM imidazole, 0.1 mM ZnSO4, 10 mM β-mercaptoethanol and EDTA-
free protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). 
 
Protein purification was via nickel-agarose chromatography (Novagen, Nottingham, UK) 
and a disposable column. The bound protein was washed with buffer (50 mM Na2HPO4 pH 
8, 300 mM NaCl, 20 mM imidazole, 0.1 mM ZnSO4, 10% glycerol, 10 mM β-
mercaptoethanol) and the NusA-LMO2 protein eluted with 50 mM Na2HPO4 pH 8, 300 mM 
NaCl, 250 mM imidazole, 0.1 mM ZnSO4, 10% glycerol, 10 mM β-mercaptoethanol. The 
eluted protein was dialysed overnight against 50 mM Na2HPO4 pH 7, 150 mM NaCl. 
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2.4.3 Expression of MBP-LMO2 
pOPIN_M-LMO2 plasmid was used to transform E. coli Rosetta pLysS (Chloramphenicol 
resistant). Bacterial cells were cultured in 1L of LB plus carbenicillin (50 µg/ml) and 
Chloramphenicol (34µg/ml), at 37˚C, to an OD600nm of 0.4 to 0.5. Prior to induction, ZnSO4 
was added at a final concentration of 0.1 mM. Protein expression was induced with IPTG 
(0.5 mM final concentration) at 16˚C for 14 hours. Cells were harvested, lysed and cell 
debris removed as in 2.4.1. MBP-LMO2 protein was extracted from the cell pellet by cell 
disruption (Constant cell disruption systems, UK) in 20 mM Tris-HCl, pH 8, 250 mM NaCl, 
0.1 mM ZnSO4, 10 mM β-mercaptoethanol and complete, EDTA free, protease inhibitor 
cocktail (Roche Diagnostics, Mannheim, Germany). Protein purification was via amylose 
resin (New England Biolabs, MA, USA) and a disposable column. The bound protein was 
washed with lysis buffer without protease inhibitor. MBP-LMO2 protein was eluted in 10 
mM Maltose, 20 mM Tris-HCl, pH 8, 250 mM NaCl, 0.1 mM ZnSO4, 10 mM β-
mercaptoethanol. The sample was concentrated using an Amicon Ultra-15 centrifugal filter 
device (Millipore, MA, USA). 
2.4.4 TEV protease purification 
pRET3a (Ampicillin resistance) plasmid was used to transform E. coli B834. Bacterial cells 
were cultured in 1L of LB plus Ampicillin (100 µg/ml) at 37˚C to an OD600nm of 0.5 and 
protein expression induced with IPTG (final 0.5 mM) at 22˚C for 4 to 6 hours. Tev protease 
was extracted from the cell pellet by cell disruption (Constant cell disruption systems, UK) 
in 50 mM Tris-HCl pH 8.0, 500 mM KCl, 1% Triton-X 100, 1 mM PMSF, 10 mM β-
mercaptoethanol. The cell lysate was spun down at 35,000 X g for 50 minutes. Protein 
purification was via nickel-agarose chromatography (Novagen, Nottingham, UK). The 
bound protein was washed with wash buffer: 50 mM Tris-HCl pH 8.0, 1 M KCl, 10% 
glycerol, 20 mM imidazole, 1 mM PMSF, 10 mM β-mercaptoethanol. Tev protease was 
eluted with 50 mM Tris-HCl, pH 8.0, 1 M KCl, 10% glycerol, 250 mM imidazole, 1 mM 
PMSF, 10 mM β-mercaptoethanol. The sample was dialysed against 50 mM Tris-HCl pH 8, 
150 mM NaCl, 20% glycerol, 1 mM DTT and concentrated using an Amicon Ultra-15 
centrifugal filter device (Millipore, MA, USA). Tev protease was divided into 500 µl 
aliquots before storage at -20˚C. 
2.4.5 Expression of VH#576-LMO2  
VH#576-LMO2 was expressed from pRK-His-Tev-VH#576-LMO2 however various N and 
C-terminal truncated versions of LMO2 were also expressed. To remove these residues the 
expression plasmid (pRK-His-Tev-VH#576-LMO2) was engineered. This was done using 
PCR mutagenesis and assembly PCR (see Appendix C for primer design). Primers were 
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designed to maintain the ribosome binding site in-between VH#576 and LMO2. This was 
followed by ligation of the fragment back into the expression vector using EcoRI and KpnI 
restriction enzyme sites.  
 
pRK-His-Tev-VH#576-LMO2 plasmid was used to transform E. coli C41. Bacterial cells 
were cultured in 1 L of LB plus Ampicillin (100µg/ml) at 37˚C, 225 rpm and allowed to 
grow until OD600nm 0.6 at which stage protein expression was induced by adding IPTG to a 
final concentration of 0.5 mM, at 16oC and cultivated for 14 hours. ZnSO4 was added prior 
to induction at a final concentration of 0.1 mM. VH#576-LMO2 protein was extracted from 
the cell pellet by cell disruption (Constant cell disruption system) in 20 mM Tris-HCl pH 8, 
250 mM NaCl, 20 mM imidazole, 1 µM ZnSO4, 10 mM β-mercaptoethanol and EDTA free, 
protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). Protein purification 
was via nickel-agarose chromatography (Novagen, Nottingham, UK). The bound protein 
was washed with lysis buffer without protease inhibitor. VH#576-LMO2 protein complex 
was eluted with 20 mM Tris-HCl, pH 8, 250 mM NaCl, 250 mM imidazole, 0.1 mM ZnSO4 
and 10 mM β-mercaptoethanol. Tev protease (see previous section for preparation) was 
added to the eluted protein at a ratio of 1:10 and dialysed (14.3 mm inflated tubing dialysis, 
Scientific laboratory services) overnight against elution buffer without imidazole. After 
passing the protein through a second Ni-NTA chromatography column (to remove the Tev 
protease), the sample was concentrated using an Amicon Ultra-15 centrifugal filter device, 
10 KDa cut-off (Millipore, MA, USA) for gel filtration chromatography. A Hi-Load 
superdex 75 column (GE Healthcare, Uppsala, Sweden) was equilibrated with 2 column 
volumes of 20 mM Tris-HCl pH 8, 150 mM NaCl, 1 mM DTT at a flow rate of 1 ml/min. 
The sample was loaded onto the column and eluted in 2 column volumes.  
2.4.6 Methylation of surface lysine residues 
VH#576-LMO2 protein was purified by Ni-NTA chromatography as described in the 
previous section, and then dialysed into 50 mM HEPES, pH 7.5, 250 mM NaCl during Tev 
protease digest and then diluted to a concentration of less than 1 mg/ml. After passing the 
protein through a second Ni-NTA chromatography column (to remove Tev protease), 20 µl 
1 M dimethyl-amine-borane complex and 40 µl 1M formaldehyde were added per ml of 
protein solution and incubated at 4°C, for 2 hours, with gentle shaking. A further 20 µl 1M 
dimethyl-amine-borane complex and 40 µl 1M formaldehyde were added, per ml of protein 
solution, and incubated at 4°C, again for 2 hours. Following a final addition of 10 µl 1M 
dimethyl-amine-borane complex, per ml of protein solution, the reaction was incubated 
overnight at 4°C. Size exclusion using 20 mM Tris-HCl, pH 7.5, 200 mM NaCl quenched 
the reaction and the purified protein sample was analysed, for modification of surface lysine 
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residues, by positive electrospray ionisation mass spectrometry. 
2.4.7 Gel Filtration Chromatography 
Gel filtration chromatography was carried out using superdex 200 10/300 GL column (GE 
Healthcare, Uppsala, Sweden) or Hi-Load superdex 75 column (GE Healthcare, Uppsala, 
Sweden) and an ÄKTA Xpress Instrument (GE Healthcare, Uppsala, Sweden). The column 
was equilibrated with 2 column volumes (CV) of distilled H2O at a flow rate of 0.3 ml/min 
(Superdex 200) or 1 ml/min (Superdex 75) followed by 2CV of equilibration buffer. The 
sample was prepared by concentration to a volume between 500 µl and 250 µl using a 10 
kDa Amicon filter (Millipore, MA, USA). All buffers were filtered using 0.2 µm filters 
(Whatman, UK) and the sample was centrifuged at 16,000 X g for 10 minutes prior to 
loading. The protein was loaded onto the column using a super loop and the 
chromatography run at 0.3 ml/min (Superdex 200) or 1 ml/min (Superdex 75). Protein was 
eluted from the column using 2 CV of equilibration buffer. The eluate was monitored, by 
measuring the UV absorption at 280nm (A280nm) and 0.5 ml or 1 ml fractions were 
collected using a fraction collector.  
2.4.8 Ion exchange chromatography 
Ion exchange chromatography was carried out using a Q sepharose column (GE Healthcare, 
Uppsala, Sweden) and ÄKTA Xpress Instrument (GE Healthcare, Uppsala, Sweden). All 
buffers and samples were filtered using 0.2 µm filters (Whatman, UK). For GST-LMO2 
purification, the column was equilibrated using 40 mM Tris-HCl, pH 8.5. A liner gradient of 
0 to 1 M NaCl over a volume of 400 ml was used to elute the protein from the column. The 
eluate was monitored, by measuring the UV absorption at 280nm.  
 
2.5 VH#576 purification and stability trials  
2.5.1 VH#576 expression vector preparation 
A VH#576 expression vector was prepared by removal of the LMO2 cDNA sequence from 
vector pRK-His-Tev-VH#576-LMO2 using restriction enzymes HindIII and EcoRI. The 
purified vector was re-ligated using a standard, T7 ligase, ligation reaction. Positive clones, 
identified by the release of no fragment upon Hind III and Eco RI double digest, were 
sequenced (DNA sequencing and services, Dundee). 
2.5.2 Purification of VH#576  
The expression vector pRK-His-Tev-VH#576 (Ampicillin resistance) was used to transform 
E. coli C41. Cell cultures were grown in labeled rich media (Silantes, München, Germany) 
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or labeled minimal media, at 37°C, 250 rpm, until the OD600nm measured 0.6. The 
temperature was then reduced to 20°C and after approximately 1 hour, IPTG was added to a 
final concentration of 0.5mM and the culture left overnight (12 to 16 hours). Cells were 
centrifuged at 4000 X g for 20 minutes (Beckman coulter, Avanti J-26 XP, rotor; JS 4.0) 
and resuspended in 30ml lysis buffer (20 mM Tris-HCl, pH 8, 250 mM NaCl, 20 mM 
Imidazole, 10 mM β-mercaptoethanol), per liter prep. EDTA-free protease inhibitor cocktail 
tablets (Roche Diagnostics, Mannheim, Germany) were also added to the lysis buffer (1 per 
50ml). The cells were lysed by cell disruption (Constant cell disruption systems, UK) at 
27Kpsi and centrifuged at 50,000 X g for 50 minutes to remove cell debris (Beckman 
coulter, Avanti J-26 XP, rotor; JA 25.50). The whole cell lysate was incubated, for 1 hour, 
with 2ml Ni-NTA agarose (Qiagen, Crawley, UK) per liter prep. The Ni-NTA resin was 
washed (lysis buffer without protease inhibitor cocktail) and eluted with elution buffer (20 
mM Tris-HCl, pH 8, 250 mM NaCl, 250 mM Imidazole, 10 mM β-mercaptoethanol).  
2.5.3 Removal of His tag from VH#576 
The His tag was removed from VH#576 by Tev digest (1:10 Tev protease:protein) during 
dialysis against 20 mM Tris-HCl, pH 8, 150 mM NaCl, 10 mM β-mercaptoethanol over 
night. This was followed by a size exclusion chromatography step using a superdex 200 
10/300 GL column. Chromatography was monitored, by measuring the UV absorption at 
280nm, and the protein fractions analysed by SDS-PAGE.  
2.5.4 VH#576 solubility trials 
VH#576 was prepared as described in the previous two sections and concentrated to 2 
mg/ml using Amicon 15 filtration columns, 10 KDa cut off (Millipore, MA, USA). A 24 
well plate was prepared with grease around each well and 1 ml of the appropriate solution 
pipetted into each well. 2 µl of protein was pipetted on a glass slide and 1 µl reservoir 
solution. The slide was inverted and sealed onto the relevant well. Plates were stored for one 
week at room temperature and observed under the microscope. A score of 0 to 4 was given 
to each well 
(0 = no precipitate 4 = heavy precipitate).  
2.5.5 Addition of CHAPS to VH#576 sample buffer 
3-[(Cholamidopropyl)-dimethylammoniol]-1-propanesulfonate (CHAPS) was obtained from 
Fisher scientific and added to the purified protein sample at a final concentration of 2 mM 
prior to concentration.  
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2.6 Purification of isotopically labeled VH#576 with unlabeled 
LMO2 
2.6.1 Purification of 15N labeled VH#576/LMO2ΔN7 protein complex  
C41 was transformed with bi-cistronic expression vector pRK-His-Tev-VH#576-
LMO2ΔN7 (Ampicillin resistance). Cell cultures were grown up using 15N labeled minimal 
media. Protein expression was induced and VH#576/LMO2ΔN7 was purified as described 
in section 2.4.5. 
2.6.2 Cloning of LMO2 expression vector 
The LMO2 expression vector was produced by removal of His-Tev-VH#576 from pRK-
His-Tev-VH#576-LMO2 using two XbaI restriction enzyme sites. The digest was run on a 
1% agarose gel and the linear vector extracted and purified using a kit (Qiagen, Crawley, 
UK). The cut vector was re-ligated in a standard T7 ligase reaction. Positive clones were 
identified by the release of no fragment upon XbaI digest and sequenced (DNA sequencing 
and services, Dundee). 
2.6.3 Cloning of NusA-Tev-LMO2 expression vector 
The NusA-Tev-LMO2 expression vector was produced by PCR amplification of Tev-
LMO2, from vector pGEX-His-Tev-LMO2, with inclusion of SpeI and AvrII restriction 
enzyme sites at either end (see Appendix C for primer sequences). The PCR product was 
cloned into SpeI-AvrII sites of pET43a. A SpeI, AvrII restriction enzyme double digest was 
used to identify positive clones and these clones were sequenced (DNA sequencing and 
services, Dundee). 
2.6.4 Co-lysis of LMO2 and VH#576  
C41 E. coli host was transformed with either pRK-LMO2ΔN7 or pET43a-Tev-LMO2 
(NusA-Tev-LMO2 expression vector). 500 mls of each were grown up in LB media at 
37°C, 255 rpm until the OD600nm measured 0.6. ZnSO4 was added to a final concentration of 
0.1 mM and the temperature was then reduced to 16°C. After 1 hour, expression was 
induced with 0.5 mM IPTG. Concurrently, C41 E. coli transformed with pRK-His-Tev-
VH#576 were grown up at 37°C, 255 rpm, until the OD600nm measured 0.6, at which point 
the temperature was reduced to 20°C and expression induced with 0.5 mM IPTG (final 
concentration). All cultures were left overnight (12 to 16 hours) and harvested by 
centrifugation at low speed (20 minutes, 4000 X g, 4°C).  
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The following cell pellets were resuspended together in lysis buffer (20 mM Tris-HCl, pH 8, 
250 mM NaCl, 20 mM Imidazole, 10 mM β-mercaptoethanol), with protease inhibitor 
cocktail (EDTA free, Roche): 
• pRK-LMO2ΔN7 and pRK-His-Tev-VH#576 
• pET43a-Tev-LMO2 and pRK-His-Tev-VH#576 
Cells were lysed and proteins co-purified via Ni-NTA affinity chromatography (see section 
2.4.5). The His tag was removed from VH#576 and the NusA tag from NusA-Tev-LMO2 
by Tev protease digest (1:10 protease:protein) during dialysis against imidazole free buffer. 
The dialysed samples were run through a disposable column with 2 ml Ni-NTA resin.  
2.6.5 Production of deuterated VH#576 
75% D2O minimal media was prepared by substituting 750 ml of H2O for 750 ml D2O 
(Silantes, Germany) per liter of media. C41 E. coli strain transformed with pRK-His-Tev-
VH#576 was adapted to growth on deuterated medium by repeat sub streaking of colonies, 
gradually increasing the deuterium content of the agar medium. LB agar (plus Ampicillin) 
plates were made with increasing percentages of D2O: 20%, 40%, 60%, 80%. A single 
colony was selected from the 80% D2O, LB agar plate and a starter culture grown up in 10 
mls 75% D2O minimal media (37°C, 255 rpm) overnight. The starter culture was used to 
inoculate 90mls 75% D2O minimal media and this culture was incubated (37°C, 255 rpm) 
until the OD600nm measured 0.7. The temperature was reduced to 20ºC and after 1 hour, 
IPTG added to a final concentration of 0.5mM. The culture was left over night (12 to 16 
hours) and spun down in a centrifuge at low speed (20 minutes, 4000 X g, 4°C). 100ml of 
pET43a-Tev-LMO2 culture was also grown up in LB, induced and spun down as described 
in 2.6.4. The two cell pellets were resuspended together, lysed and purified as previously 
described in 2.4.5. 
2.6.6 Increasing the yield of deuterated VH#576 protein 
Protocol one: C41 were grown up in LB until OD600nm of 0.7 and then the cell pellet re-
suspended in 4 times less 75% D2O minimal media (Marley et al., 2001). The cells were left 
to recover for 1 to 2 hours followed by induction of recombinant protein expression with 0.5 
mM IPTG at the appropriate temperature (in this case 20ºC). Protocol two: C41 were grown 
up in LB until OD600nm of 3 to 5, then the cell pellet was resuspended in the same volume of 
75% D2O minimal media (Sivashanmugam et al., 2009). Again, this was followed by a 1 to 
2 hour recovery period and induction initiated by the addition of 0.5 mM IPTG. Both 
cultures were left overnight and purified as previously described (section 2.4.5). 
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2.6.7 VH#576/LMO2 stability trials 
Aliquots of 50% deuterated VH#576 bound to LMO2 (expressed and purified according to 
protocol two of the previous section) were exchanged into the appropriate buffer (20 mM 
Tris-HCl, 1 mM DTT and either 50 mM, 100 mM or 150 mM NaCl) using Amicon 
concentration filter units (Y3) with molecular weight cut off 10 KDa and concentrated to 
10µl at 10mg/ml. Samples were left for one week at the appropriate temperature. After one 
week, all samples were centrifuged at 16 000 X g for 15 minutes and the protein transferred 
to new eppendorfs being careful not to disturb any precipitate. The concentration was 
measured using a Nanodrop spectrophotometer (samples denatured). Samples were also 
analysed by SDS-PAGE and visualised using Coomassie brilliant blue.  
2.6.8 Purification of 15N/13C/2H labeled VH#576 with LMO2 
For VH#576 expression, protocol two (section 2.6.7) was used to generate cell mass in 
unlabeled LB media and then transferred into the same volume of minimal media (75% 
D2O) labeled with 15N labeled NH4Cl (Silantes, Germany) and 13C labeled (Sigma-Aldrich, 
Dorset, UK) glucose. 4.5 liters of minimal media was used to express triple labeled 
VH#576. 4.5L of LB was used to express NusA-LMO2 and the proteins co-purified as 
previously described (section 2.4.5). 
2.6.9 Purification of 15N labeled VH#576 with LMO2 
VH#576 was expressed in 5 L minimal media with 15N labeled NH4Cl (Silantes, Germany). 
5 L of LB was used to express LMO2ΔN7ΔC11. The cell pellets of each culture were re-
suspended together, in lysis buffer, and then co-lysed by cell disruption (Constant cell 
disruption systems, UK) at 27 KPsi. The VH#576/LMO2ΔN7ΔC11 complex was purified as 
described in 2.4.5. 
 
2.7 Protein analysis  
2.7.1 Protein quantification 
Protein was denatured using 6 M guanidium HCl as this allows improved estimation of 
protein concentration from the sum of Trp, Tyr, and Phe components. A blank of 6 M 
guanidium HCl was used to calibrate the NanoDrop 8000 (Thermo Scientific). The protein 
sample was diluted (1 µl protein to 9 µl 6M guanidium HCl) and 2 µl loaded onto the 
optical surface of the NanoDrop. The “protein A280nm” analysis module was used to 
measure protein absorbance at 280nm. The sample type was set to “Other protein (E+MW)” 
and the protein’s molar extinction coefficient (M-1cm-1) and molecular weight (MW) in 
kilodaltons entered. The protein concentration is automatically calculated in mg/ml and this 
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was multiplied by 10 to get the final concentration of the protein sample. The A260/280 
ratio was also noted, as this should be approximately 0.57, anything above this indicates 
DNA contamination. 
2.7.2 SDS-PAGE  
0.75 mm glass plates were assembled and 5 ml of 10%, 12% or 15% resolving gel prepared 
and pipetted into the plates. Isopropanol was overlayed to promote polymerisation by 
preventing oxygen diffusing into the gel. After 30 minutes, the overlay was poured away 
and the gel top washed with milli Q H2O. The stacking gel solution was pipetted directly 
onto the resolving gel and a clean Teflon comb inserted. Samples for analysis were prepared 
by adding 15 µl to 5 µl of 4X loading buffer and were heated at 100˚C for 5 minutes along 
with 20 µl broad range, protein marker (Invitrogen, Paisley, UK). 1X sample buffer was 
prepared as a blank for any spare lanes. The gel was mounted in the electrophoresis 
equipment and 1X Tris-glycine buffer added to the top of the reservoirs. All protein markers 
and samples were loaded onto the gel and a voltage of 180V applied until the dye front 
reached the bottom of the gel. The glass plates were removed from the electrophoresis 
apparatus and carefully pulled apart. The gel was placed in Coomassie brilliant blue stain 
for 1 hour and then into destain for 30 minutes. 
2.7.3 Western blot Analysis 
SDS-PAGE was run as detailed previously. Polyvinylidene fluoride (PVDF) membrane was 
soaked in methanol for 5 minutes, followed by a further 5 minute incubation in ice cold 
transfer buffer. The gel was also incubated for 5 minutes in ice cold transfer buffer. The 
PVDF membrane was placed on the gel in the blotting cassette with 2 pieces of filter paper 
either side and one sponge either side. Electrophoresis was used to drive the negatively 
charged protein bands onto the positively charged membrane using 300 mA for 1 hour. The 
membrane was then rinsed with TBST and placed in blocking buffer for 1 hour. Antibodies 
were diluted in blocking buffer as follows: 
• Anti-LMO2 – 1:3000 (Obtained from T. Rabbitts. Polyclonal) 
• Anti-HIS – 1:3000 (Sigma. Monoclonal, anti-polyhistidine peroxide conjugated 
therefore secondary antibody was not required.) 
• Anti-GST – 1:2000 (Cell signaling technology) 
After rinsing with TBST, 10ml of the appropriate diluted antibody was added to the 
membrane and incubated overnight, at 4˚C, with gentle shaking. The membrane was then 
incubated with Tris buffered saline with tween 20 (TBST); 4 fast washes, followed by 4 
washes of 15 minutes each. The appropriate secondary antibody (for both anti-LMO2 and 
anti-GST primary antibodies this was anti-rabbit horseradish peroxidase conjugated 
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antibody, derived from Sigma) was diluted 1:10,000 in blocking buffer and incubated with 
the membrane for 1 hour at room temperature. The membrane was then washed with TBST 
(4 fast washes, followed by 4 washes of 15 minutes each). The Western blot was analysed 
using ECL kit (Thermo fisher scientific, Loughborough, UK). Standard X-ray film was 
exposed to the membrane at ambient temperature behind a Hi Speed intensifying screen for 
an appropriate length of time, depending on the strength of the signal. Films were developed 
in a SRX 101A developer (Photon Imaging, Swindon, UK). 
2.7.4 Circular Dichroism 
The protein samples were prepared at a concentration of approximately 0.22 mg/ml in 25 
mM NaH2PO4, pH 8. 350 µl of protein was pipetted into the cell (1mm path length). CD 
spectra were recorded on a Jasco J-715 spectropolarimeter equipped with peltier 
temperature control. CD data were collected over a wavelength range of 190 to 260 nm and 
with a step resolution of 1 nm, and a response time of 8 seconds (see Table 2.4). Final 
spectra were the sum of three scans accumulated at a speed of 50 nm/min.  
 
Table 2.4: CD parameters  
Wavelength Scan 
Start 260 
End 190 
Step res 1nm 
Speed 50nm/min 
Scans accumulated 1 
Response 8 seconds 
Sensitivity 50mdeg 
 
2.7.5 Analytical centrifugation 
2 sector cells were used for this experiment. MBP-LMO2 was analysed in 20 mM Tris-HCl, 
250 mM NaCl, 0.1 mM ZnSO4, 10 mM β-mercaptoethanol and at three different 
concentrations, 0.1 mg/ml, 1 mg/ml and 7 mg/ml. A blank of buffer without 10mM β-
mercaptoethanol was used. 420 µl of sample was loaded into each cell. Sedimentation 
velocity was performed over 2 hours, at 50,000 X g, using a Beckman XL-I Analytical 
Ultracentrifuge. The protein was then resuspended and the experiment repeated at       
60,000 X g over 2 hours. The Rayleigh interference system detects solute concentration 
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differences by changes in the refractive index. A graph of S-value distributions normalised 
to loading concentration was plotted. 
2.7.6 Mass spectrometry 
Further identification was performed using Mass spectrometry (MS). MALDI-MS 
fingerprinting was used for protein identification by partially matching the sequence of the 
protein to the data generated. MALDI-MS fingerprinting does not give a native molecular 
weight as it is carried out under denaturing conditions. Positive ionisation electrospray mass 
spectrometry was used to ascertain the precise molecular weight of the protein both under 
native and denaturing conditions. 
2.7.6.1 MALDI-MS fingerprinting 
MALDI-MS (Matrix assisted laser desorption ionisation) fingerprinting was carried out by 
Dr. Jeff N. Keen. This was done through protein separation using SDS-PAGE, the protein 
band of interest was then excised using a scalpel. The protein slice was cut into 4 pieces, 2 
of which were transferred to duplicate wells of a microtitre plate for automated trypsin 
digestion using a MassPREP workstation (Waters UK Ltd). The Coomassie brilliant blue-
stained gel pieces were first subjected to automated destaining using 50 mM ammonium 
bicarbonate/50% (v/v) acetonitrile.  The proteins were reduced using 10 mM dithiothreitol 
(in 100 mM ammonium bicarbonate, 30 minutes) and alkylated using 55 mM iodoacetamide 
(in 100 mM ammonium bicarbonate, 20 minutes), then the gel pieces were washed with 100 
mM ammonium bicarbonate and dehydrated using acetonitrile prior to the addition of 25 µl 
trypsin (Promega, Southampton, UK) solution (6ng/µl in 50mM ammonium bicarbonate). 
Digestion was allowed to proceed for 5 hours at 37 ºC. Peptides were then extracted using 
30 µl 1% (v/v) formic acid/2% (v/v) acetonitrile and an aliquot (1µl) applied to a stainless 
steel MALDI plate together with 1µl matrix solution (2mg/ml α-cyano-4-hydroxycinnamic 
acid in 60% (v/v) acetonitrile/0.08% aqueous TFA). This mixture of peptide fragments were 
analysed by MALDI. The dried plate was transferred to a M@LDI L/R mass spectrometer 
(Waters UK Ltd) and the digest was analysed in reflectron mode using standard operating 
parameters. Briefly, the instrument used a N2 laser at 337 nm, source voltage was set at 
15000 V, microchannel plate detector voltage was set at 1950 V, pulse voltage was set at 
2450 V, reflectron voltage was set at 2000 V, coarse laser energy was set to low, with fine 
adjustment used for each sample to  optimise the signal. At least 100 laser shots were 
accumulated and combined to produce a raw spectrum. Spectra were processed (background 
subtraction, smoothing and peak centroiding) and calibrated externally using a tryptic digest 
of alcohol dehydrogenase (mass error typically less than 100 ppm). The data is mapped to 
the theoretical sequence to determine identity. 
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2.7.6.2 Electrospray ionisation mass spectrometry 
Protein samples were analysed on the Synapt HDMS (Waters UK Ltd) mass spectrometer 
by Dr. James R. Ault. The samples were analysed both in 150mM ammonium acetate buffer 
(Sigma-Aldrich, Dorset, UK) and under denaturing conditions where the sample was diluted 
to a buffer composition of 50% methanol/0.1% aqueous formic acid. A minimum protein 
concentration of 40 µM was used. The instrument was calibrated using a separate injection 
of sodium iodide. The mass spectrum shows multiply charged ions and these were then 
transformed on to a molecular mass scale using the maximum entropy processing technique. 
 
2.8 X-ray crystallography methods  
2.8.1 Crystallography screen 
Protein was concentrated to approximately 10 mg/ml using Amicon Ultra-15 centrifugal 
unit, 10 KDa cut-off (Millipore, MA, USA) and subjected to a pre crystallisation test (PCT, 
Hampton Research, CA, USA) to check the concentration was suitable. Reagents from 
commercially available crystallisation screening kits were reformatted into sets of 96 in 
deep well blocks. Precipitant solutions were then dispensed into reservoirs of a Greiner 96 
well plate. Using a robot (Cartesian) 100nl from each reservoir was dispensed onto each 
platform along with 100 nl of protein to form a single droplet. Each plate was sealed 
manually, using self adhesive transparent film (Viewseal, Greiner). Crystallisation plates 
were stored at 21 °C and imaged regularly.  
2.8.2 Diffraction data collection 
Diffraction data was collected at Diamond light source, Oxfordshire, using macromolecular 
crystallography beamline IO2 and detector type ADSC Q315 CCD. 30% glycerol was 
added to the mother liquor to act as a cryoprotectant. The crystal was placed in a loop and 
mounted onto the goniometer head, in a stream of liquid nitrogen. The three point centering 
method was used to align the crystal accurately in the X-ray beam. An adsorption edge scan 
was collected to ascertain the wavelengths required for multiple wavelength anomalous 
diffraction (MAD) data collection. MAD data was collected at the Zn K-edge. The crystal 
was rotated through 360° and images collected at each degree of rotation. This was done for 
all three wavelengths. 
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2.9 NMR methods  
2.9.1 Protein sample preparation 
Proteins were uniformly labeled with stable isotopes 15N and/or 13C by expressing proteins 
in E. coli in a minimal media that contains 15N-labeled NH4Cl (Silantes, München, 
Germany) and/or 13C-labeled glucose (Silantes, München, Germany) as the sole nitrogen 
and/or carbon sources. Protein was purified and concentrated, using an Amicon 
concentration filter, 10 KDa cut off (Millipore, MA, USA), to a minimum volume of 320 µl 
and concentration of at least 0.3 mM.  
2.9.2 Experiment preparation 
10% Deuterium oxide (DTO) and 0.5 mM Azide, to prevent bacterial growth, were added to 
the sample. The sample was loaded into an outer 5mm glass Shigemi Advanced NMR 
microtube (Sigma-Aldrich, Dorset, UK) using a long-tip pipette (Sigma-Aldrich, Dorset, 
UK). The inner Shigemi tube was inserted so that there were no bubbles between the inner 
and outer tubes and sealed using parafilm. The length of the sample portion was set to 
17mm. In most cases the instrument temperature was set to 10ºC and then the tube was 
loaded into the magnet. The probe was tuned as variations in the polarity and dielectric 
constant of the lock solvent affect tuning. Tuning was carried out, until the power versus 
frequency display read zero, for the resonance frequency of the nucleus being measured. 
Pulse length was altered to give a 90° rotation. Field shimming was done to make the 
magnetic field more homogeneous and to obtain better spectral resolution. Data was 
acquired at 10°C using a Varian Unity Inova spectrophotometer unless otherwise stated. 
2.9.3 1H-15N HSQC 
1H-15N HSQC experiments were recorded using a 600 MHz NMR instrument (Varian Unity 
Inova spectrometer). A 1H-15N HSQC provides a 2D heteronuclear chemical shift 
correlation map between directly bonded 1H and 15N. Due to the neutral pH that is required 
to maintain VH#576 in solution, a pulse sequence that contains water flip-back pulses was 
applied to maintain maximum signal for the exchanging amides. The following parameters 
were used to run a HSQC experiment. Pulse widths for 15N and 1H were 45µs and 10µs 
respectively. Decoupling 15N pulse width was 220 µs. A total of 1024 complex points for 
the acquisition dimension with a spectral width of 8012 Hz and 128 complex points for the 
indirect dimension with a spectral width of 2083 Hz, were recorded with 160 scans per 
increment for an overnight experiment. Experiments were recorded at various temperatures 
from 10 to 25 °C 
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2.9.4 1H-13C HSQC 
1H-13C HSQC experiments were recorded using a 600 MHz NMR instrument (Varian Unity 
Inova spectrometer). The experiment was recorded with 120 (13C) x 1024 (1H) complex 
points and spectral windows of 12, 000 (13C) and 10, 000 (1H) Hz. 64 scans per increment 
were used at a temperature of 15°C. 
2.9.5 HNCA and HN(CO)CA 
HNCA and HN(CO)CA were run sequentially using a 750 MHz and 500 MHz spectrometer 
respectively. For the HNCA, 32 (13C) x 24 (15N) x 1024 (1H) complex points and spectral 
windows of 5500 (13C), 2750 (15N) and 10, 473 (1H) Hz were used, with 64 scans per 
increment, at 10°C. For the HN(CO)CA, 28 (13C) x 24 (15N) x 1024 (1H) complex points and 
spectral windows of 3300 (13C), 1800 (15N) and 7509 (1H) Hz were used, with 80 scans per 
increment, at 10°C. 
2.9.6 NOESY and TOCSY 
A 3D 15N NOESY-HSQC was recorded on a 900 MHz NMR system at Birmingham (HWB 
NMR large scale facility), with a mixing time of 150ms. The pulse sequence used was 
provided through the Biopack library (Varian). The experiment was recorded with 116 
(NOE) x 26 (15N) x 1024 (1H) complex points and spectral windows of 10, 000 (NOE), 3050 
(15N) and 12, 608 (1H) Hz. 8 scans per increment were used. 
 
A 3D 15N TOCSY-HSQC was also recorded at 900 MHz with a mixing time of 40ms. This 
was recorded with 86 (TOCSY) x 24 (15N) x 1024 (1H) complex points and spectral 
windows of 10, 000 (TOCSY), 3050 (15N) and 12, 608 (1H) Hz, with 16 scans per 
increment. Both spectra were acquired at 10°C. 
2.9.7 Data processing 
Spectra were processed using nmrPipe (Delaglio et al., 1995) and analysed in CCPN 
analysis (Vranken et al., 2005). 
 
2.10 Cell culture methods  
2.10.1 Chinese hamster ovary cell transfection 
Chinese hamster ovary (CHO) cells were harvested from growing cultures and seeded into 
12 well plates, at a density of 105 cells per well, in 2mls of DMEM glutamax (Invitrogen, 
Paisley, UK) and 10% FCS. The plate was incubated over night at 37˚C, 5% CO2. After 16 
hours the cells were 50 to 80% confluent and lipofection was performed. In a sterile tube 
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(A) 24 µl of Lipofectamine (Invitrogen, Paisley, UK) was added to 576 µl Optimem 
(Invitrogen, Paisley, UK). In a sterile tubes (B) 300 ng pM3-LMO2, 300 ng pEF-VP16-
VH#576 (or appropriate mutant), 60 ng pRL-CMV, and 600 ng pG5 luciferase reporter 
vector were added to 50 µl Optimem. For the negative control pEF-VP16-VH#576 was 
replaced with pEF-VP16-Y#6VH. 50 µl of (A) was added to each reaction (B) and left to 
incubate at ambient temperature for 45 minutes. 400 µl of Optimem was added to each 
complexed sample. The cells were aspirated, washed with Hanks media (Invitrogen, Paisley, 
UK) and the 500 µl of Optimem complexed sample added. The cells were incubated for 3 to 
5 hours at 37˚C, 5% CO2. After incubation the media was replaced, with 2 mls of DMEM 
glutamax and 10% FCS per well, and the cells left for 48 hours to express (37˚C, 5% CO2). 
2.10.2 Luciferase reporter assay 
Cells were aspirated and washed with Hanks media (Invitrogen, Paisley, UK), 150 µl of 
Trypsin/EDTA was added to each well and once cells were trypsinised, 150µl of DMEM 
glutamax and 10% FCS were added to quench the reaction. Cells were transferred to labeled 
eppendorfs and 75 µl of each added to a white 96 well, flat bottomed plate. The remainder 
was centrifuged at 13,000 X g for 3 minutes and the cell pellet frozen at -80˚C for analysis 
by Western blot. To the appropriate wells of the 96 well plate, 75µl of dual glo reagent 
(Promega, Southampton, UK) was added and left for 10 minutes and a luminescence 
reading was taken. 75 µl of stop glo combined with 1/100 activator (Promega, Southampton, 
UK) was then added to the appropriate wells and left for 10 minutes before a second reading 
was taken (this gives the renilla levels for use as a transfection efficiency control). 
Luminescence readings were performed using a Mithras LB940 plate reader (Berthold 
Technologies, Harpenden, UK), for 2 seconds per well. A graph of Firefly/Renilla was 
plotted for VH#576 mutants and controls.  
2.10.3 Western blot analysis 
The cell pellet was resuspended in 37.5 µl of PBS/EDTA and 12.5 µl of 4X SDS loading 
buffer added before the sample was heated at 100˚C for 5 minutes. 20µl of each sample was 
loaded onto a 15% acrylamide gel, the proteins separated by SDS-PAGE and transferred to 
a PVDF membrane. After an incubation of 1 hour with 4% blocking buffer, anti-VP16 (14-5 
Santa Cruz biotechnology) was added at 1:1000 and left overnight at 4˚C. After four 15 
minute washes with TBST, anti-mouse conjugated HRP antibody was added at a 
concentration of 1:1000 in 4% blocking buffer. After four 15 minute washes with TBST, the 
Western blot was analysed using ECL kit (Thermo fisher scientific, Loughborough, UK). 
Standard X-ray film was exposed to the membrane at ambient temperature behind a Hi 
Speed intensifying screen for an appropriate length of time, depending on the strength of the 
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signal. Films were developed in a SRX 101A developer (Photon Imaging, Swindon, UK). 
Commonly used reagents 
2.10.4 Buffers and solutions 
All buffers were sterilised by filtration through a 0.2µm nalgene filter. 
2.10.4.1 Buffers for DNA analysis 
• 1L of 5 X TBE buffer (Tris/borate/EDTA): 54 g Tris-HCl base, 27.5 g boric acid, 
20 ml 0.5 M EDTA, pH 8. 
• 1% agarose: 1g agarose (Sigma-Aldrich, Dorset, UK), 100ml 1 X TBE buffer 
• 6 X DNA loading buffer: 30% (v/v) glycerol, 0.25% (w/v) bromophenol blue, 
0.25% (w/v) xylene cyanol FF 
2.10.4.2 Buffers for protein analysis 
• 12ml SDS gel loading buffer (4X): 3ml 1M Tris-HCl pH 6.8, 4.8 ml 10% SDS,  
2.4 ml 100% glycerol, 0.024 g bromophenol blue, 0.58 ml milli Q H2O,                 
10% β-mercaptoethanol (add to stock solution just prior to use).  
• 5 X Tris glycine: 15.1 g Tris Base, 94 g glycine, 50 ml 10% SDS, milli Q H2O to 1 
L. 
• 12% SDS-PAGE gel: 3.3 ml milli Q H2O, 4 ml 30% acrylamide, 3.8 ml Tris-HCl 
(1.5 M, pH 8.8), 0.15 ml 10% SDS, 0.15 ml 10% ammonium persulfate, 6 µl 
TEMED. 
• 5% stacking gel for Tris-glycine SDS-PAGE: 2.7 ml milli Q H2O, 0.67 ml 30% 
acrylamide, 0.5 ml Tris-HCl (1M, pH 6.8), 0.04 ml 10% SDS, 0.04 ml 10% 
ammonium persulfate, 4 µl TEMED. 
• Coomassie brilliant blue stain: 50 ml milli Q H2O, 40 ml methanol, 10 ml acetic 
acid, Coomassie brilliant blue (0.2%). 
• Coomassie brilliant blue de-stain: 50 ml milli Q H2O, 40 ml methanol, 10 ml 
acetic acid. 
• Transfer Buffer: 5.8 g Tris base, 2.9 g glycine, 200 ml methanol, milli Q H2O to   
1 L. 
• 10X TBS: 24.23 g Tris-HCl, 80.06 g NaCl, 800 ml milli Q H2O. pH to 7.6 with HCl 
and add milli Q H2O to 1 L. 
• TBS-T: 100ml TBS (10X): 900 ml milli Q H2O, 1 ml Tween 20. 
• Blocking Buffer: 4 g fat-free milk powder, 100 mls TBST 
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2.10.5 Nutrients broths 
Luria Bertani (LB) broth: 10 g bactotryptone, 10 g bactoyeast, 5 g NaCl, milli Q H2O to  
1 L. 
LB agar plates: LB plus 15 g bactoagar per liter. 
2TY: 16 g bactotryptone, 10 g bactoyeast, 5 g NaCl, milli Q H2O to 1 L. 
SOC: 20 g bactotryptone, 5 g bactoyeast, 0.5 g NaCl, 10 ml 250 mM solution of KCl, pH to 
7.0 with NaOH. Add milli Q H2O to 975 ml. Sterilised and just prior to use, 5 ml of sterile  
2 M MgCl2 and 20 ml of sterile (by 0.2 µm filter) 1 M glucose solution were added.  
M9 minimal media (components autoclaved separately): 200 ml 5 X M9 salts (see 
below), 2 ml 1 M MgSO4, 20 ml 20% glucose (sterilised by filtration), 1 M CaCl2, 10 ml 
100 X MEM vitamins (Invitrogen, Paisley, UK) and made up to 1 L with sterile H2O.   
5 X M9 salts (1L): 64 g Na2HPO4• 7H2O, 15 g KH2PO4, 2.5 g NaCl, 5 g NH4Cl and made 
up to 1 L with sterile H2O. 
 
LB media and agar, SOC medium and 2TY medium were all sterilised by autoclaving for 20 
minutes at 15 lb/sq on a liquid cycle. Unless otherwise stated the antibiotic concentrations 
of the plates and media were: 
Ampicillin (Amp): 100 µg/ml 
Chloramphenicol (Cam): 34 µg/ml 
Tetracycline (Tet): 20 µg/ml 
LB agar was made up as stated. If required, antibiotics were added to cooled agar (40 to 
50˚C) and 25 ml poured immediately into petri dishes, using aseptic techniques, under a 
fume hood. Plates were allowed to set at room temperature and stored at 4˚C for a 
maximum of two weeks.  
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2.11 Theory behind methods used for structural analysis 
2.11.1 NMR theory 
Biomolecular NMR requires proteins enriched with 15N or both 15N and 13C. Atomic nuclei 
1H, 15N and 13C have net nuclear spins as a result of the magnetic moments of their 
component protons and neutrons. For spin ½ nuclei the energy levels split into parallel and 
anti parallel orientations, upon application of a magnetic field. Spins aligned parallel with 
external magnetic fields are of a slightly lower energy than those aligned in an antiparallel 
orientation. The orientation of nuclear spins can be altered by pulses of electromagnetic 
radiation, in the radio frequency range (Rhodes, 2006). Nuclei in different chemical 
environments absorb different frequencies of energy and this allows specific nuclei to be 
detected by their specific absorption energy. The result is called the chemical shift and is 
expressed in parts per million (ppm). Chemical shifts signify the position of a resonance 
along a frequency axis and are defined relative to a standard such as 4,4-dimethyl-4-
silapentane-1-sulfonic acid (DSS). Nuclear spins also interact magnetically, exchanging 
energy with each other, in a process called spin-spin coupling. As nuclei must be within a 
few bonds of each other to couple, this effect can be used to determine which nuclei are 
neighbours within the molecule (Whitford, 2005). 
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Figure 2.1: NMR experiment setup 
In this diagram of an NMR instrument, the major components are the magnet containing the 
probe, the ‘shim’ to maintain homogeneity and electronics to ‘lock’ the field at a given 
frequency. The radio frequency transmitters provide pulses designed by a pulse programmer 
and a frequency synthesiser together with a detection system of numerous amplifiers, filters 
and analogue-digital converters (ADC).  
Figure taken from (Whitford, 2005). 
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Nuclear spins in a sample can be viewed as precessing about an axis, z, aligned with the 
magnetic field H (Figure 2.1). The excess of spins aligned with the field means there is a net 
magnetisation vector pointing in the positive direction along z at equilibrium. The receiver 
coils, encircle the x-axis and detect radio frequency radiation in the xy plane. Detection of a 
radio frequency requires that the net magnetisation vector be moved into the xy plane and 
this is achieved by the application of a 90° pulse of radio frequency at the correct intensity, 
applied along the x axis. The resulting radio frequency signal contains the characteristic 
absorption frequencies of all the nuclei in the sample from which chemical shifts can be 
derived.  
 
Nuclear spins lose energy to their surroundings, a process known as spin lattice relaxation. 
The longitudinal relaxation time T1 reflects the rate at which magnetisation returns to the 
longitudinal axis after a pulse and is measured in seconds. In solution, T1 is correlated with 
the overall rate of tumbling of a macromolecule but is also affected by internal molecular 
motion arising from conformational flexibility. The transverse relaxation time T2 describes 
the decay rate of transverse magnetisation in the xy plane. T2 is always shorter than T1 and is 
correlated with dynamic processes occurring within a protein. The most important factors, 
which influence T2 are molecular mass, temperature, solvent viscosity and exchange 
processes (Whitford, 2005). 
 
Two dimensional (2D) NMR spectroscopy involves the application of successive pulses that 
lead to magnetisation transfer between nuclei (Aue et al., 1976). The mechanism of transfer 
proceeds either through bond (scalar mechanism) or through space (dipolar) interaction. A 
2D experiment consists of 4 time periods. The preparation period is a single pulse or series 
of pulses and delays, which create the magnetisation terms that, will make up the indirect 
dimension. The terms evolve during the evolution period. The evolution of magnetisation is 
followed by a second pulse that initiates the mixing period which results in magnetisation 
transfer to other spins via through bond or through space interactions. The decay of the free 
induction decay signal is detected during the acquisition period. The whole pulse scheme is 
repeated to allow for signal averaging and other instrumental factors including relaxation. 
The experiment is then repeated by incrementing the evolution period to build up a series of 
free induction decays recorded at different intervals. A 2D experiment contains two time 
variables and Fourier transformation of this dataset yields a 2D contour plot, where the 
precision frequencies occurring during the evolution and detection periods determine peak 
positions in the 2D plot. This can be extended to three dimensional (3D) NMR by including 
a second indirect evolution period and a second mixing period. 
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As amide nitrogens are sequentially connected through alpha and carbonyl carbons a 15N 
and 13C labeled protein sample is used to carry out three dimensional (3D) experiments in 
order to assign backbone amide signals. HNCA and HN(CO)CA, are generally run 
sequentially (Kay et al., 1990). The experiment name denotes the observed signal 
correlations in the spectra, for example, HNCA provides correlations of signals from the 
amide (HN) in the ith residue to the attached Cα in the ith and i-1 residue. HN(CO)CA 
provides correlation between HN in the ith residue to the Cα in the i-1 residue. In this case 
the CO is a relay nucleus and, therefore, its frequency is not detected. 
 
Assignment is a critical stage of determining protein structure by NMR and can prove 
problematic. The known protein sequence is used to connect nuclei of amino acid residues 
that are neighbours in the sequence using information from the spectra (Dubs et al., 1979). 
Upon assignment of a HSQC spectrum, the crucial information for structure determination, 
comes from Nuclear Overhauser effect (NOE) measurements that provide distance 
information between pairs of protons. Supplementary constraints can be derived from 
through bond correlations in the form of dihedral angles (Guntert, 1998). Furthermore, 
chemical shift data provides information on the type of secondary structure and hydrogen 
bonds can be detected via through-bond interactions (Spera and Bax, 1991) or inferred from 
slow hydrogen exchange.  
2.11.2 X-ray crystallography theory 
X-ray diffraction results from the interaction between incident X-rays and the electrons of 
atoms within the crystal. As electrons are localised around the nucleus of atoms, the electron 
density is a good indication of atomic position within the molecule. Braggs law (Equation 
2.1) is the relationship between the crystal structure and its diffraction pattern (Bragg, 
1913). Each spot on the diffraction pattern is a Bragg reflection or reflection. 
 
Equation 2.1 
Braggs law = nλ = 2d sin θ  
(where λ = wavelength d = spacing between the planes and θ = the glancing angle) 
 
Schematically a crystal can be described as a lattice (Blow, 2005). A series of equally 
spaced parallel lines will cover all the points in a lattice. All the possible sets of planes, 
which cover all the lattice points, can be described by different values of h, k and l (Miller 
indices). The interplanar distance associated with any reflection can be determined directly 
by observation of its θ angle and use of Bragg’s law. The diffraction pattern of a crystal 
lattice is also a lattice but with dimensions which are inversely proportional. A set of planes 
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(h, k and l) produce the reflection h, k and l in the diffraction pattern. Diffracted rays reflect 
from hkl planes of spacing dhkl only at angles (θ) for which 2dhkl Sin θ = nλ (an integral 
number of wavelengths). The crystal is rotated through a small angle (1-2°), such that the 
new oscillating range overlaps the previous one slightly. From this new position, oscillation 
produces additional reflections in the second frame. This process is continued until all 
unique reflections have been recorded. When screw rotational symmetry is present, there are 
systematic absences among reflections in lattice planes perpendicular to the screw axis.   
 
The result of X-ray data collection is a list of intensities, each assigned an index hkl 
corresponding to its position in the reciprocal lattice. Indicies are counted from the origin, 
which lies in the direct path of the X-ray beam (indices 000). As indicies increase, there is a 
corresponding decrease in the spacing dhkl of the real space planes represented by the indices 
and thus these reflections carry far more information about the fine details of the structure. 
Software is used to index the reflections, determine unit cell parameters and spacegroup. 
Indexing takes into account the mosaic spread of the reflections collected. Mosaicity is an 
angular measure of the degree of long range order of the unit cells within a crystal. Lower 
mosaicity indicates more ordered crystals and hence better X-ray diffraction. Indexing is 
followed by integration, a process that converts all images into a single file. It provides the 
miller index of each reflection and intensities. Scaling is used to scale the relative images so 
that they have a consistent intensity scale. Data analysis yields a list of reflections 
(positions) and their intensities (amplitudes) but the phases of the scattered X-rays are 
unknown. 
 
All reciprocal lattices possess a symmetry element called a centre of symmetry or point of 
inversion at the origin (Rhodes, 2006). The computed sum for the reflection hkl is called the 
structure factor Fhkl. The amplitude of Fhkl is proportional to the square route of reflection 
intensity Ihkl. The frequency of the structure factor is equal to 1/dhkl, making the wavelength 
the same as the spacing of the planes producing the reflection. In three dimensions, Friedel’s 
law requires that |Fhkl| = |F –h,-k,-l|. Reflections are known as Friedel’s pairs. The structure 
factors from Friedel’s pairs have the same amplitude but opposite phase angles. If the 
amplitude and the phase of the structure factor are known for all reflections, the electron 
density map can be calculated and the crystal structure solved. However, no phase 
information is directly available from the intensities of the diffracted X-rays. Therefore 
various experimental methods are in use to solve the phase problem.  
 
One method employed to solve the phase problem is anomalous scattering. The zinc present 
in LMO2, for example, have the ability to scatter X-rays anomalously. The use of multiple 
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wavelengths near the absorption edge of a heavy atom can be used to identify heavy atom 
positions, providing powerful phase information. Multiple wavelength anomalous 
dispersion (MAD) data is collected at three different wavelengths; peak, edge and remote. 
At the peak wavelength, anomalous scattering should have its largest value. At the edge the 
normal scattering is reduced to its lowest possible value and at the remote normal scattering 
is close to its normal value. Atoms, which scatter anomalously, do not obey Fridel’s law as 
the reflections hkl and –hkl are not equal in intensity. The difference of scattered intensities 
between Ihkl and I–h,-k,-l is known as Bijvoet difference and the difference between |Fhkl| and 
|F –h,-k,-l| Bijvoet amplitude difference (Bijvoet, 1954). Changing the wavelength changes the 
intensities of the individual reflections, which can be used to directly calculate the phase 
angle for each reflection. The magnitude, of anomalous differences, may be indicated by an 
R factor (Equation 2.2). 
 
Equation 2.2 
Ranom = mean Bijvoet amplitude difference / mean amplitude 
 
Phase information may be obtained from measurement of |FPH| (reflection of amplitude for 
protein plus heavy atom) for each member of the Friedel pair. In this case only data 
collected at the peak wavelength was processed (single anomalous diffraction) and used to 
identify the position of zinc atoms.  
 
Another method for phase determination is molecular replacement. Molecular replacement 
can be used to solve a structure when you have a good model for a reasonably large fraction 
of the structure in the crystal. The model should have at least 30% sequence identity. Both 
maximum likelihood and Patterson based molecular replacement were used for the work 
described in this chapter. The Patterson function can be computed without phases. A 
preliminary model of the crystal structure is obtained, by first orienting (rotating) and then 
positioning (translating) the model molecule in the crystal lattice (Rossmann and Blow, 
1962). The phases are then calculated from the model and combined with the observed 
structure factor amplitudes. The electron density map produced using this method contains a 
strong bias towards the starting model however values are enough for refinement.  
 
“The accuracy of a 3D structure depends on the refinement, the resolution and the restraints 
that are introduced in the structure analysis (Blundell et al., 2002).” Before refinement 
begins a series of test reflections are picked at random (5%) and are not available for the 
refinement procedure; the Rfree. This is done to make sure that any improvements are an 
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accurate representation of the model. The difference between the Rfactor and the Rfree should 
be no more than 5%. The Rfactor is used to judge the crystal model, it is a measure of how 
well the modified electron density fits the observed structural amplitudes and can be 
calculated, as shown in Equation 2.3. R factors for good structures should be approximately 
1/10th of the resolution of the data. 
 
Equation 2.3 
R = ∑ | Fobs – Fcal | / ∑ Fobs 
(Where Fobs = observed structural factors. Fcal = calculated structural factors 
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3 Expression and purification of LMO2 for X-ray 
crystallography trials 
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3.1 Introduction 
Non random chromosomal translocations are common in the malignant cells of patients with 
acute and chronic leukaemia. LMO2 (LIM domain only 2) is encoded by a gene located on 
chromosome 11p13 and is associated with specific chromosomal translocations 
t(11;14)(p13;q11) and t(7;11)(q35;p13) in patients with T-cell acute lymphoblastic 
leukaemia (T-ALL). T-ALL is an aggressive malignancy of thymocytes in which multiple 
genetic defects combine during pathogenesis resulting in uncontrolled cell growth (Van 
Vlierberghe et al., 2008). At present, treatment involves multi-agent chemotherapy (Bernard 
et al., 1998) however only 30 to 40% of adult patients are long term survivors. Current 
treatments cure over 70% of children with acute lymphoblastic leukaemia, although many 
patients develop serious acute and late complications due to the side effects (van 
Vlierberghe et al., 2008). 
 
LMO2 has been shown to have an important role in T-ALL (Grutz et al., 1998b). 
Transgenic mouse models of LMO2-induced T cell neoplasias showed that enforced LMO2 
expression caused accumulation of immature thymic T cells, followed by clonal T cell 
tumours with long latency (Larson et al., 1995). LMO2 is therefore a specific therapeutic 
target as not only is it associated with chromosomal translocations and retroviral insertions 
(Hacein-Bey-Abina et al., 2003) but also is expressed in approximately 50% of T-ALL 
patients (Aplan, 2004). In addition, LMO2 has been implicated in diffuse large B cell 
lymphomas (Natkunam et al., 2007) and its aberrant expression has been detected in 
prostate tumours (Ma et al., 2007) and pancreatic cancer (Nakata et al., 2008, Nakata et al., 
2009).  
 
LMO2 is a nuclear LIM only protein made up of two tandem LIM domains. Each LIM 
domain is composed of two zinc binding finger like motifs (LIM fingers). LMO proteins 
have been identified as important motifs that mediate specific protein-protein interactions. 
As such LMO2 is an important protein to understand and a potential drug target. The 
structure based drug design approach, described in this thesis, requires a three-dimensional 
structure of the drug target, LMO2. The two routinely used methods, to study 
macromolecular structure, are X-ray crystallography and Nuclear magnetic resonance 
(NMR). The focus of this chapter is the crystallisation of LMO2 for the purpose of X-ray 
crystallography. 
 
The first stage of X-ray crystallography is purification of the target protein to both a high 
concentration and purity. A commonly used strategy is to express different versions of the 
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target protein until a well expressing, soluble, and correctly folded construct is identified 
(Braun and LaBaer, 2004). Further variations of the protein, such as point mutations or 
amino or carboxy-terminal truncations may be required in order for crystallisation to be 
successful (Williams et al., 2000).  
 
The first half of this chapter explores the use of three different N-terminal fusion tags, GST, 
NusA and MBP, to aid the solubility and purification of LMO2. All three constructs proved 
problematic and as a result an alternative strategy was investigated. An anti-LMO2, heavy 
chain variable immunoglobulin domain, VH#576, had been previously isolated (Tanaka and 
Rabbitts, 2010). VH#576 was co-expressed with LMO2 and used to co-purify the 
heterodimeric complex. This construct failed to crystallise even after methylation of the 
surface lysine residues. Deletion analysis of LMO2 amino (N)-terminus and carboxy (C)-
terminus revealed seven N-terminal residues could be removed and eleven C-terminal 
residues, while still retaining protein solubility and complex stability. Finally, a complex of 
human LMO2 spanning amino acid residues 9 to 147, bound to an antibody single domain, 
was crystallised. X-ray diffraction data was collected for structural determination as will be 
discussed in chapter five. 
 
3.2 Protein expression and purification methods 
The general methods employed for recombinant protein expression and purification are 
outlined in chapter two, section 2.4. The crystallography screens were set up as described in 
section 2.8. Any modifications are stated in the appropriate section of this results chapter.  
 
3.3 Purification of GST-LMO2 fusion protein 
Glutathione S-transferase (GST) is a 26 KDa protein that can be fused to a protein of 
interest and purified via glutathione affinity chromatography. The method is based on the 
affinity of GST to the glutathione ligand coupled to a matrix. GST fusion proteins can be 
competitively eluted using reduced glutathione, which does not affect the proteins native 
structure and function. It is important to know, when considering the stoichiometry of a 
GST fusion protein, that GST can undergo dimerisation (Nishida et al., 1998). 
3.3.1 Expression and purification of GST-LMO2  
Expression of GST-LMO2 was induced in the E. coli Rosetta strain harbouring the 
expression plasmid pGEX-His-Tev-LMO2 (Ampicillin resistant). Protein expression was 
induced and the whole cell lysate was analysed by Western blot (Figure 3.1).  
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Two negative controls were also included as a means of confirming the expression of   
GST-LMO2: 
I. Rosetta cells transformed with pGEX-His-Tev-LMO2 and not induced with IPTG 
(transformed only) 
II. Rosetta cells which have not been transformed with an expression vector but 
induced with IPTG (induced only) 
The GST-LMO2 construct also has a His tag, as shown in the expression vector map 
(Appendix C). Figure 3.1 shows anti-LMO2 and anti-His Western blots, both of which show 
a band corresponding to the size of GST-LMO2 (46.03kDa) in lane two (induced and 
transformed). This band also appears in lane three of both Western blots, the transformed 
only control, and this suggests the T7 promoter is slightly “leaky”. Analysis of 
untransformed Rosetta E. coli cells (lane four) confirms that the Western blot signal is 
specific to transformation with the appropriate construct. Both Western blots show break 
down of GST-LMO2 represented by the bands below that of GST-LMO2. This is likely due 
to proteolytic degradation via host cell protease. 
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Figure 3.1: Western blot analysis of GST-LMO2 whole cell lysate 
A: Western blot analysis of cell lysate (soluble fraction) using anti-LMO2 polyclonal 
primary antibody. A crude extract of cellular proteins was separated by 12% SDS-PAGE, 
transferred onto PVDF membrane and incubated with affinity purified anti-LMO2 rabbit 
antiserum followed by horseradish peroxidase conjugated anti-rabbit antibody. Arrows 
indicate the presence or absence of GST-LMO2.  
B: Further analysis of the cell lysate was performed using anti-polyhistidine peroxidase 
conjugate antibody. PVDF membrane was incubated with monoclonal anti-polyhistidine 
peroxidase conjugate, mouse IgG2a isotype (Sigma-Aldrich, Dorset, UK). Both Western 
blots show GST-LMO2 is expressed in the transformed and induced cells but also in the 
transformed only cells. Again, arrows indicate the presence or absence of GST-LMO2. 
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GST-LMO2 was then purified via glutathione sepharose chromatography and eluted using 
10mM reduced glutathione. SDS-PAGE analysis of the eluate (Figure 3.2) shows a band 
running at the correct size for GST-LMO2 (46.03 KDa), along with an additional intense 
band representing a protein of approximately 60 KDa. Two further bands are also visible 
which run below GST-LMO2. The bands of lower molecular weight were shown to be 
degradation products by Western blot. The 60 KDa contaminant protein does not contain 
GST, His or LMO2, as it is not present in any of the Western blots. Further experiments 
revealed this 60 KDa contaminant protein could not be removed by extensive column 
washing with 0.5% triton X-100 (data not shown). 
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Figure 3.2: Purification of GST-LMO2 via glutathione sepharose affinity chromatography 
Purification of GST-LMO2, after recombinant expression in E. coli (Rosetta). Samples were 
taken at each stage of the chromatography (load, unbound fraction, wash fraction and 
eluate) and analysed by 12% SDS-PAGE. The gel was stained with Coomassie brilliant 
blue. Arrows indicate the proteins present in the eluate. GST-LMO2 (46.03 KDa) is shown 
to undergo a degree of degradation and there is a strong contaminating protein of 
approximately 60 KDa.  
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3.3.2 Strategy to reduce GST-LMO2 degradation 
As protease inhibitors (Roche Diagnostics, Mannheim, Germany) did not prevent the 
degradation of GST-LMO2, a strategy was investigated to decrease the rate of protein 
degradation. An alternative explanation for the rapid degradation observed during GST-
LMO2 purification (Figure 3.2) is the inability of the protein to form a correct tertiary 
structure due to anomalies in protein folding. In some cases, over expression of the E. coli 
chaperone complex GroEL-ES has facilitated correct protein folding and enhanced the 
production of active proteins (Wall and Pluckthun, 1995). It was anticipated that the 
controlled over expression of GroEL-ES would enhance GST-LMO2 stability and thus 
reduce degradation.  
 
Many newly synthesised proteins reach their folded state spontaneously, without assistance, 
however folding efficiency may be limited by side-reactions such as aggregation promoted 
by transiently expressed hydrophobic surfaces. The GroEL-ES chaperone complex is 
essential for E. coli growth and designed to ensure protein folding occurs efficiently 
(Whitford, 2005). GroEL and GroES are composed of seven and fourteen identical subunits, 
respectively and are organised to form a large isolation chamber within which proteins can 
fold.  
 
Three different chaperone vectors were obtained; pA6, pGroES-EL and pGTF2 (Madrid, 
Spain). pA6 and pGroES-EL express GroEL-GroES chaperones. pGTF2 expresses GroEL-
GroES chaperones and trigger factor, a protein thought to facilitate protein folding by 
interacting with GroEL and strengthening substrate binding (Nishihara, K. et al, 1999). Each 
plasmid was co-transformed into E. coli (C41) along with pGEX-His-Tev-LMO2 and 
protein expressed as previously described. C41 was used, in place of Rosetta pLysS, as all 
three chaperone expression plasmids have a Chloramphenicol selection marker, as does 
Rosetta pLysS. C41 is defective in OmpT and Lon protease production and therefore may 
aid in the expression of fusion proteins by minimising the effects of proteolytic degradation 
by the host (Miroux and Walker, 1996). The cell lysates were purified by glutathione 
sepharose chromatography and eluates analysed by SDS-PAGE (Figure 3.3). The gel shows 
less degradation occurred when GST-LMO2 was co-expressed with GroEL-GroES and 
trigger factor (pGTF2). 
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Figure 3.3: Addition of chaperone expression vectors to reduce GST-LMO2 degradation 
12% SDS-PAGE stained with Coomassie brilliant blue. The gel suggests degradation of 
GST-LMO2 is reduced by the over expression of GroEL-GroES and that the pGTF2 vector, 
expressing GroEL-GroES chaperone complex and trigger factor (TF), was the most 
effective. 
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3.3.3 Identification of the 60 KDa contaminant protein and removal strategy  
Figure 3.3 shows the 60 KDa protein band increases in intensity for cells over expressing 
chaperone GroEL, this suggests that the original 60 KDa contaminant was in fact 
endogenous GroEL bound to GST-LMO2. A similar problem has been described during the 
purification of a Papillomavirus capsid protein, HPV16 L1 (Chen, X.S. et al., 2001). In the 
case of Chen et al. the 60 kDa contaminant protein, which could not be removed by 
extensive washing, size exclusion, or ion exchange chromatography, was identified as 
GroEL by N-terminal sequencing. The addition of ATP-MgCl2 (2mM, 5mM respectively) 
has been demonstrated to releases GroEL from its substrate (Chen, X.S. 2001). pGTF2 
(Chloramphenicol resistance) and pGEX-His-Tev-LMO2 (Ampicillin resistance) were co-
transformed into C41 and expression induced in the usual way. The cell lysate (soluble 
fraction) was split into three aliquots and ATP-MgCl2 added to a final concentration of: 
1) 2mM ATP and 5mM MgCl2 
2) 4mM ATP and 10mM MgCl2 
3) 8mM ATP and 20mM MgCl2 
 
Glutathione sepharose resin (50% slurry) was added to each lysate and incubated for 2hours, 
at 4˚C, with gentle rotation. Each column was washed with 100ml of washing buffer 
containing ATP and MgCl2 at the appropriate final concentration (listed above). This was 
followed by a 50ml wash without ATP-MgCl2. The eluate of each column was analysed by 
SDS-PAGE (Figure 3.4). The addition of ATP-MgCl2 virtually eliminated GroEL from each 
eluate with 2mM ATP and 5mM MgCl2 being most effective. 
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Figure 3.4: Addition of ATP-MgCl2 for removal of bound chaperone  
12% SDS-PAGE stained with Coomassie brilliant blue. 
A: The cell lysate (soluble fraction) was analysed along with the three unbound fractions. 
Lanes three, four and five represent unbound fractions from lysates which have mixed with: 
1) 2mM ATP and 5mM MgCl2 2) 4mM ATP and 10mM MgCl2 3) 8mM ATP and 20mM 
MgCl2 respectively. No unbound fraction can be seen in lane five and this may be due to 
experimental error. 
B: Each column eluate was concentrated and analysed. The gel shows 2mM ATP and 5mM 
MgCl2 are the most effective concentrations for removal of the GroEL contamination while 
still maintaining a practical yield of 1.25mg per liter culture. 
Expression and purification of LMO2 for X-ray crystallography trials 
 
 77 
3.3.4 Size exclusion chromatography to remove GST only from GST-LMO2  
Figure 3.5 shows more than 60% of the protein eluted from the glutathione column to be 
GST only; this is a common problem when purifying proteins fused with GST. Therefore, in 
order for the protein to be pure enough for crystallography studies, an additional 
chromatography step was required. The first method tested was size exclusion 
chromatography. Previous size exclusion chromatography had little success (data not 
shown) so a larger column (25mm diameter by 600mm in length) was used to increase the 
resolution of separation. The column resin was superdex 75, which separates proteins in the 
range of 3 to 600 KDa. A total of 4mg (28.89µM) GST-LMO2 in 2ml phosphate buffer was 
loaded onto the column and a flow rate of 2.8ml/min was used. 4ml fractions were 
collected, over an elution volume of 300mls, and analysed by SDS-PAGE (Figure 3.6). 
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Figure 3.5: Western blot analysis of GST-LMO2 co-expressed with chaperone and trigger 
factor proteins 
The eluate was separated by size using 12% SDS-PAGE and then transferred onto PVDF 
membrane. One membrane was incubated with anti-GST antibody solution and the other 
anti-LMO2 antibody solution. Both membranes were then incubated with horseradish 
peroxidase conjugated anti-rabbit antibody. The figure compares the Western blots, to the 
Coomassie brilliant blue stained gel, and reveals the majority of GST-LMO2 degradation is 
GST only. 
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A: 
 
B: 
 
Figure 3.6: GST-LMO2 size exclusion chromatography 
A: A chromatogram to show the UV absorbance at 280nm over the course of the size 
exclusion chromatography. The fractions relating to each gel lane are highlighted. 4ml 
fractions were collected using a fraction collector in serpentine mode. 
B: 12% SDS-PAGE stained with Coomassie brilliant blue. Fractions B12 to B7 show a 
higher molecular weight protein (60 KDa), which is likely to be GroEL. All fractions show 
GST-LMO2 degradation. 
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3.3.5 Purification of GST-LMO2 via ion exchange chromatography  
SDS-PAGE analysis of the size exclusion fractions B12 to B8 (Figure 3.6) shows evidence 
of GroEL chaperone protein. GroEL is a made up of 14 subunits each of which are 60 KDa. 
Thus, the interaction of GST-LMO2 with GroEL would greatly increase the overall 
molecular weight and cause GST-LMO2 to be eluted early in the size exclusion run. This 
suggests a fraction of chaperone GroEL remains tightly bound to GST-LMO2, even after 
incubation with 2mM ATP and 5mM MgCl2. The next step was to investigate the option of 
ion exchange chromatography; a high resolution technique, which separates proteins 
according to differences in their net surface charge. The estimated PI of GST-LMO2 is 6.88 
therefore Q sepharose anion exchange resin was selected, with a pH 8.5 buffer. At pH 8.5 
GST-LMO2 would have a net negative charge and bind the positive cationic groups of the 
resin in the process of anion exchange. 7mg of GST-LMO2 was loaded onto the column and 
a gradient of 0 to 1M NaCl was used to elute the protein over a volume of 400ml. 
Approximately 90% of the protein loaded was eluted in the first 80ml (Figure 3.7) with GST 
only being the major component of all of these fractions. 
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A:  
 
B: 
 
Figure 3.7: GST-LMO2 anion exchange chromatography 
A: A chromatogram to show the UV absorbance at 280nm and the NaCl elution gradient  
(0-1M over 400mls). The fractions collected are also indicated. 
B: 4ml fractions were concentrated and analysed by 12% SDS-PAGE stained with 
Coomassie brilliant blue. The fractions analysed are indicated on the chromatogram (A). 
The majority of GST-LMO2 (46.03 KDa) was eluted in the first peak along with, over 60%, 
GST only (26.22 KDa).  
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Anion exchange appears to have removed GroEL from the protein sample completely. 
However, the majority of GST-LMO2 was eluted in the main peak along with a large 
percentage of GST only contaminant (Figure 3.7). A Mono Q anion exchange column 
(5/50GL) was the next option as it has a higher resolution capacity due to the efficiency of 
small, perfectly spherical monodispersed particles. Approximately 11.7mg of GST-LMO2, 
in 60ml of 40mM Tris-HCl, pH 8.5 was loaded onto the column. A flow rate of 2.0 ml/min 
was used and a gradient of 0 to 1M NaCl, over 500ml, was used to elute the protein. 
However the column failed to separate the proteins further (Figure 3.8). The GST only 
protein remained a major contaminant; this could potentially be removed by a TEV protease 
cleavage of GST, followed by further purification of LMO2 such as size exclusion or ion 
exchange chromatography. However, due to the large number of problems described, a new 
strategy was employed and this will be discussed in the next section. 
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A: 
 
 
B: 
 
 
Figure 3.8: Mono Q anion exchange chromatography  
A: A chromatogram to show the UV absorbance at 280nm and the NaCl elution gradient. 
The fractions collected are also indicated.  
B: 3ml fractions were concentrated and analysed by 12% SDS-PAGE stained with 
Coomassie brilliant blue. The fractions analysed are from the peak indicated on the 
chromatogram (A). Again the peak contains both GST-LMO2 (46.03 KDa) and GST only 
(26.22 KDa). 
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3.4 Expression and purification of NusA-LMO2 
The problems with GST-LMO2 purification, highlighted in the previous section, warranted 
experimentation of an alternative approach for the expression of LMO2. Different gene 
fusions have been shown to increase the solubility and stability of a target protein (Arnau et 
al., 2006). NusA (55 KDa) was chosen as an alternative fusion protein due to its high 
solubility when over expressed in E. coli (Harrison R.G., 2000). It cannot itself be used as 
an affinity tag therefore the fusion construct employs an N-terminal His tag for purification. 
His tags are widely used for purification via immobilized-metal affinity chromatography. In 
this case chelated Ni2+ ions were used as the affinity ligand. The Ni2+ is complexed with an 
immobilised chelating agent, Nitrilotriacetic acid (NTA). NTA occupies four of the six 
ligand binding sites in the coordination sphere of the nickel ion, leaving two sites free to 
interact with the His tag. 
 
E. coli host strains may also affect recombinant protein expression therefore two were tested 
in this investigation. C41 and B834 E. coli strains were transformed with expression vector 
pET43a-NusA-LMO2 (Ampicillin resistant) and the expression levels from both strains 
compared to that of GST-LMO2 from C41. Cell cultures were grown up and protein 
purified as previously described. Figure 3.9 shows a comparison of the LMO2 fusion 
proteins purified. In both cases (C41 and B834 strains) the purification of NusA-LMO2 had 
a high background of contaminant proteins; this was later reduced by the addition of a size 
exclusion chromatography step. E. coli strain C41 provided a higher level of NusA-LMO2 
protein expression and was therefore selected as the host strain for further purification 
experiments. NusA-LMO2 (78.5 KDa) size exclusion chromatography (superdex 200, 
10/300 GL) gave an efficient separation of proteins (Figure 3.10) with a final NusA-LMO2 
purity of around 95% as estimated by the assessment of SDS-PAGE (Figure 3.10). 
Expression and purification of LMO2 for X-ray crystallography trials 
 
 85 
 
 
 
 
 
Figure 3.9: Comparison of LMO2 fusion tags  
12% SDS-PAGE analysis shows NusA-LMO2 (78.5 KDa) is expressed at a higher yield 
than GST-LMO2 (46.03 KDa). E. coli strain C41 provided a higher level of NusA-LMO2 
protein expression than B834. However, the purity of NusA-LMO2 was low due to a high 
level of background contaminant proteins, which were later removed by size exclusion 
chromatography. 
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A: 
 
 
B: 
 
 
Figure 3.10 NusA-LMO2 size exclusion chromatography 
A: Size exclusion chromatography analysed by measuring UV absorbance at 280nm. 0.5ml 
fractions were collected as indicated in red. 
B: 12% SDS-PAGE stained with Coomassie brilliant blue. The fractions analysed are 
indicated on the chromatogram (A). Fractions from each peak were pooled and 
concentrated. From the calibration curve for this column (Appendix A, figure 1), peak three 
corresponds most accurately to the weight of NusA-LMO2 (78.5 KDa). There is a larger 
contaminant protein of approximately 80 KDa causing a percentage of NusA-LMO2 to elute 
in peak two. 
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The use of NusA as a fusion partner has greatly improved the purification of LMO2 as a 
fusion protein. NusA-LMO2 shows limited degradation in comparison with GST-LMO2 
and can be further purified effectively by size exclusion chromatography. Nevertheless, the 
next section will describe the implementation of a protein expression screen to ascertain if 
further improvements could be made upon the purification of LMO2 as a fusion protein.  
 
3.5 Protein expression and purification screen 
Oxford protein production facility (OPPF) specialise in high throughput structural biology 
with particular expertise in vector construction and protein expression screening. This 
section will describe work, carried out by H. Sewell, at this research complex. For cloning 
and protein purification methods please refer to chapter two, section 2.3. 
3.5.1 OPPF Expression and purification screen 
To investigate whether LMO2 could be purified more successfully, a high throughput 
expression screen was carried out at Oxford protein production facility (OPPF). The OPPF 
vector suite was used to make expression vector constructs for LMO2, LDB1 and TAL1bhlh, 
using the In-fusion (Clontech, France) ligation independent cloning method. LDB1 and 
TAL1 interact with LMO2 in a DNA binding complex therefore, it may be possible to co-
express LMO2 with either TAL1bhlh (minimal interaction region of the protein) or LDB1 to 
increase its stability and solubility. The expression vectors produced are listed in the Table 
3.1.  
 
The expression vectors were designed so all fusion proteins expressed are also fused to a 
His tag. Ni-NTA magnetic beads were used to purify all proteins expressed in the screen in 
a high throughput, semi automated manner. The results (Figure 3.11) showed the best 
candidates for scale up were: 
I. His-MBP-3C-LMO2 
II. His-MBP-3C- TAL1bhlh 
III. His-MBP-3C-LDB1 
 
The maltose binding protein (MBP) and LMO2 fusion protein expressed and purified to the 
highest yield of more than 5mg/ml. MBP (44 KDa) can be used for affinity purification with 
amylose resin followed by mild elution using maltose. The advantages of this method are 
that both binding capacity and specificity are high meaning high yields and purity can be 
achieved in one step.  
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Table 3.1: Fusion proteins and respective solubility 
Lane Protein Expression Tag Expected size Soluble expression 
M Protein marker    
1 LMO2 His-SUMO 30.65  
2 TAL1bhlh K His (kanomycin resistance) 10.09  
3 TAL1bhlh MAHHHHHHSSGLEVLFQGP 10.09  
4 TAL1bhlh His-GST-3C 33.8 <0.5mg/l 
5 LMO2 K His (kanomycin resistance) 20.44  
6 LMO2 MAHHHHHHSSGLEVLFQGP 20.44  
7 LMO2 His-GST-3C 44.15 <0.5mg/l 
8 LMO2 His-MBP-3C 58.9 >5mg/l 
9 LDB1 His-GST-3C 72.3  
10 LDB1 His-MBP-3C 87.05 0.5-5mg/l 
11 LDB1 His-SUMO 58.8  
12 TAL1bhlh His-SUMO 20.3  
13 TAL1bhlh His-MBP-3C 48.55 0.5-5mg/l 
14 LDB1 K His (kanomycin resistance) 48.59  
15 LDB1 MAHHHHHHSSGLEVLFQGP 48.59  
 
 
Figure 3.11: OPPF protein expression screen 
Fusion protein expression was analysed by SDS-PAGE and stained using SafeStain. Table 
3.1 indicates the protein and fusion partner purified along with its expected size, solubility 
and lane number. The results show that MBP protein is an effective fusion partner for 
LMO2, LDB1 and TAL1bhlh as all constructs purify to a yield of more than 0.5mg per liter. 
Other fusion proteins expressed and purified successfully, although to a lower yield (less 
than 0.5mg/l), were His-GST-3C-LMO2 and His-GST-3C-Tal1bhlh.  
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3.5.2 Comparison and further analysis of NusA-LMO2 and MBP-LMO2  
SDS-PAGE analysis provided an initial assessment of protein sample quality and purity. 
Mass spectrometry was then employed to ensure the identity of the purified protein. Protein 
identification of NusA-LMO2 and MBP-LMO2 was confirmed by peptide mass 
fingerprinting using mass spectrometry. This work was carried out by Dr. Jeff N. Keen 
(Leeds Institute of Genetics, Health and Therapeutics, The University of Leeds). Peptides 
were generated by trypsin digest of the fusion protein and the mass of each peptide was 
accurately measured using a matrix assisted laser desorption time of flight (MALDI-TOF) 
mass spectrometry method. The mass/charge (m/z) ratios were recorded along with their 
relative abundance in the form of a m/z spectrum, which is shown in Appendix A, figure 2 
and 3. Peptide peaks were matched between those predicted and the actual spectrum. Both 
proteins were confirmed to be correct with NusA-LMO2 and MBP-LMO2 giving 49% and 
60% peptide sequence coverage respectively. 
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Figure 3.12: Comparison of NusA-LMO2 and MBP-LMO2 purification 
10% SDS-PAGE stained with Coomassie brilliant blue. Samples were taken at each stage of 
both purifications (lysate, unbound, wash and eluate) and analysed as shown. Eluate bands 
from both NusA-LMO2 and MBP-LMO2 were excised and used to carry out MALDI-MS 
peptide mass fingerprinting to confirm the identity of the proteins. 
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3.5.3 Analysis of NusA-LMO2 and MBP-LMO2 by Circular Dichroism 
Further analysis of the quality of the LMO2 fusion proteins purified took the form of 
Circular Dichroism. “Circular Dichroism spectroscopy plays an important role in the study 
of protein folding and it allows the characterisation of secondary and tertiary structures of 
proteins in native, unfolded and partially folded states” (van Mierlo and Steensma, 2000). 
Although Circular Dichroism spectra would mainly reflect the structure of the large LMO2 
fusion tags, data was collected to determine if NusA-LMO2 and MBP-LMO2 were folded 
or not. Circular Dichroism spectroscopy measures differences in absorbance of right and left 
circularly polarised light. Peptide bonds dominate the far-UV region (190-250 nm) of the 
spectra and can be used to characterise the secondary structure.  
 
The Circular Dichroism spectra of NusA-LMO2 and MBP-LMO2 can be found in 
Appendix A, figure 7 and both have the characteristic minimum at around 215nm; this is 
typical for a structure with considerable β-sheet content. From this data, we can confirm that 
both proteins are folded, as the spectra of both are negative at more than 208nm. CDSSTR 
(Johnson, 1999) obtained from DICHROWEB (Whitmore and Wallace, 2004) was used to 
analyse the spectra further. CDSSTR uses a set of 43 proteins as a reference for fitting the 
experimental spectrum. The content of various secondary structures obtained for NusA-
LMO2 by this method were: 38% α-helix, 16% β-sheet, 22% β-turn and 24% unordered. 
For MBP-LMO2 the results, by this method were: 20% α-helix, 30% β-sheet, 26% β-turn 
and 24% unordered.  
Expression and purification of LMO2 for X-ray crystallography trials 
 
 92 
 
3.5.4 MBP-LMO2 for crystallography trials 
For crystallography purposes protein tags are ideally removed usually by digestion with a 
protease, providing that an appropriate recognition site has been engineered into the 
expression vector. This is because tags may influence the structure of the target protein and 
may also be flexible, inhibiting crystal formation. As such, a favourable strategy for LMO2 
crystallisation would be to remove the N-terminal His-MBP purification tag by 3C protease 
cleavage. HRV 3C protease is a recombinant form of the 3C protease from human 
rhinovirus type 14. In this case, the 3C protease (22 KDa) was fused to an N-terminal His 
tag providing a means to separate the protease, along with His-MBP, from the target protein 
post cleavage. This was done using a second Ni-NTA chromatography step.  
 
An initial titration experiment was designed to estimate the appropriate ratio of enzyme to 
target protein. From this experiment it could be concluded that a 1:5 (protease:target 
protein) ratio was the most effective, with the digest going to completion after 1 hour. A 
large-scale digest was then carried out overnight at 4°C, during dialysis against imidazole 
free buffer. Conversely, during this protease reaction, a large amount of free LMO2 
precipitated (Figure 3.13). The precipitate was removed by spinning down the dialysed 
solution (4000 X g) and retained for analysis. The dialysed solution was then passed 
through 2ml of Ni-NTA resin in a disposable column. Theoretically, LMO2 should pass 
through the column while His-MBP and His tagged 3C protease should remain bound to the 
column. However as shown by Figure 3.13, some His-MBP is present in the flowthrough. 
Nevertheless, the beads were eluted with 250mM imidazole and the eluate analysed showed 
some His-MBP was retained by the Ni-NTA resin (Figure 3.13). 
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Figure 3.13: His-MBP-LMO2 3C protease digest  
12% SDS-PAGE stained with Coomassie brilliant blue. Unfortunately most of the LMO2 
protein precipitates upon removal of the His-MBP tag (lane 7). Separation of His-MBP from 
LMO2, via Ni-NTA chromatography is poor. This can be seen by the presence of His-MBP 
in the flowthrough fraction (lane six). However the Ni-NTA resin did retain some His-MBP 
as can be seen by the analysis of the Ni-NTA eluate (lane 8). 
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3.5.5 MBP-LMO2 rigid linker strategy  
Cleavage of the MBP expression tag, from MBP-LMO2, resulted in precipitation of free 
LMO2, even at low concentrations (Figure 3.13, lane 7). One strategy investigated, to 
prevent the precipitation of LMO2 upon cleavage from MBP, was to leave the affinity tag in 
place for crystallisation trials. Leaving the MBP tag in place would have some advantages 
for crystallography, such as providing a known structure to facilitate phase determination by 
molecular replacement. The flexible linker region, between MBP and LMO2, was 
engineered to give a short rigid linker with the anticipation that this would reduce the 
potential for conformational heterogeneity (Smyth et al., 2003). 
 
The MBP expression vector, pOPIN_M, was modified to include a NotI site. This provided 
a DNA sequence to code for two alanine amino acids with potential for addition of further 
residues to create the rigid linker. This was achieved using appropriately designed primers 
(see Appendix C for primer sequences) to amplify LMO2 and at the same time incorporate 
5’ additions (linker region). Three expression plasmids were constructed to express: 
I. MBP-AAA-LMO2 
II. MBP-AAAAA-LMO2 
III. MBP-AAAEF-LMO2 
 
The expression vectors were used to transform E. coli Rosetta and protein expression 
induced. Amylose resin was used to purify the protein, which was then eluted in 10mM 
Maltose. All constructs were expressed and highly soluble with a yield of approximately 
40mg per liter.  
 
The appropriate protein bands from the gel shown in Figure 3.14 were excised and analysed 
by MALDI-MS fingerprinting (carried out by Dr. Jeff N. Keen) to confirm the identity of 
the purified products (see Appendix A, figure 4). Size exclusion chromatography was used 
to determine the quarternary structure of MBP-AAA-LMO2 i.e. if it is forming a 
dimer/trimer/tetramer. The protein eluted at a volume equivalent to a protein size of         
120 KDa, which would make MBP-AAA-LMO2 (60.22 KDa) a dimer although, this was 
further investigated by Analytical ultracentrifugation as described in the next section. 
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Figure 3.14: Expression and purification of MBP-LMO2 rigid linker constructs  
12% SDS-PAGE stained with Coomassie brilliant blue. The gel shows all constructs can be 
successfully expressed and purified to a high degree of purity, estimated to be more than 
90%. 
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Figure 3.15: Size exclusion chromatography of MBP-AAA-LMO2 
MBP-AAA-LMO2 protein was concentrated to 10mg/ml and loaded onto a Superdex 200 
10/300 GL column (void volume of 8mls). The chromatography was analysed by measuring 
UV absorbance at 280nm. The protein sample eluted at a volume of 9.5mls, which equates 
to a protein size of 120 KDa; this suggests MBP-AAA-LMO2 is forming a dimer. However, 
further analysis confirmed MBP-AAA-LMO2 was actually a soluble aggregate so eluting in 
the void volume.  
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Size exclusion can be used to predict native protein molecular weight although limitations 
include poor resolution for larger proteins. Furthermore, dilution during the chromatography 
may reverse any weak interactions as the protein concentration decreases (Liu et al., 2006). 
MBP-AAA-LMO2 eluted at an elution volume close to the void volume of the size 
exclusion column and consequently, Analytical ultracentrifugation was utilised to determine 
a more precise molecular weight for the protein under native conditions. MBP-AAA-LMO2 
was analysed at three different concentrations. A form of Analytical ultracentrifugation, 
termed Sedimentation velocity, was used to analyse the rate at which MBP-AAA-LMO2 
formed a unique boundary at a characteristic speed. The velocity and shape of this moving 
boundary was used to estimate the sedimentation coefficient and molecular weight of the 
protein. The results showed that all samples contained aggregated material sedimenting in 
the range of 10 to 50 S (Svedbergs), representing molecular masses in the range of 200 KDa 
to 3 MDa. Larger particles have higher Svedberg values, which are measured using equation 
3.1: 
 
Equation 3.1 
Sedimentation Coefficient (S) = Constant speed of sedimentation (ms−1)/ acceleration applied (ms−2)    
 
In all samples, a small proportion of material sedimented in the range 3.5 to 4.8 S. The 
molecular mass of this material was calculated at between 35 and 100 KDa, however the 
data was not good enough to support a more definite figure. Figure 3.16 shows the results in 
the form of a graph of S-value distributions normalised to loading concentration, which 
indicates MBP-AAA-LMO2 soluble aggregate formation is dependent on concentration. 
Figure 3.16 gives the exact percentage of soluble aggregate for each concentration of 
protein analysed. Another observation that supported the conclusion MBP-AAA-LMO2 was 
a soluble aggregate was the ease at which the sedimented protein could be resuspended. 
This rendered MBP-AAA-LMO2 rigid linker protein a non-viable option for 
crystallography.  
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Figure 3.16: Beckman XL-I Analytical ultracentrifugation  
This is a plot of S-value distributions normalised to loading concentration and shows that 
the proportion of aggregated MBP-AAA-LMO2 protein was dependent on concentration. 
For each protein concentration of 0.1mg/ml, 1mg/ml and 7mg/ml, the percentage of soluble 
aggregate was calculated as 39%, 85% and 93% respectively.  
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3.6 Expression and purification of LMO2 with antibody single 
domain, VH#576 
The option of co-expressing LMO2 with an antibody domain was explored as a means to 
stabilise LMO2, preventing its aggregation in solution. In the past antibody fragments have 
also been used to aid crystallisation (Kovari et al., 1995). An anti-LMO2 antibody, variable 
heavy chain, single domain (VH#576) has been previously identified using yeast 
intracellular antibody capture technology (Tanaka and Rabbitts, 2010). 
 
LMO2 and VH#576 were co-expressed from a single plasmid, pRK-His-Tev-VH#576-
LMO2 (obtained from T. Tanaka, THR lab) made up of bicistronic mRNA with an internal 
ribosome entry site. The complex was purified using nickel-agarose affinity 
chromatography (Figure 3.17) followed by further purification step using a Hi load 16/60 
superdex 75 (S75) prep grade size exclusion column. The UV absorbance at 280nm (Figure 
3.18) was monitored and fractions from the appropriate peak pooled and concentrated. The 
protein eluted at a volume, which reflects the molecular weight of a 1:1 protein complex, 
32.3 KDa. The final protein sample, in a buffer of 20mM Tris-HCl, pH 8, 200mM NaCl, 
and 1mM DTT, was concentrated to 11.3mg/ml and used to set up crystallography trials 
(Figure 3.19). 
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Figure 3.17: His-VH#576/LMO2 purification by Ni-NTA chromatography 
15% SDS-PAGE stained with Coomassie brilliant blue. VH#576/LMO2 complex was 
purified via the N-terminal His tag of VH#576 and the eluate is shown in lane five. The 
eluate of the second Ni-NTA chromatography step is shown in lane six. The concentrated 
eluate (size exclusion load) shown in lane seven suggests the complex stoichiometry is not 
1:1 with more VH#576 present than LMO2. There are also some high molecular weight 
contaminant proteins present, with molecular weights greater than 62 KDa. 
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Figure 3.18: VH#576/LMO2 size exclusion chromatography chromatogram 
VH#576/LMO2 complex was concentrated to 500µl at 10mg/ml and loaded on S75 16/60 
size exclusion column. Large molecular weight proteins and aggregated VH#576/LMO2 
were eluted in the void volume (first peak). The excess VH#576 protein was separated from 
the LMO2 bound VH#576 as shown by the final peak. The complex elutes at a volume, 
which represents an appropriate molecular weight of 32.3 KDa, and this reflects a protein 
complex stoichiometry of 1:1. Fractions from the appropriate peak (peak two) were pooled 
and concentrated to 11.3mg/ml for crystallography screens. 
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Figure 3.19: VH#576/LMO2 size exclusion chromatography load and pooled fractions 
15% SDS-PAGE stained with Coomassie brilliant blue. The purified protein was overloaded 
on the gel so that any impurities could be visualised. The final protein product was 
estimated to be around 90% pure with the major contaminant being Tev protease. The 
protein sample (lane seven) was used immediately to set up crystallisation screens. 
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3.6.1 X-ray crystallography screen with VH#576/LMO2 protein complex 
The first step in setting up initial crystallography screens was making sure the target protein 
was at an appropriate concentration, for crystallography, using a pre crystallisation test 
(PCT, Hampton Research, CA, USA). Setting up crystallisation screens with an optimised 
protein concentration should reduce the number of clear and precipitate results thus 
increasing the chances of crystallisation. The PCT was carried out using VH#576/LMO2 
protein at a concentration of 11.3mg/ml. The results, which are shown in Table 3.2, 
indicated that lighter crystallisation screens (weaker precipitants) were more appropriate. 
The screens were performed with the protein at 11.3mg/ml. 
 
Table 3.2: Results of the pre crystallisation test 
 PCT reagent A1/B1 result PCT reagent A2/B2 Suggested action 
A1/A2 Heavy amorphous 
precipitate 
Heavy amorphous 
precipitate 
Dilute sample 1:1 
B1/B2 Clear Light granular precipitate Perform screen 
 
Initial crystallisation trials were performed using the facilities at the Astbury centre for 
structural molecular biology (The University of Leeds). The sitting drop vapour diffusion 
method for crystallisation was implemented along with the following commercial screening 
kits (Hampton Research, CA, USA): 
I. Hampton I and II 
II. Salt RX 
III. Index 
IV. Natrix 
V. MembFac 
Ten 96 well plates (MRC2, Hampton Research, CA, USA) were used for the crystallisation 
trials. The plates were set up by dispensing 100µl (per well) of the screening solution from 
the master block to the reservoir of the crystallisation plate. An Impax automatic protein 
crystallisation system robot (Douglas Instrument, Hungerford, UK) was then used to 
dispense 1µl drops onto the platform of each well: 0.5µl of reservoir solution plus 0.5µl of 
protein (VH#576/LMO2 complex). The plates were then sealed with clear seal film 
(Hampton Research, CA, USA). Plates were prepared in duplicate so that one could be 
stored at 4°C and the other at 18°C.  
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Plates were left for one week and then inspected under a microscope (Leica MZ6 and Leica 
MZ12) for crystals, precipitate, crystalline precipitate, or clear drops. Any crystals were 
then tested for the presence of protein. This can be done in many ways: 
I. Izit dye staining (Hampton Research, CA, USA); Izit is a small molecule dye which 
will fill the solvent channels in protein crystals, colouring the crystals blue. Salt 
crystals do not possess these large solvent channels therefore, the dye cannot enter 
the crystals and they remain clear. 
II. Gel electrophoresis and silver staining. 
III. Mount the crystal and analyse the diffraction pattern. 
IV. Shine UV light on the crystal, if it absorbs and emits the UV light it is likely to be 
protein. 
In this case option four was used, however no protein crystals resulted from any of the 
crystallisation screens. 
3.6.2 Removal of N-terminal residues from LMO2 and expression with antibody 
single domain, VH#576 
Disordered regions of a protein may affect the solubility and crystallisation of a protein. 
“Many proteins contain local regions of such disorder, and some appear to be totally 
unfolded in their native states” (Yang et al., 2005). Structure determination by X-ray 
crystallography relies on ensembles of identical structures to amplify the experimental 
signal and therefore it was crucial to identify any disordered regions of LMO2. To predict 
disorder an algorithm has been developed, termed Regional order neural network (RONN) 
(Yang et al., 2005), based on data sets of protein disorder from the protein data bank (PDB). 
Figure 3.20 shows the probability of disorder of LMO2 as predicted by RONN. The graph 
suggests the first twenty N-terminal residues of LMO2 have a high probability (greater than 
0.5) of being disordered. 
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Figure 3.20: Probability of disorder of LMO2 as predicted by RONN 
The graph suggests the first twenty residues of LMO2 have a high probability (greater than 
0.5) of being natively disordered, i.e. do not form a well defined three-dimensional 
structure. The results of this algorithm suggest the N-terminal tail of LMO2 may hinder 
crystal formation. 
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To remove these residues the expression plasmid (pRK-His-Tev-VH#576-LMO2) was 
engineered, removing varying numbers of amino acids from the N-terminus of LMO2. A 
protein expression screen was carried out, purifying each of the constructs by Ni-NTA 
chromatography only. As shown by Figure 3.21, removing more than seven N-terminal 
residues, from LMO2, reduced solubility and stability of the complex. Consequently, 
VH#576/LMO2ΔN7 was fully purified (Figure 3.22 and Figure 3.23), concentrated to 
8mg/ml and used to set up further crystallisation trials.  Unfortunately, all screens were once 
again unsuccessful.  
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Figure 3.21: Effect of various LMO2 N-terminal truncations on the purification with 
VH#576 
15% SDS PAGE stained with Coomassie brilliant blue. The gel shows that the construct 
expressing LMO2ΔN7 was co-purified most efficiently with VH#576. Removing more than 
seven residues from the N-terminal of LMO2 reduces the yield of the complex purified. 
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Figure 3.22: Purification of VH#576/LMO2ΔN7 complex 
A: Calibration of Hi load 16/60 superdex 75 prep grade. The chromatogram represents the 
UV absorbance at 280nm.   
B: Purification of VH#576/LMO2ΔN7 protein complex by size exclusion chromatography 
using a Hi load 16/60 superdex 75 (S75) prep grade column. The complex eluted at a 
volume, which reflects a protein size of 31.5 KDa 
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Figure 3.23: VH#576/LMO2ΔN7 purification by size exclusion 
15% SDS-PAGE gel stained with Coomassie brilliant blue. The gel shows the 
VH#576/LMO2ΔN7 size exclusion chromatography protein load and the fractions from the 
relevant peak (Figure 3.22).  
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3.6.3 Lysine methylation of VH#576/LMO2ΔN7 protein complex 
Lysine methylation was suggested (Personal communication from T. Walter) as an 
alternative strategy to improve the chance of successful crystallisation. Recently, 
methylation of surface lysines has been used to chemically modify the surface of a protein, 
reducing surface entropy with a view to increasing the chance of crystal formation (Kim et 
al., 2008). Only lysine residues on the surface of the protein are methylated and not those at 
the interface of a strong protein-protein interaction. Primary amines of lysine residues and 
N-termini are modified to tertiary amines, by reductive methylation. Mass spectrometry was 
used to determine the extent of methylation. For structures solved using this method, 
methylated lysine residues were found at crystal contact points, therefore surface 
methylation may promote protein-protein interaction (Walter et al., 2006). 
 
VH#576/LMO2ΔN7 was expressed and purified by Ni-NTA chromatography as per the 
usual protocol. This was followed by removal of the His tag from VH#576 and subsequent 
methylation of the surface lysine residues. The reaction was quenched using size exclusion 
chromatography and this resulted in a well resolved peak, at the expected elution volume 
(Figure 3.24). The overall yield was 1mg per liter prep.  
 
Positive electrospray mass spectrometry (Appendix A, figure 5) was performed by Dr. 
James Ault (The University of Leeds) and used to measure the molecular weight of the 
purified proteins. The mass spectrum shows multiply charged ions, and this data was 
transformed on to a molecular mass scale using the maximum entropy processing technique. 
The results indicated VH#576 had four lysines methylated and LMO2 had ten and therefore 
all lysine residues in the complex had been successfully methylated plus the N terminal 
amine of both proteins. 
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Figure 3.24: The purification of lysine methylated VH#576/LMO2ΔN7 by size exclusion 
chromatography 
The chromatogram represents the UV absorbance at 280nm and shows a well resolved peak 
for the methylated VH#576/LMO2ΔN7 protein sample. 
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Crystallisation screens were set up using VH#576/LMO2ΔN7 lysine methylated protein 
complex at a concentration of 8mg/ml (determined using pre crystallisation kit from 
Hampton Research, CA, USA). In this case lysine methylation did not aid crystallisation as, 
again, all screens were unsuccessful. 
3.6.4 Removal of C-terminal residues from LMO2 and expression with antibody 
domain VH#576 
The final approach was to remove any C-terminal residues from LMO2 not involved in the 
interaction with VH#576. The C-terminus of LMO2 may disrupt the formation of crystals if 
it is flexible and undergoes large-scale motions. Four versions of the expression plasmid 
(pRK-His-Tev-VH#576-LMO2ΔN7) were engineered removing varying numbers of 
residues from the C-terminus of LMO2. The four constructs were expressed and purified by 
Ni-NTA chromatography (Figure 3.25). As well as C41 E. coli host strain, Shuffle T7 
express lysY (New England Biolabs, MA, USA) was also tested for protein expression with 
a view to improving the conformation and thus stability of the protein expressed. Shuffle T7 
express lysY is an engineered E. coli B strain designed to provide disulfide bond formation 
in the cytoplasm and constitutively express disulfide bond isomerase (DsbC), which assists 
in protein folding and correction of misoxidation. 
 
The construct, with the largest number of C-terminal residues removed, which still retained 
its stability and solubility, was VH#576/LMO2ΔN7ΔC11. This complex was expressed 
from E. coli strain C41 on a large scale and purified using both Ni-NTA and size exclusion 
chromatography (Figure 3.26). VH#576/LMO2ΔN7ΔC11 protein was also purified via the 
lysine methylation strategy. These two samples (methylated and un-methylated) were 
analysed by positive electrospray mass spectroscopy (Appendix A, figure 6). This was both 
to ensure surface lysine methylation had been successful and also to ensure the un-
methylated protein sample had the correct molecular weight and had not been truncated or 
cleaved in any way. Mass spectrometry analysis of methylated VH#576/LMO2ΔN7ΔC11 
indicates all thirteen possible methylation sites have been successfully methylated. An 
additional species at a higher molecular mass of 58.014 KDa was also identified which may 
be a slight GroEL chaperone protein contamination. The VH#576 monomer was also 
detected under native conditions. 
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Figure 3.25: Purification of LMO2, with various C-terminal truncations, with VH#576 
15% SDS PAGE stained with Coomassie brilliant blue. The gel shows that 
VH#576/LMO2ΔN7ΔC11 complex was expressed most efficiently. The gel also shows the 
protein yield is higher when expressed from C41 rather than Shuffle. 
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A: 
 
B: 
 
Figure 3.26: Size exclusion purification of VH#576/LMO2ΔN7ΔC11 expressed from C41  
A: VH#576/LMO2ΔN7ΔC11 purified by size exclusion using Hi load 16/60 superdex S75 
prep grade size exclusion column. The chromatogram is a measure of UV absorbance at 
280nm and is shown in full.  
B: UV280nm chromatogram focusing on the peak corresponding to 
VH#576/LMO2ΔN7ΔC11. 
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Figure 3.27: VH#576/LMO2ΔN7ΔC11 expressed from C41 and purified by size exclusion  
15% SDS-PAGE stained with Coomassie brilliant blue. The gel shows the     
VH#576/LMO2ΔN7ΔC11 size exclusion load and the fractions from the relevant peak 
(Figure 3.26). 
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The VH#576/LMO2ΔN7ΔC11 complex was subjected to far-ultraviolet (UV) Circular 
Dichroism spectropolarimetry (see Appendix A, figure 8) in order to determine if the 
protein complex was folded and to estimate the proportions of different secondary structural 
elements present. The Circular Dichroism spectrum has a characteristic minimum at around 
215nm; this is typical for a structure with considerable β-sheet content. From these data, we 
could confirm the protein complex was folded as the spectrum was negative at more than 
208nm. The Circular Dichroism spectrum was analysed by CDSSTR (Johnson, 1999) 
obtained from DICHROWEB (Whitmore and Wallace, 2004). The content of various 
secondary structures obtained, for VH#576/LMO2ΔN7ΔC11, by this method were: 8% α 
helix, 38% β sheet, 24% β turn and 30% unordered. These values are a fair indication that 
both the VH antibody single domain and LMO2 were present, as a complex, in the purified 
protein sample.  
3.6.5 VH#576/LMO2ΔN7ΔC11 X-ray crystallography screens  
VH#576/LMO2ΔN7ΔC11 protein complex, expressed from E. coli strain C41, was taken 
forward for crystallography trials. For this trial a simple protein sample buffer of 20mM 
Tris-HCl, pH 8 was chosen with the aim of increasing the degree to which the reagent 
buffers, of the crystal screen, could manipulate the pH and overall environment of the 
protein sample. A sample of protein (final concentration 8mg/ml) was snap frozen by 
immersion in liquid nitrogen and sent on dry ice to Oxford protein production facility 
(OPPF). The OPPF have developed a high throughput crystallisation facility (Walter et al., 
2003, Walter et al., 2005). 
 
Initially six blocks (576 conditions) of crystallisation screening kits (Hampton Research, 
CA, USA) were used: 
I. Hampton screens I and II 
II. PEG/ Ion, Grid screens PEG 6000 and Ammonium sulphate  
III. Natrix and cryoscreens  
IV. Gris screens PEG/Li, NaCl, MPD and ‘Quick screen’ Phosphate  
V. Salt RX 
VI. Index 
Crystallisation screens were performed (by Thomas S. Walter) using the Cartesian 
Technologies MicroSys MIS4000 pipetting instrument to execute nano-liter-scale sitting 
drop vapor diffusion crystallisation experiments. Drops dispensed consisted of 100nl protein 
and 100nl reagent. Crystallisation plates were stored at 21°C and imaged automatically thus 
maintaining a digital time course of crystal growth (Walter et al., 2005). Images of each 
well of the crystallisation screens were accessed remotely using a web browser allowing 
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rapid assessment of each drop. As shown by Figure 3.28 and Table 3.3, this crystallisation 
trial resulted in the identification of a number of reagents with the capacity to crystallise 
VH#576/LMO2ΔN7ΔC11 using the sitting drop vapour diffusion method. 
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Figure 3.28: Microscope image of crystal from reagent N5 of the Natrix screen  
Crystal growth was observed for reagent N5 of the Natrix crystallisation screen (0.2 M 
Potassium chloride, 0.01 M Magnesium chloride hexahydrate, 0.05 M MES monohydrate 
pH 5.6, 5% w/v Polyethylene glycol 8,000). The crystal was weakly birefringent (typical of 
biological crystal). 
 
 
Figure 3.29: Time course of crystal growth 
A time course of crystal growth observed for reagent N5 of the Natrix crystallisation screen. 
The crystal of interest (bottom right of drop) can be seen at 1 day 11 hours (image 1) and 
reaches full size by 4 days 19 hours (image 4). 
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Table 3.3: Further crystallisation reagents identified 
Microscope image Condition 
 
Natrix N3 
100mM Magnesium acetate 
tetrahydrate, 50mM MES 
monohydrate, pH 5.6,  
20% v/v 2-methyl-2,4-
pentanediol 
 
Natrix N38 
5% PEG 4000 
200mM Ammonium acetate 
150mM Magnesium acetate, 
50mM Sodium HEPES,   
pH 7 
 
Ammonium sulphate A3 
100mM MES monohydrate 
pH 6.0,  
0.8 M Ammonium sulfate 
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As the crystals could potentially be formed of VH#576 alone, LMO2ΔN7ΔC11 alone or 
from the complex (VH#576/LMO2ΔN7ΔC11), four crystals grown from the initial screen 
were tested for protein content by SDS-PAGE and silver stain analysis (Figure 3.30). 
Crystals from the Natrix screen, condition N3, were shown to be formed from the complex. 
 
 
 
 
 
 
 
Figure 3.30: Silver stain analysis of VH#576/LMO2ΔN7ΔC11 crystals 
Analysis of two crystals from the Natrix N5 reagent failed. Analysis of two crystals from 
the Natrix N3 reagent showed the VH#576/LMO2ΔN7ΔC11 complex to be present in both 
cases. No protein was present in the final crystal washes indicating that the crystals had 
been washed effectively with no protein residue present from the drop.  
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3.6.6 Crystallisation optimisation 
The following optimisation work was carried out by H. Sewell with guidance from             
T. S. Walter, Dr. E. J. Mancini and Dr. K. El Omari. Six conditions were taken forward for 
crystallisation optimisation experiments. Standard sitting drop vapour diffusion experiments 
were again utilised varying pH, reservoir dilution and protein concentration as shown by 
Figure 3.31. Additive screens (Hampton Research, CA, USA) were also set up. For a full 
list of the optimisation screens carried out and the results see Appendix A, table 1. 
 
 
 
A: 
 
B: 
 
Figure 3.31: Optimisation experiments 
A: Three row dilution optimisation; the top row shows how the reservoir concentration was 
decreased from 100% to 67%. The final column shows how the protein to reservoir volume 
ratios were changed for each row, thus varying protein concentration. The bottom three 
rows (F, G and H) of a Greiner 96 well plate were used. 
B: Three row pH optimisation; the pH was shifted from that of the original condition by 
+0.5 and -0.5. Within these pH changes, reservoir concentration was also varied from 100% 
to 55% (as indicated by the top row). Protein to reservoir drop volumes were also different 
for each row as shown by the final column. 
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These optimisation trials resulted in a number of crystals that were subsequently tested for 
diffraction. Diffraction data was collected by Dr. E. J. Mancini and Dr. K. El Omari at The 
European Synchrotron Research Facility (ESRF) in Grenoble and provided information on 
how well crystals from each condition were able to diffract. Crystals from the Ammonium 
sulphate A3 additive screen diffracted to the highest resolution (3.5Å to 3Å) and as such, 
this condition was optimised further by analysing the effect of different additives. This work 
was carried out by H. Sewell. Six optimisation plates were set up using the three row 
dilution technique (100 to 78%, 2% steps), one for each of the additives listed below. 100nl 
of the following additives were added to all wells of each optimisation plate: 
•Jeffamine M-600 
•2, 5 Hexanediol 
•1, 3 Butanediol 
•1, 6 Hexanediol 
•Pentaerythritol ethoxylate 
•Glycerol 
Crystals were visible after two days and continued to grow up until day four. Of these 
optimisation screens the additives 1, 3 Butanediol, 1, 6 Hexanediol, Jeffamine M-600 and 
Glycerol gave hexagonal plate shaped crystals with sharp edges (Figure 3.32). Optimisation 
plates were also set up by hand (by H. Sewell) using a similar method: 24 well Cryschem 
plates (Hampton Research, CA, USA) were used with reagent dilution varied horizontally 
(100 to 75%, 5% steps) and drop ratio vertically (1µl:1µl, 1µl:2µl, 2µl:1µl, 2µl:2µl). Three 
plates were set up, one for each additive; 1, 3 Butanediol, 1, 6 Hexanediol, and Glycerol. All 
three plates gave crystals. 
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Figure 3.32: Crystal from three row optimisation dilution screen  
Reagent: Ammonium sulphate (A3): 100mM MES monohydrate pH 6.0, 0.8 M Ammonium 
sulfate 
Additive: 1,3 Butanediol 
Well G6: 200nl protein/100nl reagent/100nl additive, reagent at 90% 
The crystal measured 100µm by 40µm. 
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As will be discussed in chapter five, the structure of VH#576/LMO2ΔN7ΔC11 was solved 
to 3.3Å using diffraction data collected at Diamond light source. The crystal diffracted was 
grown in 0.8M Ammonium sulphate, 0.1M MES monohydrate pH 6 (diluted with H2O to 
88%) and additive 1, 6 Hexanediol with a drop ratio of 200nl of protein to 100nl of reagent. 
 
3.7 Discussion  
This chapter describes the successful crystallisation of LMO2. The overall pipeline, from 
gene to structure included cloning, expression, purification, crystallisation screening and 
finally optimisation of conditions to produce structure yielding crystals. The use of VH#576 
effectively transformed LMO2 from an aggregated protein to a soluble, monodispersed 
protein complex suitable for crystallisation.  
 
The use of VH#576 to enhance the stability and hence solubility of LMO2 is analogous to 
the strategy utilised by Deane et al. The group stabilised the LIM1 domain of LMO2 
through interaction with the LIM interacting domain (LID) of LDB1, a member of the 
LMO2 DNA binding complex (Deane et al., 2001). The authors found that upon incubation 
with LDB1(LID), micro-gram quantities of LMO2 could be recovered. However, the 
complex degraded over time and therefore the group engineered a flexible linker between 
the C-terminus of the LIM1 domain of LMO2, and LDB1(LID) (Deane et al., 2001). 
LDB1(LID) was shown to stabilise LIM1 of LMO2 and enable its purification to sufficient 
quantities for structural studies by NMR (Matthews et al., 2001). 
 
In this case, it was necessary to make LMO2 more amenable to crystallisation by removal of 
amino and carboxy terminal residues, in order to reduce flexible regions and improve the 
crystal packing. Terminal residues of LMO2, not involved in the interaction with VH#576, 
were systematically deleted, thus eliminating any flexible regions that might interfere with 
crystallisation. A final construct of LMO2 spanning residues 9 to 147 (LMO2ΔN7ΔC11) 
bound to antibody single domain, VH#576, was crystallised under a number of conditions.  
 
The crystallisation screen employed the sitting drop vapour diffusion method and nano liter 
scale drops (Walter et al., 2003) to provide favourable kinetics for the crystallisation 
reaction. Many factors influence crystallisation including temperature, rate of equilibration, 
precipitant type and concentration, pH, protein concentration, detergents and impurities. 
These are all factors that were optimised when trying to produce crystals suitable for X-ray 
diffraction and improve the resolution of diffraction. Ammonium sulphate, A3 (Hampton 
Research, CA, USA); 0.8 M Ammonium sulfate, 100mM MES monohydrate pH 6.0, with 
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additive 1, 6 Hexanediol gave hexagonal plate shaped structure yielding crystals. The 
addition of additive 1, 6 Hexanediol to this condition dramatically improved the quality of 
crystals grown and this may be due to manipulation of protein-protein or protein-solvent 
interactions or perturbation of water structure.  
 
Co-expression of a target protein with an antibody fragment may increase its stability upon 
purification (Warke and Momany, 2007) and there have been instances of successful 
applications of this approach previously, an example of which is HIV capsid protein p24. 
When the protein was purified alone, interactions between the oligomerisation domains in 
the viral coat caused the viral capsid protein to aggregate (Prongay et al., 1990). Upon 
purification with a Fab fragment, the complex could be crystallised. Interestingly, the 
crystal contact points were primarily between Fab fragments. The advantage of using a VH 
single domain over a Fab fragment is the absence of the flexible hinge region that could 
potentially inhibit crystallisation.  
 
Many research groups have identified the potential of generating antibody domains for use 
as co-crystallisation chaperones (Nettleship et al., 2008, Tereshko et al., 2008), to enable the 
crystallisation of a protein or improve the resolution of its crystal structure. Crystallisation is 
often hindered by the inherent conformational heterogeneity of proteins and this limits the 
number of productive lattice contacts that are available for crystallisation. Crystallisation 
chaperones, such as VH or Fab antibody domains, bind to a specific conformation and thus 
minimise conformational heterogeneity and increase the chances of gaining well-ordered 
crystals. As such, the antibody single domain strategy described in this chapter may well be 
applicable as a generic tool to facilitate protein purification, crystal growth and improve 
crystal quality. Furthermore, VH#576 is a member of the VH3 family of heavy chain 
antibody domains, which are particularly suitable for this application as the framework is 
stable and well expressed. As will be shown in chapter five, the antibody single domain can 
also provide valuable phasing information. 
 
In conclusion, we have exposed the relative instability of free LMO2 and demonstrated its 
purification with an anti-LMO2 VH antibody single domain. Upon removal of the flexible 
N and C-terminal residues of LMO2, the complex was crystallised. A high throughput mode 
of crystallisation screening was utilised to identify a number of crystallisation conditions, a 
subset of which were optimised. Diffraction data has been collected and the structure solved 
to a resolution of 3.3Å, as will be described in chapter five. 
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4 Structural analysis of an anti-LMO2 antibody single 
domain by NMR 
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4.1 Introduction 
LMO2 is an attractive drug target for the treatment of a subset of patients with T-cell acute 
lymphoblastic leukaemia (T-ALL). Despite this there are currently no anti-LMO2 therapies. 
Antibodies have the qualities of specificity and affinity required for such a therapy. 
However, LMO2, as with most oncogenic proteins, is located inside the cell and not 
available for antibody mediated targeting. Consequent developments in antibody 
engineering have enabled stable antibody domains to be expressed in the reducing 
environment of the cell with no requirement for disulphide bond formation for correct 
folding (Tanaka and Rabbitts, 2008). It has been shown that single variable region domains 
are highly efficient as intrabodies. Accordingly, intracellular antibody capture (Tanaka and 
Rabbitts, 2010), based on in vitro yeast two-hybrid screening has been used to derive a 
single domain VH intrabody which binds specifically to LMO2 with high affinity 
(equilibrium dissociation constant of 94nM). This antibody domain, termed VH#576, has 
the potential to inhibit LMO2 from interacting with its natural protein partners and thus may 
prevent its aberrant activity as a transcription factor within T-cells of patients with T-ALL. 
However, due to significant problems with the delivery of antibody domains it is necessary 
to evolve VH#576 into a small drug like molecule.  
 
Structural data for small molecule drug design can be either explicit, for example the 
availability of a single X-ray structure of the target protein, or implicit, for example enough 
structural data on the ligand, or in this case the antibody domain, to develop a three 
dimensional pharmacophore map. Such a pharmacophore is then utilised in the usual way, 
for example, to search a three dimensional database in silico in order to identify mimetic 
compounds for focused screening. There are instances in which the rational structure based 
drug design of inhibitors can be performed without the target structure (McGregor, 2007).  
 
Nuclear magnetic resonance (NMR) spectroscopy is a powerful tool for determining protein 
structure. Various NMR experiments are implemented in order to acquire enough 
information to assign peaks of the spectral profile to individual atoms and eventually 
assemble a structure. However, as protein size increases the complexity of the task becomes 
greater as larger proteins tumble more slowly and their relaxation process becomes more 
efficient therefore the signal decays rapidly. Thus, VH#576/LMO2 was considered too large 
for structural analysis by NMR. VH#576, however, is far more suitable for detailed NMR 
investigations. Furthermore, the structure can be utilised to aid anti-LMO2 small molecule 
drug design. NMR is also an ideal tool for mapping the precise interaction sites of antibody 
domains (Wilkinson et al., 2009). Therefore, the aim of the work described in this chapter 
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was to gain structural data on the anti-LMO2 VH domain, VH#576, both in the 
uncomplexed and complexed state. This chapter focuses on the use of NMR to collect 
structural data; though the work was carried out in parallel with crystallisation and X-ray 
crystallography studies of the VH#576/LMO2 complex.  
 
VH#576 was identified from a library that belongs to the VH3 subgroup (Tanaka and 
Rabbitts, 2003). Previous studies on purified human VH fragments, from the same human 
VH3 subgroup, have shown poor expression and aggregation probably due to the exposed 
VH-VL interface (Davies and Riechmann, 1994, Dudgeon et al., 2009). However this 
chapter shows VH#576 can be expressed and purified from E. coli to a level sufficient for 
NMR. This is most likely due to the long CDR three region (17 residues as opposed to the 
more usual 12 residues) folding back onto the former, hydrophobic, VH-VL interface 
(Riechmann and Muyldermans, 1999).  
 
Previously a VH human antibody domain (VH-P8), from the human VH3 gene subgroup, 
has been studied by solution NMR. This was enabled by three mutations to the VH/VL 
interface region (based on the Camelid VH domains) and the addition of CHAPS to the 
sample buffer. These modifications enabled 90% of the 1H and 15N main chain signals to be 
assigned. Studies were carried out to analyse the interaction between VH-P8 and Protein A. 
In this case the binding site of Protein A lies in the VH not in the Fc portion, which is the 
more commonly known Ig isotype binding site. Upon binding, the chemical shift changes 
were identified for many residues (Riechmann and Davies, 1995). The ability to bind 
Protein A is a unique trait of VH domains originating from the human VH3 subgroup of 
genes. 
 
Isolated human VH domain HEL4 (based on human germline VH3 framework) is highly 
soluble at concentration of more than 3mM and its structure has been solved by X-ray 
crystallography to 2Å resolution. The structure shows the standard fold of an 
immunoglobulin variable domain with nine anti-parallel β strands. The structure also 
reveals, interestingly, the Trp 47 is flipped into a cavity formed by Gly 35 of CDR1 
increasing the hydrophilicity of the VH-VL interface (Jespers et al., 2004). 
 
This chapter describes the NMR structural studies of VH#576 and the strategies employed 
in order to stabilise the antibody single domain in solution. A protocol was developed to 
purify a complex of 15N, 13C labeled VH#576 bound to unlabeled LMO2. Amide chemical 
shift changes after complex formation have been observed however they cannot be mapped 
onto the sequence due to limitations encountered during assignment. Further data collection 
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is required for assignment of VH#576 to be possible.  
 
4.2 Protein expression and purification methods 
The general methods employed for recombinant protein expression and purification are 
outlined in chapter two, section 2.5 and 2.6. Any modifications are stated in the appropriate 
section of this results chapter. NMR data acquisition was carried out as described in chapter 
two, section 2.9. 
 
4.3 VH#576 protein purification and NMR results 
4.3.1 Initial VH#576 purification 
For the initial NMR experiments His-VH#576 was expressed from E. coli C41 cells grown 
up in 500ml 15N labeled rich growth media (E.coli-OD2 N Silantes, Germany) and purified 
by Ni-NTA affinity chromatography. His-VH#576 (16.3 KDa) was then dialysed into 
20mM Tris-HCl, pH 8, 150mM NaCl followed by concentration of the protein sample to 
320µl at 0.12mM. The results of this purification are shown in Figure 4.1.  
 
HSQC experiments are often used to screen proteins, for structure determination potential 
by NMR, and as such this semi-purified VH#576 protein sample, was used immediately for 
this purpose. The spectrum of VH#576 (Figure 4.2) looked of sufficient quality to support a 
structure determination by NMR, with good chemical shift dispersion of a number of 
signals. The protein remained stable for approximately 48 hours and therefore, the purpose 
of subsequent experiments was to optimise the stability of the protein sample to increase the 
time period available for NMR data acquisition. 
 
Natural antigen binding antibodies, lacking light chains, have been found in Camels. As 
such a series of papers, relating to antibody fragment stability, suggest mutating residues in 
the framework region of the VH domain, near CDR2 (former VH/VL interface) to the 
corresponding residue present in Camelid VH domains (G44E, L45R, W47I) (Barthelemy et 
al., 2008, Davies and Riechmann, 1994). However, when such mutations were introduced in 
the VH framework of the anti-RAS VH, antigen binding activity was destroyed in vivo as 
revealed by the results of a luciferase reporter assay (Tanaka et al., 2003). VH#576 and 
VH#6 (anti-RAS VH) are based on the same intracellular antibody capture consensus 
scaffold and this suggests that modifications may not be applicable to improving the 
stability of VH#576.  
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Figure 4.1: Purification of VH#576 via N-terminal His tag 
15% SDS-PAGE stained with Coomassie brilliant blue. Samples were taken at each stage of 
the purification and analysed as shown above. The purification yield was 1.4mg per liter 
culture. The eluate was concentrated to 320µl at 0.12mM. 
 
 
Figure 4.2: 1H-15N HSQC spectrum for antibody single domain VH#576  
1H-15N HSQC spectrum for VH#576 protein suspended in 20mM Tris-HCl, pH 8, 150mM 
NaCl. A HSQC spectrum provides a map of the protein backbone with approximately one 
cross peak for each amino acid (each H-N amide pair), except for proline. Peaks are well 
dispersed representing a well folded protein. The number of peaks should roughly equal the 
number of residues in the protein, in this case 147 residues, of which approximately 120 are 
seen on the spectrum. Peaks for the remaining residues may not have been detected due to 
the high pH resulting in amide exchange with water molecules. 
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4.3.2 VH#576 size exclusion chromatography 
The initial 1H-15N HSQC spectrum recorded for His-VH#576 was encouraging and in light 
of this, modifications were made to the expression conditions and purification protocol. This 
was to improve both the solubility and stability of VH#576. 
 
His tags have been found to cause aggregation (personal communication from T. Tanaka) 
and therefore, to improve the stability of VH#576 in solution the His tag was removed via a 
Tev protease digest. In view of the large number of contaminant proteins, the Tev digest 
was followed by a size exclusion chromatography step. The results of this purification are 
shown in Figure 4.3. VH#576 fractions from the appropriate size exclusion peak were 
analysed by SDS-PAGE and were estimated to be around 90% pure. The final yield of 
0.7mg per liter prep was adequate for the purpose of NMR. The VH#576 purification 
strategy was optimal at this point nevertheless, to further improve the long-term stability of 
the protein, a solubility trial was completed as will be described in the next section.  
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Figure 4.3: Purification of VH#576 via Ni-NTA affinity and size exclusion chromatography 
VH#576 protein was expressed in 2L M9 minimal media with N15 labeled ammonium 
chloride. Samples were taken at each stage of the purification and analysed as shown above. 
A: 15% SDS-PAGE stained with Coomassie brilliant blue.  
B: VH#576 size exclusion UV280nm chromatogram. 
Purification yield was 1.4mg from 2L. The appropriate size exclusion fractions were pooled 
and concentrated to 320µl at 0.3mM for NMR data acquisition.  
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4.3.3 VH#576 stability trials 
As mentioned previously, VH#576 precipitated over the course of two days in the NMR 
tube at ambient temperature. In order to identify a sample buffer which improves the long-
term stability of the protein sample, a microdrop screening experiment was set up to 
examine different concentrations, pH, buffer type and stabilisers (Lepre and Moore, 1998). 
The most stable condition was identified as 100mM NaCl, 100mM HEPES, pH 7. CHAPS 
was also shown to improve the long term stability of VH#576. To establish the effectiveness 
of 100mM NaCl, 100mM HEPES, pH 7 as a sample buffer a HSQC spectrum was acquired 
for 15N labeled VH#576. Once again the protein precipitated out of solution over a period of 
48 hours, despite the positive result during the screen. The screen did however highlight the 
value of CHAPS in order to stabilise VH#576 and therefore, it was decided to revert back to 
the original buffer of 20mM Tris-HCl pH 8, 150mM NaCl, 1mM DTT, but with the addition 
of 2mM CHAPS; this dramatically improved the stability of the protein during NMR data 
acquisition thus increasing the time frame for data collection.  
4.3.4 Effect of pH on VH#576 NMR experiments 
Over the course of the experiments carried out to increase stability of the VH#576 protein 
the optimal purification strategy identified was: VH#576 purified by Ni-NTA affinity 
chromatography followed by removal of the His tag and further purification by size 
exclusion chromatography. The most appropriate buffer identified was 20mM Tris-HCl, pH 
8, 150mM NaCl, 1mM DTT with the addition of detergent, 2mM CHAPS. The maximum 
protein concentration obtained was 0.3mM. NMR experiments were carried out at a 
temperature of 10°C again to maintain the long-term stability of the protein in solution; this 
gave a window of approximately one week for data acquisition. An example of a HSQC run 
under these conditions is shown in Figure 4.4.  
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Figure 4.4: 1H-15N HSQC spectrum for antibody single domain VH#576  
1H-15N HSQC spectrum recorded overnight. VH#576 protein was suspended in 20mM      
Tris-HCl pH 8, 150mM NaCl, 1mM DTT, 2mM CHAPS. The HSQC spectrum was 
recorded at 10°C. 123 residues should be present of which approximately 80 can be seen 
and this is potentially due to the high pH of the sample buffer. 
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NMR analysis was carried out at 10°C as the lower temperature also has a strong, positive 
influence on protein stability. The HSQC recorded had 80 of the 123 residues expected 
presumably due to the high pH of the protein sample buffer. The protein was most stable at 
pH 8 however at such a high pH, labile amide protons exposed to the solvent are likely to 
exchange rapidly with the solvent protons reducing the sensitivity of the experiment (Vu et 
al., 2009).  
 
An experiment was carried out to ascertain if the pH of the VH#576 sample buffer could be 
reduced while still maintaining the protein stability. Two samples were prepared, one at   
pH 7 and one at pH 8 and HSQC spectra were recorded for both samples as displayed in 
Figure 4.5. Approximately fifteen more peaks were observed at pH 7 due to the decreased 
amide exchange with the solvent protons. For the purpose of residue assignment, NOESY-
HSQC and TOCSY-HSQC three dimensional spectra were also collected using the same 
sample at pH 7, which remained stable.  
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Figure 4.5: 1H-15N HSQC spectra comparison for VH#576 at pH 7 and pH 8 
The blue spectrum represents the protein at pH 7 and the red spectrum at pH 8. The 
exchange rates of backbone amide protons with water are minimal at pH 3 to 4 and increase 
linearly with the concentration of the hydroxy ions. Signal loss upon pre-saturation becomes 
significant at a pH above 5 to 6 and increases rapidly with the pH. However, usually 
antibody domains are only stable at above neutral pH therefore, a pH was chosen to be the 
minimum value at which the antibody sample remains stable during the length of the NMR 
procedure. 123 residues should be present of which approximately 95 can be seen at pH 7 
and approximately 80 at pH 8. 
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In order to produce a 15N/13C-labeled VH#576 sample for further NMR experiments, C41 E. 
coli cells were grown up in double labeled (15N/13C) minimal media and purified as 
previously described. The pH of the final sample buffer was pH 7. To check the quality of 
the NMR sample prepared, a 1H-13C HSQC spectrum was recorded overnight (Figure 4.6). 
For 1H-13C HSQC spectrum, each peak represents a proton linked to a carbon. Unlike 1H-
15N HSQC, 1H-13C HSQC are not affected by amide exchange, therefore most peaks should 
be seen for each residue.  
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Figure 4.6: 1H-13C HSQC spectrum for antibody single domain VH#576  
1H-13C HSQC spectrum recorded overnight at 10°C. This spectrum shows the proton to 
carbon bonds therefore each peak represents part of an amino acid side chain. VH#576 
protein was suspended in 20mM Tris-HCl pH 7, 150mM NaCl, 1mM DTT, 2mM CHAPS. 
The section of the spectrum shaded in grey shows the methyl fingerprint region of 
methionine, alanine, threonine, valine, isoleucine and leucine (left to right). All 41 amino 
acids (with a methyl group in their side chain) out of the 41 present in the VH#576 
sequence, are represented by peaks in the section. This demonstrates the well folded nature 
of VH#576, despite the reduced number of cross peaks that are visible in the 1H-15N HSQC. 
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70% of the expected number of peaks, for VH#576, were observed in the 1H-13C HSQC 
spectrum recorded (Figure 4.6). This result was very encouraging particularly given that the 
protein stability has also been significantly improved. Identification of optimal protein 
sample conditions enabled collection of three dimensional spectra HNCA, HN(CO)CA, 
NOESY-HSQC and TOCSY-HSQC. However the signal was too weak for recording less 
sensitive spectra such as HN(CA)CB, HN(COCA)CB and HN(CA)CO. Furthermore, the 
TOCSY-HSQC only showed cross peaks to the Hα but not further into the side chain. As 
the amino acid type identification for the cross peaks is very reliant on Cβ chemical shift 
information, a sequential assignment was impossible in the absence of spectra correlating 
the Cβ shift with the amide chemical shift.  
 
The low signal strength observed can be attributed to the low concentration of VH#576 
(0.2mM to 0.3mM) purified and unfavourable NMR conditions (low temperature of 10°C 
and addition of CHAPS detergent). In response to this problem, a strategy was developed to 
purify VH#576/LMO2 complex, with only VH#576 isotopically labeled, on the basis that 
this complex was extremely stable when stored for crystallography studies. The aim was to 
increase the concentration and long-term stability of the purified protein sample and thus 
increase NMR signal strength. 
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4.4 VH#576/LMO2 protein purification and NMR data acquisition 
It was reasoned that purification of VH#576 as a complex with LMO2 may well stabilise 
VH#576 and allow subsequent concentration of the complex for detailed NMR analysis 
with the purpose of structural determination. The average peak number detected for 
VH#576 was 86 out of a possible 123. This leaves 37 residues missing which roughly 
equates to the number of residues that make up the CDR regions (33). A well documented 
(Vranken et al., 2002) problem when analysing antibody domains by NMR, is the flexibility 
of the hypervariable loops which sometimes means the residues can not be detected. This 
flexibility results in a conformational exchange process on a microsecond-millisecond time 
scale and fast hydrogen exchange. VH#576 bound to LMO2 has a specific conformation 
and thus reduced flexibility. Subsequent NMR analysis was likely to result in an increase in 
both sensitivity and the number of residues observed. It would be difficult to assign the 
complex fully due to its large size (32 KDa) therefore, once it was demonstrated that the 
complex was stable during NMR data acquisition, a protocol was developed to purify 
isotopically labeled VH#576 bound to unlabeled LMO2. Furthermore, any chemical shift 
changes upon binding could also by detected by overlaying HSQC spectra of complexed 
VH#576 with uncomplexed VH#576.  
4.4.1 15N labeled VH#576/LMO2ΔN7 
Prior to the development of a strategy to purify labeled VH#576 bound to unlabeled LMO2, 
the stability of the complex was tested using fully labeled (15N) VH#576/LMO2ΔN7 protein 
complex (Figure 4.7). The final sample buffer was 20mM Tris-HCl pH 7, 50mM NaCl, 
1mM DTT, with a protein concentration of 0.2mM. 
 
The HSQC spectra recorded for the VH#576/LMO2ΔN7 complex (Figure 4.7) was weak 
with a lot of peaks in the complex being too weak to detect. This was due, in part, to the low 
sample concentration (0.2mM). Furthermore, the relatively large size of the complex means 
NMR peak height was decreased due to a decrease in the rate of molecular diffusion. 
Therefore, a higher protein concentration and/or a deuterated protein sample would be 
required to study this complex further. However, in this case, the aim was to collect NMR 
data on the VH#576 half of the complex only and therefore, based on the long term stability 
of this complex (more than two weeks), a strategy was developed to isotopically label 
VH#576 and purify this protein with unlabeled LMO2.   
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Figure 4.7: 1H-15N HSQC spectra comparison for VH#576 and VH#576/LMO2ΔN7 
complex 
The blue spectra represents uncomplexed VH#576 and the red spectra VH#576/LMO2ΔN7. 
The spectra for VH#576/LMO2ΔN7 is weak compared to that of VH#576 due to the low 
concentration of the protein. However, importantly, the VH#576/LMO2ΔN7 complex 
remained stable in the NMR tube during experiments and for more than two weeks 
afterwards. 
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4.4.2 Co lysis of VH#576 and LMO2 
LMO2 is a protein of low solubility and stability in solution and as such cannot be purified 
alone. As a result of this, it was necessary to develop a strategy to effectively purify 
unlabeled LMO2 with uniformly labeled VH#576. In order to investigate this 
experimentally, two LMO2 expression vectors were produced; one expressing LMO2ΔN7 
alone and one expressing LMO2 as a fusion protein with NusA (NusA-LMO2). A Tev 
protease recognition site was engineered between NusA and LMO2 making cleavage of 
NusA possible. LMO2 (NusA tagged or untagged) and VH#576 were expressed from 
separate cultures, co-lysed and purified as a complex. The two purified protein complexes 
were analysed by SDS-PAGE (Figure 4.8). When LMO2 was expressed as a fusion protein 
(NusA-LMO2) and purified with VH#576 the yield was 6mg per liter (therefore 
approximately 2mg per liter of VH#576/LMO2 complex without NusA). In comparison the 
yield obtained when LMO2ΔN7 was expressed alone and purified with VH#576 was 
0.12mg per liter. The NusA-LMO2 co-lysed with His-VH#576 was taken forward as the 
best option due to its relatively high level of expression and solubility upon purification.  
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Figure 4.8: Co-lysis and Ni-NTA affinity chromatography purification of VH#576 and 
LMO2  
15% SDS-PAGE stained with Coomassie brilliant blue  
A: LMO2ΔN7 or NusA-LMO2 were co-lysed with VH#576 by cell disruption. Purification 
of the complex was via the N-terminal His tag of VH#576 and Ni-NTA purification. The 
eluate (soluble fraction) was analysed by SDS-PAGE, and shows both complexes were 
purified successfully. The cell pellet, from each purification, was re-suspended and analysed 
(insoluble fraction); a large band of insoluble LMO2ΔN7 can be seen. 
B: The eluate from Ni-NTA chromatography was digested with Tev protease in order to 
cleave the His tag from VH#576 and NusA from NusA-LMO2. Fractions were analysed 
post Tev digest and post Ni-NTA affinity chromatography two (to remove Tev protease and 
His tag). The yield was highest for VH#576/LMO2 protein complex purified from the 
NusA-LMO2 fusion protein. 
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4.4.3 Deuterated VH#576 
Large proteins (more than 30 KDa) have increased transverse relaxation rate constants that 
decrease the sensitivity of NMR experiments as less magnetisation persists, through pulse 
sequence delays, until detection. These resonances have larger line widths. Transverse 
relaxation rate constants can be reduced in larger proteins by eliminating unfavourable 
relaxation pathways such as relaxation of spins by the 1H-13C dipolar interaction or the 
relaxation of 1HN spins resulting from dipolar interactions with proximal aliphatic 1H spins. 
An increase in both sensitivity and resolution can be achieved by reducing specific 
interaction pathways, thereby reducing the relaxation properties for both 13C and 15N spins 
(Venters et al., 1995). This is done by replacing a percentage (more than 50%) of carbon-
bound hydrogen atoms in a protein with deuterium. 1HN spins are reintroduced through 
amide proton solvent exchange by dissolving the protein in H2O buffer. Reintroduction of 
1HN spins is slow for amide moieties that are highly protected from solvent exchange and a 
reduction in sensitivity for these residues may be observed. As the overall complex size will 
be 32.4 KDa, ideally, VH#576 needed to be perdeuterated (over 50%) and labeled with 15N 
and 13C. Non labile hydrogens in proteins are deuterated using D2O instead of H2O in the 
protein expression medium.  
 
A protocol was developed to purify 50% deuterated (final) VH#576, labeled with 15N and 
13C. A series of experiments were carried out using deuterated minimal media (no 15N / 13C) 
to check the viability of purification prior to the preparation of triple labeled VH#576 
protein sample complexed with unlabeled LMO2.  
 
Initially, VH#576 was expressed in 100mls of 75% D2O minimal media and purified with 
NusA-LMO2 (Figure 4.9). C41 E. coli strain transformed with pRK-His-Tev-VH#576 was 
adapted for growth on deuterated medium by repeat sub streaking of colonies. The proteins 
were expressed and purified as described in chapter two, section 2.6.5. The yield was too 
low to give an informative chromatogram from the size exclusion chromatography step 
however this problem was solved by the development of an alternative cell culture method. 
The method was developed based on previous research (Sivashanmugam et al., 2009) (Cai 
et al., 1998, Marley et al., 2001) which described a protocol designed to generate cell mass 
in unlabeled rich media followed by exchange into labeled media at high cell densities.  
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Figure 4.9: Purification of 50% deuterated VH#576 bound to LMO2 
15% SDS-PAGE stained with Coomassie brilliant blue. 
A: VH#576 was expressed in 75% D2O minimal media while NusA-LMO2 was expressed 
in LB. The complex was purified by Ni-NTA affinity chromatography and the eluate 
analysed. The yield from a 100ml culture was 0.3mg. 
B: Both the His tag and NusA tag were removed from VH#576 and LMO2 respectively, 
using Tev protease. The protein complex was then passed through a further Ni-NTA affinity 
chromatography column to separate both the His tag and Tev protease from the 
VH#576/LMO2 complex. The yield from a 100ml culture was 0.15mg (total protein). 
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4.4.4 Increasing the yield of deuterated VH#576  
To improve the yield of VH/LMO2 purification further two protocols, based on increasing 
cell mass before induction of recombinant protein expression, were investigated. As the 
protocols varied in the two papers indicated, they were both tested and the final yields 
compared (see chapter two, section 2.6.6). Protocol one (Cai et al., 1998, Marley et al., 
2001) entailed growing up E. coli cells in LB media until an OD600nm of 0.7, the cells were 
then re-suspended in four times less labeled minimal media. Protocol two (Sivashanmugam 
et al., 2009) was similar however cells were grown up in LB and then re-suspended in the 
same volume of minimal media. Uniform isotope labeling is essential for NMR, thus it is 
vital the expression vector is not translated before media exchange. Western blot analysis, of 
a sample taken just prior to growth media exchange, confirmed there was no ‘leaky’ 
expression of the vector (Figure 4.10). Ni-NTA purification yields, per 50ml culture, were 
0.2mg and 0.3mg for protocols one and two respectively. These results were very promising 
and therefore, based on a higher yield, protocol two (Sivashanmugam et al., 2009) was the 
chosen media exchange protocol, for the next experiment. 
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Figure 4.10: Revised strategy for expression of 50% deuterated VH#576  
15% SDS-PAGE acrylamide gel  
A: Anti-His Western blot analysis of samples taken just prior to media exchange. As a 
positive control, a relative amount of the Ni-NTA purified His-VH#576 sample was also 
analysed. The Western blot shows no protein induction prior to media exchange. 
B: Analysis of Ni-NTA chromatography eluates by SDS-PAGE. Protocol one gave a His-
VH#576 yield of 0.2mg (4mg per liter) and protocol two gave a yield of 0.3mg (6mg per 
liter).
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4.4.5 Scale up of the purification of deuterated VH#576 with LMO2 
The previous trial prep was not analysed by size exclusion chromatography. To achieve this, 
a scale up of the culture volumes was required; 500mls of 75% D2O minimal media (His-
VH#576) and 500mls LB (NusA-LMO2) were used for bacterial growth and protein 
expression. This was to check the viability of a larger prep for the production of triple 
labeled VH#576 bound to LMO2. The total protein yield obtained from the first Ni-NTA 
chromatography step was 12mg. Protein was then subjected to a Tev digest during dialysis 
and the complex concentrated for size exclusion chromatography (superdex 200 10/300 GL 
column). Figure 4.11 shows that fractions from the appropriate peak of the size exclusion 
chromatogram contain both the VH#576/LMO2 complex and a NusA contaminant. This is 
due to the resolution capacity of the column. Consequently, a further chromatography step 
was investigated, ion exchange. A pH of 6 was chosen so that NusA would have a net 
negative charge and should bind the anion exchange resin whereas the majority of 
VH#576/LMO2 should remain unbound. Two anion exchange resins were tested; DEAE 
sepharose and Q sepharose. The relevant size exclusion fractions were pooled and diluted 
with sodium phosphate buffer, pH 6. Anion exchange flowthrough and eluate samples were 
concentrated and analysed by SDS-PAGE (Figure 4.11). Both resins retained NusA, 
separating it from the VH#576/LMO2 complex however, DEAE sepharose retained less of 
the VH#576/LMO2 complex so was utilised for the final purification experiment.  
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Figure 4.11: Purification of 50% deuterated VH#576 bound to LMO2 
A: 15% SDS-PAGE stained with Coomassie brilliant blue. 50% deuterated VH#576 co-
lysed with unlabeled NusA-LMO2 and purified by Ni-NTA affinity chromatography. 
B: Purification of the VH/LMO2 complex by size exclusion and ion exchange. The size 
exclusion fractions analysed are indicated in C. Size exclusion chromatography was unable 
to resolve NusA and VH/LMO2 proteins and therefore two anion exchange resins were 
tested for their ability to retain NusA at pH 6 with DEAE being most suitable.   
C: A280nm chromatogram for the size exclusion chromatography step. 
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4.4.6 VH#576 stability trial 
As discussed previously the optimisation of NMR sample conditions is essential, as the 
protein must remain stable in solution for the duration of the NMR experimental procedure, 
which can be more than one month. From previous work with the complex it was known to 
be stable at pH 7 and therefore a stability trial was designed to test the effect of NaCl 
concentration and temperature on stability. Analysis by SDS-PAGE (Figure 4.12) shows 
degradation of LMO2 in all buffers at room temperature but not at 16°C. The most effective 
NMR sample conditions were identified as: 20mM Tris-HCl pH 7, 50mM NaCl, 1mM DTT 
at a temperature of less than 16°C. 10°C was chosen so that the spectra could be more 
directly compared to those of uncomplexed VH#576. 
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Figure 4.12: NMR protein sample stability trial 
Samples of 50% deuterated VH#576 purified with unlabeled LMO2 were exchanged into 
20mM Tris-HCl, 1mM DTT buffer with various NaCl concentrations. Protein samples were 
stored for one week at either 16ºC or room temperature. Samples were then analysed by 
15% SDS-PAGE stained with Coomassie brilliant blue. The red arrow indicates slight 
degradation of LMO2 when stored at room temperature; this did not occur at 16ºC. The gel 
also shows the complex remains stable in 20mM Tris-HCl, pH 7, 50mM NaCl, 1mM DTT. 
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4.4.7 Final VH#576/LMO2 sample for analysis 
50% deuterated VH#576 labeled with both 13C and 15N was purified successfully with 
LMO2 using the strategy developed (Figure 4.13). The sample was concentrated to 320µl at 
0.4mM. 900 MHz NMR Spectrometer (Oxford Instruments magnet) with 4-channel Varian 
INOVA console (Birmingham Biomolecular NMR Facility) was used to record a 1H-15N 
HSQC spectrum for the protein in Tris-HCl buffer, pH 7.0, 50mM NaCl, 1mM DTT, at a 
temperature of 10°C. Despite thorough stability and temperature trials to define optimum 
conditions for the stability of the protein complex, 15N/13C/2H labeled VH#576 bound to 
unlabeled LMO2 precipitated out of solution, consequently no spectra were collected. The 
protein sample was re-purified by size exclusion (superdex 200 10/300 GL column) and 
concentrated to 0.1mM. The size exclusion step showed evidence of aggregation as a large 
percentage of the complex eluted in the void volume. This aggregation may have occurred 
due to the higher concentration of the initial protein sample (13mg/ml) or it may have been 
due to the slight NusA protein contamination. Despite this loss of protein, a 1H-15N HSQC 
spectrum was successfully recorded for the re-purified sample, at 10°C, using 750MHz 
Varian Unity Inova spectrometer and this was compared to a HSQC recorded for 
uncomplexed VH#576 at 10°C (Figure 4.14).  
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Figure 4.13: VH#576 labeled with 15N/13C/2H bound to unlabeled LMO2 
50% deuterated VH#576 was purified with unlabeled LMO2 by a process of Ni-NTA 
affinity, size exclusion and ion exchange chromatography. The purified protein complex 
was exchanged into 20mM Tris-HCl pH 7, 50mM NaCl, 1mM DTT and analysed by 15% 
SDS-PAGE stained with Coomassie brilliant blue as show. The DEAE sepharose anion 
exchange step successfully removed some of the NusA protein contaminant as shown in the 
eluate (final lane of the gel). However, the final sample still contains a slight NusA protein 
contamination therefore, can be estimated to be approximately 85% pure.  
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Figure 4.14: 1H-15N HSQC spectra comparison for VH#576 in uncomplexed and complexed 
states 
Data acquisition was carried out at 10ºC. The black spectra represents complexed VH#576 
and the red spectra uncomplexed VH#576. Due to the low concentration of the re-purified 
VH#576/LMO2 sample (0.05mM), the spectra for complexed VH#576 is weak (black) 
therefore, an accurate comparison with uncomplexed VH#576 cannot be made. However, 
chemical shift changes can be seen for approximately ten residues. 
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4.4.8 Comparison of free and bound VH#576 at 20°C 
As a result of aggregation of the previous purification, 15N labeled VH#576 was purified 
with LMO2ΔN7ΔC11 as it may be that the flexible ends of LMO2 were responsible for the 
aggregation of the complex. C41 E. coli host was transformed with pRK-LMO2ΔN7ΔC11 
and grown up in LB media as described previously (section 5.4.1). VH#576 was expressed 
in 15N labeled minimal media without deuterium; therefore no media exchange process was 
required. The purified complex was concentrated to 0.2mM in a buffer of 20mM Tris-HCl 
pH 7, 50mM NaCl, 1mM DTT. The HSQC recorded for the complex was of an improved 
quality compared to the previous spectrum (Figure 4.15). Moreover, the complex did not 
aggregate and was stable for more than one week. Thus, the strategy developed represents a 
mechanism to study VH#576 in complex with LMO2. Further data collection could 
potentially result in a solution structure for VH#576.  
 
Chemical shift mapping is a highly sensitive tool for identification of protein binding sites 
and as such an overlay of uncomplexed and complexed VH#576 HSQC 1H-15N correlation 
spectra was produced using nmrPipe (Figure 4.15). Perturbation of chemical shifts can be 
seen for a number of residues as a result of complex formation. This would suggest that the 
residues, missing from the free VH#576 HSQC spectrum, are not entirely from the CDR 
regions (LMO2 interacting sites). However, resonances in the spectrum may be shifted 
because the associated nuclei are proximal to the interaction interface or because 
conformational changes upon binding have resulted in altered local magnetic environments, 
even for nuclear spins distant from the interaction site (local structural effects) (Cavanagh et 
al., 2007). Spectral assignment will be necessary to identify the residues associated with 
each chemical shift change. Until then it can only be predicted that these chemical shifts are 
associated with the residues of the three CDR regions of VH#576. 
Structural analysis of an anti-LMO2 antibody single domain by NMR 
 
 156 
 
Figure 4.15: 1H-15N HSQC spectra comparison for VH#576 in uncomplexed and complexed 
states 
Data acquisition was carried out using 15N labeled VH#576 bound to unlabeled 
LMO2ΔN7ΔC11, at 20ºC. The black spectra represents complexed VH#576 and the red 
spectra uncomplexed VH#576. Chemical shift changes can be seen for many residues 
however some are larger than others. Larger chemical shift changes are likely to represent 
residues which interact with LMO2. 
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4.5 Discussion 
In this chapter VH#576 was taken forward for structural studies due to an initial well 
dispersed HSQC spectrum recorded for the antibody single domain reflecting a well folded 
protein. The long CDR three loop is thought to aid the solubility of VH#576 by folding over 
the side chain of hydrophobic amino acids at the former VH/VL interface, however this may 
be transient due to the loops conformational mobility (Bond et al., 2003). Strategies to 
stabilise VH#576 in solution were developed effectively and enabled NMR data acquisition. 
 
As with VH-P8, CHAPS was used to increase the stability of VH#576 in solution making it 
possible to collect three dimensional spectra HNCA, HN(CO)CA, NOESY-HSQC and 
TOCSY-HSQC. These data enabled sequential linking of amino acids. However, signal 
strength was too low for less sensitive three dimensional experiments, making assignment 
impossible. Low signal strength was due to the low concentration of the VH#576 protein 
sample (0.2mM to 0.3mM) and unfavourable NMR conditions of low temperature (10°C) 
and addition of a detergent (CHAPS). Furthermore, spin systems were often incomplete as a 
result of the flexible CDR regions undergoing a chemical exchange process on a slow 
microsecond-to-millisecond time scale. 
 
Evidence was collected to support the theory that VH#576 in complex with LMO2 would be 
more stable in solution and could be purified to a higher concentration without the need for 
the addition of CHAPS to the sample buffer. Structure determination of large proteins 
(greater than 30 KDa) by NMR is complex and therefore a protocol was developed to 
produce labeled VH#576 bound to unlabeled LMO2 thus reducing the complexity of the 
task by analysis of bound VH#576 only. The strategies described in this chapter represent 
methods that not only transform LMO2 from an insoluble protein but also allow separate 
analysis of the two halves of the VH#576/LMO2 complex via NMR. A HSQC spectrum 
was recorded for complexed VH#576 but the sample was not at a high enough concentration 
for further data collection. The strategy has scope for further improvements with the 
potential of data collection for structural determination of complexed VH#576. 
 
Comparison of VH#576 HSQC two dimensional correlation spectra, in the complexed (with 
LMO2) and uncomplexed state, reveals chemical shift changes which may be associated to 
the residues interacting with LMO2, in the CDR regions, or may be associated to residues 
proximal to the interaction interface. Alternatively they may be attributed to conformational 
changes upon binding. Residue assignment upon further data collection would enable these 
residues to be mapped.  
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The purpose of this work was to gain enough structural information on VH#576 to produce 
a three dimensional pharmacophore model for screening small molecule libraries. However, 
the X-ray crystallography approach carried out in parallel to this research proved successful 
leading to a crystal structure of VH#576/LMO2ΔN7ΔC11 (as will be described in chapter 
five) therefore, it is debatable whether further collection of NMR data for structure 
determination is still a requirement in order to fulfill the overall aim of developing an anti-
LMO2 small molecule inhibitor. From a structural point of view it would be interesting to 
compare NMR solution structures of complexed and uncomplexed VH#576 with further 
comparisons between NMR solution structures and the crystal structure. Comparison of the 
NMR structure and crystal structure would enable the detection of any crystallisation 
artifacts due to crystal packing as an NMR solution structure represents a more 
physiological environment. Crystal packing can reduce local protein dynamics, particularly 
in solvent exposed loop regions, or distort relative domain orientations and protein-protein 
interactions (Eyal et al., 2005). This is particularly significant in this case as VH#576 has 
many exposed loops and the rigid nature of the crystal structure may not portray accurately 
the range of possible orientations for these flexible loops. Furthermore, the crystal structure 
demonstrates interactions between LMO2 and the former VH/VL interface of VH#576 and 
this would be confirmed by the observation of chemical shift changes in this region.  
 
In terms of feasibility, it may well be possible to solve the NMR solution structure of both 
complexed and uncomplexed VH#576 with the aid of high magnetic field strength 
(900MHz) and cryogenically cooled probes to improve experiment sensitivity. 
 
4.6 Conclusion 
The addition of CHAPS detergent has enabled the NMR analysis of an anti-LMO2 antibody 
single domain. HNCA, HN(CO)CA three dimensional spectra have been collected for free 
VH#576 and allow sequential linking of amino acid residues however residues could not be 
identified due to an extremely weak HNCACB spectra. 
 
VH#576 chemical shift changes were observed upon binding LMO2 but until assignment of 
uncomplexed VH#576 has been completed it is not known whether they are associated with 
residues of the CDR regions. Future work would include recording HNCACB, 
CBCA(CO)NH for uncomplexed VH#576 to enable complete assignment, identify residues 
missing from the spectra and residues that undergo chemical shift changes upon binding 
LMO2.  
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VH#576 structure determination would involve collecting details of the local backbone 
geometry by measuring nuclear Overhauser effects (NOEs). Comparison of a complexed 
VH#576 NMR solution structure and complexed VH#576 crystal structure may show slight 
differences due to the influence of crystal packing. 
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5 Structural determination of LMO2 bound to              
anti-LMO2 antibody single domain and 
characterisation of critical interaction residues 
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5.1 Introduction 
It has been shown that LMO2 has a vital role in T-cell acute lymphoblastic leukaemia (T-
ALL) and has been implicated in diffuse large B-cell lymphoma, where it has prognostic 
significance (Natkunam et al., 2007). Current, the only available treatment for T-ALL 
involves intensive chemotherapy, which has significant short and long term side effects 
(Aifantis et al., 2008). Therefore, LMO2 is an important target for development of novel 
therapies, in particular new drugs to modulate the interaction of LMO2 with its natural 
partners. The protein complex in which LMO2 is involved is an attractive target for therapy 
development. 
 
Preliminary work, in response to this problem included the identification of VH#576, an 
antibody single domain that binds to LMO2 with high affinity and specificity. VH#576 has 
the capacity to modulate the function of LMO2 inside the cell (T. Tanaka, personal 
communication). Using VH#576, a macrodrug, as a therapeutic agent presents a number of 
serious problems among them delivery, degradation, and immunogenicity. The long-term 
goal therefore, is to evolve VH#576 into a small, drug-like, chemical compound. 
Computational tools can be used to complement and guide the drug discovery process. 
Structure-based drug design requires the three-dimensional (3D) structure of the protein of 
interest and as such, the 3D structure of LMO2 bound to VH#576 was solved as described 
in this chapter. The information obtained from the crystal structure will be used to guide the 
design of small molecules able to mimic VH#576, i.e. able to bind to LMO2, preventing the 
interaction with its natural partners.  
 
Historically, the targeting of protein-protein interactions has proved difficult because the 
surfaces of the proteins involved are often large and flat, with no potential binding pockets 
or grooves. In addition, protein-protein interactions typically have a large interface of 750-
1500Å2 (Petros et al., 2006). Therefore, it may not be possible to inhibit the whole 
interaction with a single small molecule. Nevertheless, there have been a number of 
successes in the discovery of small molecules able to modulate protein-protein interactions 
(Wells and McClendon, 2007); the majority of these were due to the realisation that most of 
the binding energy can be ascribed to a set of complementary residues, a hot spot, 
surrounded by weaker interactions. Mutation of residues at the interface of a protein-protein 
interaction, to alanine or glycine, can identify these critical regions of interaction. Upon 
mutation of a critical residue, binding is ablated or greatly impaired. Moreover, 
identification of a hotspot significantly aids the design of small molecules that alter protein-
protein interactions (Zhang and Palzkill, 2004) as the target area is significantly reduced. 
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Analogous analysis of an anti-RAS VH provided biochemical data that matched the precise 
interaction of residues determined by X-ray crystal structure (Tanaka et al., 2007). 
 
An example of the successful development of a small molecule to inhibit a protein-protein 
interaction is the identification of anti HDM2 (human protein double minute 2) small 
molecule inhibitor, termed Nutlin-3. HDM2 interacts with and blocks the activity of P53, an 
important transcription factor and tumour suppressor. P53 has many functions to maintain 
genetic stability such as cell cycle arrest, apoptosis and senescence (Gaidarenko and Xu, 
2009). Therefore blocking the interaction between HDM2 and P53 could lead to activation 
of P53 and thus inhibition of tumour growth. The crystal structure of MDM2 (mouse 
homologue) bound to a P53 transactivation domain (an α helical region of fifteen amino 
acids), shows the interface is mainly hydrophobic. Mutational analysis of the P53 (Picksley 
et al., 1994) transactivation domain by alanine scanning identified a hotspot of three amino 
acids (Phe19, Trp23 and Leu26) that were critical for interaction with MDM2. A synthetic 
chemical library screen identified an MDM2 inhibitor, Nutlin-3, which binds in the same 
area as the hotspot residues of P53. The high binding compound displaces P53 from the 
MDM2 protein with a half maximal inhibitory concentration of 90nM, as determined by 
Surface plasmon resonance. The binding mode of Nutlin-3 has been illustrated by a high 
resolution X-ray structure (Vassilev et al., 2004), which shows the P53 hotspot residue 
Phe19 is mimicked by the isopropyloxy phenyl moiety of Nutlin-3.  
 
For the purpose of structure determination, NMR and X-ray crystallography were 
investigated in parallel. A third approach, which was considered in the interim, when no 
crystallography data was available, was homology modeling. Proteins with similar amino 
acid sequences have similar conformations therefore proteins of known structure can be 
used as a basis for building structural models. Models of LMO2 and VH#576 were 
produced in this way and docked in silico. Mutagenesis of residues in the CDR regions of 
VH#576 enabled the identification of crucial VH#576 residues for the interaction with 
LMO2 and this information was utilised by the docking program (HADDOCK) to produce a 
structural model of the complex (Dominguez et al., 2003). Finally, once 
VH#576/LMO2ΔN7ΔC11 crystallisation was successful; diffraction data was collected and 
processed. The structure has been solved to a medium resolution of 3.3Å. The structure 
reveals hydrophobic interactions between LMO2 and the former VH/VL interface and 
demonstrates the plasticity of LMO2. Information derived from the 
VH#576/LMO2ΔN7ΔC11 crystal structure will be essential to guide the process of structure 
based drug design.  
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5.2 VH#576 and LMO2 mutagenesis 
5.2.1 Analysis of VH#576 point mutations using a mammalian two-hybrid luciferase 
reporter assay 
The critical, or hotspot, VH#576 residues that mediate the interaction with LMO2 were 
identified using a mutagenesis screen. Residues were mutated to glycine and alanine as they 
are non-polar, aliphatic amino acids with non-reactive side chains of a single hydrogen atom 
and methyl group respectively. The interaction between VH#576-VP16 and                     
GAL4-LMO2ΔN24 (LMO2 residues 25 to 147) was measured through a mammalian two-
hybrid luciferase reporter assay in which VP16 activation domain can interact with GAL4 
DNA binding domain (Figure 5.1). This interaction induces functional transcriptional 
activation from RNA polymerase II basal promoters with upstream GAL4 binding sites and 
thus cis-activation of firefly luciferase reporter genes. The mammalian GAL4 dependent 
reporter plasmid (pG5), contains five GAL4 responsive binding sites in front of the 
luciferase cassette. pRL-CMV plasmid for the expression of Renilla luciferase acts as an 
internal control to which firefly expression can be normalised; this minimises experimental 
variability caused by, for example, differences in cell viability and transfection efficiency. 
The expression of luciferase is quantified sequentially, using a luminometer.  
 
An amino acid sequence alignment of VH#576 with anti-Ras antibody single domain, VH#6 
(see Appendix B, figure 1) was used to aid the choice of residues to mutate. Residues were 
selected based on a combination of differences in the sequence alignment and residues, 
which were shown to be important for the interaction between RAS and anti-RAS (VH#6).  
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Figure 5.1 Mammalian two-hybrid luciferase reporter assay 
Co-transfection of mammalian Chinese hamster ovary (CHO) cells with vectors expressing 
GAL4-LMO2ΔN24 and VP16-VH#576. LMO2 and VH#576 binding results in a close 
interaction of GAL4 and VP16 domains. The GAL4 promoters are then functionally 
activated with associated increases in the luciferase reporter expression. 
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5.2.2 Mammalian two-hybrid method 
Mammalian expression vectors pEF-VP16-VH#576 and pM3-GAL4-LMO2ΔN24 were 
obtained from T. Tanaka (THR laboratory). Selected residues in the CDR regions of 
VH#576 were mutated, from the base vector template, to either glycine or alanine (see 
Appendix C for primer sequence) by point mutation followed by assembly PCR. The PCR 
product was cloned back into pEF-VP16. All expression vectors were sequenced using ‘The 
sequencing service’ (The University of Dundee). The effect of each point mutation was 
analysed using mammalian two-hybrid luciferase reporter assay, each clone was tested in 
duplicate. If the first round mutation resulted in no interaction then the reciprocal 
glycine/alanine mutation was also tested. Five rounds of mutagenesis experiments were 
completed with a positive and negative control for each. The positive control used was 
original VH#576 and the negative control, anti-Ras VH#6. The expression of the mutated 
VH#576-VP16 fusion protein was checked by anti-VP16 Western blot (for full blots see 
Appendix B).  
5.2.3 Effect of VH#576 point mutations on the interaction with LMO2 
Figure 5.2 brings together results of all five rounds of mutagenesis experiments as analysed 
by a mammalian two-hybrid luciferase reporter assay. It is important to note that a given 
point mutation of VH#576 may destroy the interaction with LMO2 in one of three ways. It 
may be that the residue mutated was critical for the interaction. Secondly, the mutation may 
result in a complete change in conformation or unfolding of the VH#576 antibody fragment. 
Thirdly, the mutation may prevent VH#576 expression however, this was checked for by 
Western blot analysis. That said, the residues selected for mutation were all located in the 
CDR loops, which are highly flexible, exposed regions of the protein, therefore it is likely 
that if the mutation suppresses the interaction it has a critical role. 
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Figure 5.2: VH#576 CDR mutagenesis to determine residues critical for the interaction with 
LMO2 
The five colours used for the bars represent five separate experiments each with a positive 
(VH#576 original protein) and negative (VH#6 anti-Ras) control. Each bar represents an 
average of luciferase activity measured for two wells (replicates) and the bar extensions 
indicate standard deviation. If interaction was inhibited by a glycine/alanine mutation in the 
first round then the reciprocal mutation was also analysed. The results suggest the majority 
of the interaction occurs through the CDR3 region with a total of seven residues identified 
as critical for the interaction. One residue in CDR1 was found to be involved in the LMO2 
interaction and two for CDR2. Anti-VP16 Western blot analysis was employed to analyse 
the prey (VH#576-VP16) expression levels and results are shown underneath each bar in the 
chart. All mutated versions of VH#576 were expressed, except for the Y113G mutated 
form. This suggests that Tyr 113 is important structurally for the stability of VH#576. 
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Many of the VH#576 residues found to be critical for the interaction, such as Ser 32, Tyr 50, 
Ser 52, Asn 54, Thr 107, have polar side chains with hydroxyl groups that are able to form 
hydrogen bonds. Therefore, this is a likely mechanism of interaction with LMO2. The 
CDR3 region contains two glutamic acids (Glu 102, Glu 105) and one aspartic acid (Asp 
109). These residues have side chains with a carboxyl group of negative charge, under 
physiological conditions, and thus the potential to form electrostatic interactions with 
positively charged groups. The side chain of leucine (Leu 104, Leu 106) is hydrophobic and 
likely to interact with other non-polar side chains such as tryptophan and phenylalanine. 
Figure 5.3 shows the side chains of each residue of VH#576 found to be critical for the 
LMO2 interaction.   
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A: 
 
B: 
1       10        20        30        40        50 
EVQLLESGGGLVQPGGSLRLSCAASGFSFSHSPMNWVRQAPGKGLEWVSYIS 
 
      60        70        80        90       100 
YNSSSIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGLTESL 
 
   110       120 
ELTADWFDYWGQGTLVTVS 
 
Figure 5.3: VH#576 residues involved in the interaction with LMO2  
A: A schematic representation of the interacting residues of VH#576. Hydroxyl (OH) 
groups are likely to form hydrogen bonds with residues of LMO2 and negative acidic side 
chains are likely to form electrostatic interactions.  
B: VH#576 amino acid sequence (single letter code) with CDR regions highlighted in 
yellow and vital LMO2 interacting residues highlighted in red. Note that the nomenclature 
used for describing the heavy chain domain structure is the IMGT (Lefranc, 2001) 
numbering system. 
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5.2.4 LMO2 interaction region 
The binding site on the surface of LMO2 is also an important factor and for that reason, 
LMO2 mutagenesis data was also collected. This experiment was carried out by Dr. T. 
Tanaka (THR laboratory). Mutations were made to match the sequence of LMO4 or ISL-1 
(both LIM domain proteins), which do not bind VH#576 (see Appendix B, figure 1, for 
further sequence information). Each LIM finger of LMO2 was mutated separately and the 
left and right sides of each LIM finger were also mutated individually. Again a mammalian 
two-hybrid luciferase reporter assay was used to measure the effect, of each mutation, on 
the VH#576 interaction (Figure 5.4). The results of the mutagenesis analysis indicate that 
the VH#576 binding site spans both LIM1 and LIM2 of LMO2 with finger two and three 
being involved in the interaction along with the left side of finger four. However, mutations 
to the right side of finger two had less of an effect on the interaction (Figure 5.4). 
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A: 
 
B: 
 
Data generated by Dr. T. Tanaka (THR laboratory) 
Figure 5.4: Regions of LMO2 involved in the interaction with VH#576  
A: Results of the mammalian two-hybrid luciferase reporter assay to analyse the interaction 
between VH#576 (dark purple bars) with various LIM finger mutants. Each of the LIM 
fingers (LF1I, LF2I, LF3I, LF4I) were mutated and the left and right side of each LIM 
finger were also mutated. According to this data, both LIM1 and LIM2 domains of LMO2 
are involved in binding VH#576, with LIM finger two, three and the left side of finger four 
being the most interactive regions.  
B: Schematic representation of LMO2. Each of the four zinc binding LIM fingers are shown 
and the two LIM domains and indicated. Adapted from (McCormack and Rabbitts, 2004). 
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5.3 VH#576/LMO2ΔN25 in silico structural model  
At the time this in silico model was produced, no crystallography data was available due to 
the difficulties described in chapter three. Therefore, a program called HADDOCK (High 
Ambiguity Driven protein-protein Docking) was used in combination with the mutagenesis 
data to produce an in silico structural model of the VH#576/LMO2ΔN25 complex 
(Dominguez et al., 2003).  
5.3.1 The use of docking software  
The methods used to create the in silico structural model will be described in this section. 
Unbound structural models were built for LMO2 and VH#576 using M4T (Fernandez-
Fuentes et al., 2007). PDB 1J2O (FLIN2: LIM1 and Ldb1_LID domain) and PDB 2DFY 
(FLINC4: LMO4 and Ldb1_LID domain) were used as templates for LMO2 and PDB 2UZI 
(anti-Ras VH#6) as a template for VH#576. The quality of the models was assessed using 
PROSA-II (Sippl, 1993) and PROCHECK (Laskowski et al., 1993). The models were then 
docked and scored using HADDOCK (Dominguez et al., 2003). The mutagenesis 
information was introduced as ambiguous interaction restraints to drive the docking process. 
Ambiguous interaction restraints were calculated from the ambiguous distance between all 
residues shown to be involved in the interaction. The HADDOCK score takes into account 
the intermolecular energy (electrostatic, van der Waals etc.) and as a general rule, the lower 
the score the more likely the two proteins will interact as predicted. This scoring system 
relies on asymmetry at the protein-protein interface due to the distribution of hydrophobic 
and hydrophilic residues and the shape complementarities of the proteins. Figure 5.5 shows 
one of ten of the lowest energy complexes. The in silico structural model was produced by 
Dr. N. Fernandez-Fuentes.  
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Figure 5.5: VH#576/LMO2ΔN25 in silico structural model 
VH#576/LMO2ΔN25 in silico model. The overall shape of the complex is displayed as a 
ribbon diagram. LMO2ΔN25 is shown in yellow, with the zinc ions in cyan and VH#576 in 
red. The model aligns the CDR regions of VH#576 with LMO2. The structure has a 
HADDOCK score of -74.4 +/- 10.6 and a buried surface area of 2207.4 Å2 +/- 118.9.  
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Figure 5.6: VH#576/LMO2ΔN25 in silico structural model: The protein-protein interface 
An enlargement of the protein-protein interaction interface with the CDR regions of 
VH#576 labeled. LMO2 is shown in yellow with surface rendering and VH#576 in red. 
Please note the orientation of LMO2 is C-terminus to N-terminus, as indicated. Residues 
involved in the interaction at the protein-protein interface are shown in ball-and-stick. A 
hydrophobic interaction between Leu 106 (VH#576) and Arg 77 (LMO2) is also indicated. 
Other interactions, not highlighted, include an electrostatic interaction between Glu 102 of 
VH#576 and Arg 86 of LMO2.  
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5.3.2 Interactions illustrated by the VH#576/LMO2ΔN25 in silico model  
The structural model shown in Figure 5.5 explains very well most of the mutagenesis data 
described in section 5.2. In particular, the hydrogen bond interactions between the side 
chain of Ser 32 in VH#576 and Arg 102 of LMO2. Electrostatic interactions are present 
between VH#576 residues Glu 102, Asp 109 and LMO2 residues Arg 86 and Arg 100 
respectively. A hydrophobic interaction also exists between Leu 104 of VH#576 and Leu 59 
of LMO2. At the end of this chapter (the discussion section) comparisons with be made 
between this in silico structural model and the VH#576/LMO2ΔN7ΔC11 crystal structure. 
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5.4 Solving the crystal structure of VH#576/LMO2ΔN7ΔC11 
protein complex 
5.4.1 Methods used to solve the structure  
The following work was carried out by H. Sewell in collaboration with Dr. E. J. Mancini 
and Dr. K. El Omari. Omari et al. have recently solved the structure of LMO2 bound, 
through a flexible linker, to the LIM interacting domain (LID) of LDB1 (Omari et al., 2010, 
manuscript in preparation). This structure will be referred to as FLINC2 (an abbreviation of 
‘fusion of LDB1-LID and the N and C-terminal LIM domains of LMO2’).  
5.4.1.1 Diffraction data collection 
For data collection, crystals were cryo-protected with a solution containing 30% glycerol 
and flash frozen in liquid nitrogen. Single anomalous dispersion (SAD) data was collected 
at the peak wavelength of 1.28240 Å for the Zn K-edge, using macromolecular 
crystallography beamline IO2 (Diamond light source, Oxfordshire, UK). 360° of data were 
collected as a series of 1.0° oscillations and acquired on detector type ADSC Q315 CCD 
using an exposure time of 1second per frame (Figure 5.7). 
5.4.1.2 Diffraction data processing 
The diffraction data was indexed, scaled and merged using HKL2000 data processing 
software (Otwinowski and Minor, 1997). The unit cell was indexed as a primitive hexagonal 
Bravais lattice and the space group was chosen as P6, amongst the possible primitive 
hexagonal space groups, based on systematic absences and Rmerge. The Rmerge, is used to 
assess the quality of the data and is a measure of the similarity of the recorded intensities for 
symmetry equivalent reflections. The data resolution was cut to 3.3Å, based on I/σ(I) (signal 
to noise ratio of recorded intensities) and Rmerge values in the highest resolution bin (see 
Table 5.1).  
 
The recorded intensities were converted to amplitudes (while setting aside 5% of reflections 
as test set reflections in order to calculate an Rfree) with the program SCALEPACK2MTZ 
from the CCP4i suite (Bailey, 1994). The number of VH#576/LMO2ΔN7ΔC11 molecules 
per asymmetric unit was determined to be 2 with a solvent content of 59.29%, using a 
Matthews volume of 3.02 Å3/Dalton of protein (Matthews, 1968). 
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Figure 5.7: Diffraction pattern collected for a VH#576/LMO2ΔN7ΔC11 crystal 
A: The crystal diffracted was grown in 0.8M Ammonium sulphate, 0.1M MES monohydrate 
pH 6 (diluted with H2O to 88%) and additive 1, 6 Hexanediol with a drop ratio of 200nl of 
protein to 100nl of reagent. The crystal was loaded onto a fiber loop and mounted onto a 
goniometer head, which was adjusted to center the crystal in the X-ray beam and to allow 
rotation of the crystal while maintaining centering. The crystal was held in a stream of cold 
nitrogen gas.  
B: The crystal was rotated through 360º and images collected as a series of 1.0° oscillations. 
This image was collected at an angle of ψ=90º. 
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5.4.2 Structure Solution 
The structure of VH#576/LMO2ΔN7ΔC11 was solved by a combination of molecular 
replacement and SAD phasing. The phases for VH#576 were determined by molecular 
replacement using the program PHASER from the CCP4i suite (Bailey, 1994). Anti-Ras FV 
heavy chain was used as a search model (PDB 2UZI). This search identified two VH 
molecules in the unit cell however one was deleted due to a lack of agreement with the 
electron density map.  
 
Using the anomalous signal originating at the Zn peak anomalous wavelength, the program 
HKL2MAP (SHELX suite) (Pape and Schneider, 2004) was able to locate and refine the 
positions of the eight Zn atoms. The eight Zn atoms and the one previously located VH#576 
molecule were imported into the program PHENIX autosol (Adams et al., 2002) which re-
calculated phases to produce an improved electron density map. The molecular replacement 
program MOLREP (Vagin and Teplyakov, 1997) was used to search within this map for 
two LIM1 domains (using the isolated LIM1 from FLINC2 as a search model) and 
successfully positioned the two molecules. PHENIX autosol was used again to recalculate 
phases, this time with the two additional LIM1 molecules, and also to produce an improved 
electron density map. The VH#576 and LIM1 for one VH#576/LMO2ΔN7ΔC11 complex in 
the asymmetric unit were superimposed onto the second LIM1 found in order to define the 
position of the remaining VH#576 and LIM1 for the second VH#576/LMO2ΔN7ΔC11 
molecule. Again PHENIX autosol was used to improve the phases and calculate a new 
electron density map. 
 
A series of molecular replacement experiments to search for the two missing LIM2 
domains, either within the map (using MOLREP) or around the positions of the known, 
fixed molecules (using PHASER) failed. Therefore one molecule of LIM2 (from FLINC2) 
was manually positioned in the electron density map using the determined Zn positions as 
anchor points. Rigid body refinement performed by the program REFMAC5 (CCP4i suite) 
(Bailey, 1994, Murshudov et al., 1997) was used to refine the position of LIM2. Finally, one 
molecule each of LIM1, LIM2 and VH#576 from one VH#576/LMO2ΔN7ΔC11 complex 
were superimposed onto LIM1 and VH#576 of the second complex to define the position of 
the second LIM2. At this point all the components of the asymmetric unit were defined and 
rigid body refinement, followed by two fold-noncrystallographic symmetry (NCS) 
restrained refinement (REFMAC5, CCP4i), were used to refine the model.  
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5.4.2.1 Structure refinement 
Once a model could be derived from the electron density map it was necessary to carry out 
structural refinement in order to adjust the structure to give the best possible fit to the 
crystallographic observations. The first stage in the refinement procedure was to rebuild the 
sections in the electron density map that were missing from the molecular replacement 
models such as the N-terminal of LMO2 (residues 9 to 26) and the CDR3 region of VH#576 
(residues 101 to 109). This was done using the program COOT (Emsley and Cowtan, 2004), 
by adding terminal residues followed by real-space refinement of the added residue into the 
electron density map. Once a series of residues had been added, the “regularise zone” 
function in COOT was used to tighten the geometry of the created bonds, angles, planes and 
non-bonded contacts. The newly created model was then inputted into the REFMAC5 
refinement program for cycles of refinement followed by more rebuilding. 
The difference map (Fobs-Fcalc), which is directly connected to the least-squares optimisation 
function and which has positive density where the model should have more electrons and 
negative density where the model should have fewer electrons, was continually visualised 
throughout rebuilding ( Figure 5.8). Other indicators of accuracy (Table 5.1) including the 
Ramachandran plot, the root mean squared deviation for bond lengths and angles, the Rfactor, 
the Rfree and the average B factors were closely monitored during refinement. The 
Ramachandran plot shows the distribution of conformational angles (φ, ψ) along the protein 
backbone. C-N-Cα-C defines the torsion angle φ, whilst N-Cα-C-N defines ψ. The plot gives 
an indication of whether conformational angles are preferred, allowed or incorrect. Glycines 
have a different plot, as they are more flexible. Values for root mean squared deviation for 
bond lengths and bond angles reflect the deviation from an ideal geometry. The Rfactor is a 
measure of how well the modified electron density fits to the observed structural 
amplitudes. The Rfree or free Rfactor is a residual function calculated during structure 
refinement in the same way as the conventional Rfactor, but applied to a small subset of 
reflections that are not used in the refinement of the structural model. The purpose of this is 
to monitor the progress of refinement and to check that the Rfactor is not being artificially 
reduced by the introduction of too many parameters. The values for Rfactor and Rfree following 
the last cycle of the current round of refinement are 29% and 33% respectively. The B-
factor, or temperature factor, which describes the degree to which the electron density is 
spread out for each atom or group of atoms, is an indication of the dynamic mobility of an 
atom and can potentially highlight errors in model building. 
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 Figure 5.8: 2Fo-Fc electron density map of VH#576/LMO2ΔN7ΔC11 
The 2Fo-Fc electron density map (blue) was contoured at 1.0 σ. The map is shown for the 
LIM1 domain of LMO2ΔN7ΔC11, specifically zinc binding LIM finger two. The zinc ion, 
represented by a grey cross, is tetra-coordinated by LMO2 residues Cys 57, Cys 60, Cys 80, 
Asp 83. VH#576, CDR2 is also shown to the left of LMO2. The low resolution of the map 
(3.3Å) makes positioning of side chains difficult.  
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Table 5.1: Data Collection and refinement statistics for VH#576/LMO2ΔN7ΔC11 structure 
Data collection statistics:  
Space group P6 
Number of molecules in the asymmetric unit 2 
Unit cell Dimensions a, b, c (Å) 
a, β, γ (°) 
a = 124.5 b = 124.5 c = 81.7 
α = 90 β = 90 γ = 120 
Observations 237175 
Unique reflections 10859 (1069) 
Completeness (%) 100 (100) 
I/σ(I) 24.2 (4.9) 
Rmerge a  (%) 24.2 (98.9) 
Refinement statistics:  
Resolution range (Å) 30 - 3.3 (3.42 – 3.30) 
Number of reflections (working/test) 10333/496 
Rfactor b (%)/Rfree c (%) 28.53/33.19 
Number of atoms 4146 
Rms Δ bond length (Å) 0.0093 
Rms Δ bond angle (°) 1.53 
Mean B-factor (Å2): main chain/side chains and 
waters 
43.19/43.29 
Ramachandran Plot statistics:  
Residues in most favoured regions (%) 70.62 
Residues in additionally allowed regions (%) 12.65 
Outliers 16.73 
 
The numbers in parentheses refer to the last (highest) resolution shell. 
 
a Rmerge = ∑h∑i  |Ii (h)- <I(h)>| /   ∑h∑i  <Ii (h) >, where Ii (h) is the ith measurement and 
<I(h)> is the weighted mean of all measurements of Ii (h). 
 
b Rfactor and c Rfree = ∑h  ||F(h)obs|- |F(h)calc|| / ∑h |F(h)obs| for reflection in the working set and 
test set respectively. 
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5.4.3 Crystal structure of VH#576/LMO2ΔN7ΔC11  
The structure of VH#576/LMO2ΔN7ΔC11 shows VH#576 displays the common 
immunoglobulin fold, composed of two β sheets made up of nine anti-parallel β strands 
(Figure 5.9). Hydrogen bonds between adjacent strands stabilise the VH#576 structure. The 
LIM1 domain possesses the characteristic LIM domain structure of four β-strands and this is 
followed by a short α helix. Each zinc atom is positioned between a pair of anti-parallel β 
strands. Truncation of the eleven C-terminal residues of LMO2 has removed the C-terminal 
α helix of LMO2, which is present in the FLINC2 structure.  
All four zinc ions are present in the structure; each zinc is coordinated in a tetrahedral 
geometry by the side chains of three cysteine residues and one histidine or aspartic acid 
residue. Specifically the zinc is coordinated by, the sulphur of cysteines, the nitrogen of the 
histidine or the oxygen of the aspartic acid. Zinc ions are important for stabilising the 
structure of LMO2, a role analogous to that of disulfide bonds, which are important in the 
folding, and stability of some proteins. Furthermore, zinc ions are stable in a cellular 
environment due to the lack of redox activity (McCall et al., 2000).  
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Figure 5.9: Crystal structure of VH#576/LMO2ΔN7ΔC11 
The overall shape of VH#576/LMO2ΔN7ΔC11 is displayed as a ribbon diagram, where the 
VH#576 is shown in red, LMO2 in yellow and the zinc spheres in cyan. The architecture of 
VH#576 is that of the common immunoglobulin fold. CDR one, two and three of VH#576 
are coloured in wheat, green and blue respectively. 
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VH#576/LMO2ΔN7ΔC11 forms a dimer in the asymmetric unit, where the dimerisation 
interface is solely between two LMO2 molecules (Figure 5.10). The N terminal tail of 
LMO2 (residue 7-26) can be seen to interact with the region comprising residues 40 to 70 of 
LIM1 in the neighbouring LMO2 molecule in the asymmetric unit. This interaction is 
intriguingly similar to the one seen between the LID domain of LDB1 and LMO2 in the 
FLINC2 structure; the N-terminal tail of LIM1 appears to mimic the LID domain of LDB1. 
Size exclusion chromatography and mass spectrometry analysis suggest 
VH#576/LMO2ΔN7ΔC11 is a monomer in solution and therefore it may be that the 
crystallographic dimer is a result of crystal packing rather than a reflection of a true dimer. 
Alternatively, dimer formation may be concentration dependent. 
 
 
Figure 5.10: LMO2 forms a dimer in the asymmetric unit 
The N-terminus of two LMO2 molecules, shown in yellow and green with respective 
VH#576 binding partners shown in pink and cyan. The long N-terminal tail of LMO2 
interacts with LIM1 domain of another LMO2 molecule in the asymmetric unit to form a 
dimer.  
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The superimposition of the FLINC2 structure (Omari et al., 2010, manuscript in 
preparation) onto the LMO2 of the VH#576/LMO2ΔN7ΔC11, highlights major 
conformational differences, specifically in the relative positioning and angle between the 
two LIM domains. The conformation of LMO2 adopted in the VH#576/LMO2ΔN7ΔC11 
structure may be influenced by the interactions with the VH#576 molecule. However, 
differences in crystal packing between the two structures could also give rise to differences 
in the conformation of the proteins. 
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Figure 5.11: Superimposition of the FLINC2 and VH#576/LMO2ΔN7ΔC11 structures 
A - The VH#576/LMO2ΔN7ΔC11 structure; LMO2 is coloured in cyan, VH#576 in green 
and the zinc ions in cyan.  
B – The structures of FLINC2 (Omari et al., 2010, manuscript in preparation) and 
VH#576/LMO2ΔN7ΔC11 were superimposed with COOT, using the LIM1 domains as 
anchoring points. 
C – The FLINC2 structure; LDB1_LID is coloured in magenta, LMO2 in yellow and the 
zinc ions in yellow.  
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5.4.4 Analysis of the interaction between VH#576 and LMO2ΔN7ΔC11 
Atomic interaction between VH#576 and LMO2 were identified using Contacts of structural 
units (CSU) software (Sobolev et al., 1999). Any type of non-bonded atomic interactions, 
i.e. hydrogen bonds, aromatic-aromatic, hydrophobic-hydrophobic and polar contacts, were 
considered. Table 5.2 and Table 5.3 compile all the observed atomic interactions between 
VH#576 and LMO2 upon analysis of the solved structure. A hydrogen bonding network 
occurs between the β-sheet of LIM2 (LIM finger three) and CDR3 of VH#576, residues Leu 
106 and Thr 107. Other interactions include electrostatic networks and hydrophobic contacts 
(Figure 5.13). A region of hydrophobic contacts lies at the former VH-VL interface of 
VH#576 that spans residues Val 37 to Tyr 50. The hydrophobic interactions occur between 
residues Leu 45 and Leu 117 and Trp 47 and Met 106 of VH#576 and LMO2, respectively 
(Figure 5.14). These hydrophobic framework interactions may explain why the orientation 
of VH#576 with respect to LMO2 appears to be distorted. The algorithm also highlighted 
the atomic interactions mediated by Trp 110 as shown in Table 5.3. This residue was not 
mutated during the alanine/glycine scan. 
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Table 5.2: Atomic contacts between VH#576 and LMO2ΔN7ΔC11 
Antibody 
region 
VH#576 
residue 
LMO2 
residue 
Distance 
(Å) 
Contact surface 
area (Å2) 
Type of interaction 
Framework Leu45 Leu117 3.2 37.1 Hydrophobic-hydrophobic 
Polar contacts 
Framework Trp 47 Met 106 3.1 64.8 Hydrogen bond 
Hydrophobic-hydrophobic 
Polar contacts 
Framework Tyr 50 Cys 60 3.5 27.4 Hydrophobic-hydrophobic 
CDR2 Ser 52 Cys 60 3.2 26.5 Polar contacts 
CDR2 Asn 54 Asp 53 3.7 21.8 Polar contacts 
CDR3 Leu 104 Arg 82 3.7 40.8 Hydrophobic-hydrophobic 
Polar contacts 
CDR3 Glu 105 Asp 83 
Arg 86 
2.7 
2.8 
51.8 
50.5 
Hydrophobic-hydrophobic 
Polar contact (salt bridge) 
CDR3 Leu 106 Thr 107 2.8 64.2 Hydrogen bond 
Hydrophobic-hydrophobic 
Polar contacts 
CDR3 Thr 107 Arg 109 2.7 33.5 Hydrogen bond 
Polar contacts 
CDR3 Asp 109 Tyr 135 2.7 43.1 Hydrophobic-hydrophobic 
 
Structural determination of LMO2 bound to anti-LMO2 antibody single domain  
 
 188 
 
Table 5.3: Further atomic contacts between VH#576 and LMO2ΔN7ΔC11 
Antibody 
region 
VH#576 
residue 
LMO2 
residue 
Distance 
(Å) 
Contact 
surface 
area (Å2) 
Type of interaction 
CDR3 Trp 110 Phe 120 
Cys 130 
Gly 132 
3.7 
3.2 
3.6 
35.0 
23.3 
27.4 
Aromatic-aromatic 
Hydrophobic-hydrophobic 
Hydrogen bond and polar 
contacts 
 
 
 
 
 
1       10        20        30        40  
EVQLLESGGGLVQPGGSLRLSCAASGFSFSHSPMNWVRQAPGKGLEWV 
 
50        60        70        80        90        
SYISYNSSSIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC 
 
 100       110       120 
ARGLTESLELTADWFDYWGQGTLVTVS 
 
Figure 5.12: Important VH#576 residues for the interaction with LMO2 
The amino acid sequence (single letter code) is shown for VH#576. The CDR regions are 
coloured in yellow. Critical residues for the interaction with LMO2, found at the protein-
protein interface, are highlighted in red. Putative critical residues at the former VH/VL 
interface (coloured green) are highlighted in purple. Residues highlighted in blue were also 
found to be critical for the interaction, according to VH#576 mutagenesis data, however the 
crystal structure suggests they do not form atomic contacts with LMO2. This would imply 
the residues are important to maintain a specific conformation of VH#576.  
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Figure 5.13: Key interactions between VH#576 and LMO2ΔN7ΔC11 
Both VH#576 and LMO2ΔN7ΔC11 are displayed as ribbon diagrams and shown in red and 
yellow respectively. Key interacting residues are shown in ball-and-stick. The critical 
VH#576 binding site lays across LIM finger two and three of LMO2ΔN7ΔC11, LIM 
domain one and two respectively (the zinc can be seen as cyan spheres). CDR1 has no role 
in the interaction with LMO2 however, Ser 32 may contribute towards the overall 
conformation of VH#576. There are two critical residues shown in CDR2 (Ser 52 and Asn 
54). Interactions can be seen at the α-helical region of LIM1 between residues Asp 83 and 
Arg 86 of LMO2ΔN7ΔC11 and Glu 105 of VH#576, CDR3. Other key interactions 
involving CDR3 residues are highlighted including that of Leu 106 and Thr 107 with the   
β-sheet of LIM2, finger three.  
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Figure 5.14: Important hydrophobic interactions between VH#576 and LMO2ΔN7ΔC11 
LMO2ΔN7ΔC11 is shown in yellow and VH#576 in red. The anti parallel β-sheets of 
LMO2ΔN7ΔC11, LIM2 form part of LIM finger three. VH#576 residues, Trp 47 and Leu 
45 at the former VH/VL interface are indicated as shown in ball-and-stick. Trp 47 and Leu 
45 of VH#576 form hydrophobic interactions with Met 106 and Leu 117 of 
LMO2ΔN7ΔC11 respectively. 
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5.4.5 Interface area 
The surface area of VH#576 which is critical for the interaction with LMO2 can be 
determined by calculating the absolute value of the difference between the solvent 
accessible surface area (SAS) in the bound state and the SAS in the unbound state. The 
calculation is shown in Table 5.4 along with the estimated size required for a small 
molecule to mimic the VH#576 interaction (Cheng et al., 2007). 
 
Table 5.4: Surface area of VH#576 required for the interaction with LMO2ΔN7ΔC11 
Surface area of VH#576 interacting 
region (Å2): 
 
 Represents a compound of molecular 
weight (Da) 
Unbound 814  
Bound 302  
SAS (unbound) - SAS (bound) 
(buried surface area) 
512 850 
 
The surface area of VH#576 required for the interaction with LMO2 has been calculated as 
512Å2, which relates to a compound of molecular weight 850 Da (Table 5.4). As will be 
discussed later in this chapter, this is larger than the 500 Da classical Lipinski limit 
(Lipinski et al., 1997) of a typical drug like compound. This calculation also includes 
residues Leu 45 and Trp 47 that are not located in the CDR regions, however the structural 
data suggest they are critical for the interaction.  
 
5.5 Discussion 
This chapter presents the crystal structure of VH#576/LMO2ΔN7ΔC11. The structure 
corresponds strongly with the VH#576 mutagenesis data and has enabled the interactions 
between VH#576 and LMO2ΔN7ΔC11 to be defined. 
 
Most of the VH#576 residues, shown to be critical by VH#576 mutagenesis studies, can be 
found at the interface of the crystal structure with the exception of Ser 32 (CDR1), Glu 102 
(CDR3) and Tyr 113 (CDR3). Changes to these residues may alter the conformation of 
VH#576, enough to inhibit other vital interactions. These results highlight the effectiveness 
of alanine/glycine scanning to identify a subset of residues at the interface, which contribute 
to high affinity binding, and this region can be defined as the hotspot. Consequently, this 
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study represents alanine/glycine scanning as a key tool to focus and restrict the target area of 
the protein-protein interface for small molecule drug design.  
Atomic contacts between VH#576 and LMO2 have been calculated using a computational 
geometry algorithm. Important interactions have been identified however, due to the low 
resolution of the crystal structure, some amino acid side chains may not have the correct 
orientation thus some interactions may not have been correctly identified. Some interactions 
predicted may be inaccurate or some may be missing due to incorrect geometry between the 
interacting residues. 
5.5.1 A comparison between VH#576/LMO2ΔN7ΔC11 crystal structure and in silico 
structural model 
Prior to the generation of X-ray crystallography data, VH#576 and LMO2 mutagenesis data 
were used to create an in silico structural model of the VH#576/LMO2ΔN25 protein 
complex. Upon comparison of this model and the crystal structure errors in the in silico 
model have been identified such as the orientation of VH#576 with respect to LMO2. 
However, the CDR3 region is coordinating with the same region of LMO2 in both the 
structural model and crystal structure, albeit from a different angle. The in silico structural 
model is a structural prediction and there are many reasons for the differences between this 
model and the crystal structure. The in silico model is based on the VH#576 mutagenesis 
data which does not include analysis of the residues at the former VH/VL interface. The 
crystal structure shows these residues interact with LMO2 and thus this is one reason for the 
difference in orientation of the VH#576 and LMO2. The VH#576 mutagenesis data also 
suggests Ser 32, of CDR1 actively interacts with LMO2 however the crystal structure shows 
this is not the case. Ser 32 is actually important to maintain the conformation of VH#576. 
The allosteric bend of LMO2 seen in the crystal structure is not present in the in silico 
model. This illustrates a limitation of protein-protein docking algorithms, as these 
computational tools do not properly account for the intrinsic conformational flexibility of 
proteins.  
5.5.2  Comparison with other LIM structures 
A comparison between crystal structures VH#576/LMO2ΔN7ΔC11 and FLINC2 (Omari et 
al., 2010) shows a degree of flexibility in the LIM2 region of LMO2. Two possible 
explanations for this are considered here. Firstly, LMO2 interacts with many different 
proteins therefore it may be that LMO2 has intrinsically disordered regions to enable its 
interaction with different protein partners such as TAL1 and LDB1. If this is the case then 
LMO2 will fold with respect to the protein with which it is interacting. Secondly, it may be 
that the VH#576 interaction induces a conformational change in LMO2, which is different 
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from its native conformation. The hydrophobic interactions between residues located on the 
surface of the hydrophobic core of LMO2 and the former VH/VL interface may contribute 
to the change in the orientation of LMO2, LIM2.  
 
Analysis of LMO4-LIM1:ldb1-LID complex (FLIN4) through NMR, 15N relaxation data, 
shows evidence of flexibility between the two zinc-binding modules. An overlay of FLIN4 
and individual zinc binding modules shows a reduction in the root mean square deviation. 
This suggests the small loops between elements of defined secondary structure have 
increased mobility in comparison with the core regions of the domain (Deane et al., 2003).  
 
The structures of other unbound LIM domains have been analysed and have shown different 
orientations and flexibility between the zinc binding fingers. Examples include the analysis 
of LIM2 of CRP2, a cysteine rich LIM-only protein. Comparison of 15N relaxation data for 
wild type CRP2-LIM2 and CRP2-LIM2_R122A (a mutation that disrupts zinc co-
coordinating Cys 144) revealed a conformational change in the zinc binding site, alteration 
in the hydrophobic core and a subsequent change in the orientation of the two LIM fingers 
(Schuler et al., 2001). These differences were not confined to the site of mutation and shows 
that LIM domains are not rigid but their structure can be variable due to the breakage and 
formation of hydrogen bonds or electrostatic interactions. LIM domains characteristically 
interact with diverse protein-binding partners and the mode of conformational flexibility 
described by this group represents a possible mechanism of allosteric control mediating 
associations with the appropriate protein partners. It has also been proposed this mechanism 
allows for enthalpic compensation of entropy loss upon binding (Kontaxis et al., 1998).  
5.5.3 Effect of VH#576 upon LMO2 activity within the cell 
The FLINC2 structure (Omari et al., 2010, manuscript in preparation) may be perceived to 
be the more native conformation as it is bound to Ldb1_LID, a natural binding partner in the 
protein complex. This change in conformation, upon VH#576 interaction, may represent the 
mechanism of functional ablation. Results of a recent differentiation assay, (T. Tanaka, 
personal communication) has provided evidence that VH#576 interferes with LMO2 
activity within the cell. The experiment can be briefly described as follows: Murine 
erythroleukaemia (MEL) cells were infected with retrovirus expressing GFP and either 
VH#576 or anti-LMO2 scFv (ALR3). Cells were sorted using FACS analysis and then 
treated with 4mM hexamethylene bisacetamide (HMBA). MEL cells undergo erythroid 
differentiation when treated with HMBA. After 4.5 days, the MEL cells were tested for 
erythroid differentiation by staining with 2,7-diaminofluorene (DAF), which sensitively 
stains haemoglobin blue. Approximately 15% of the MEL cells infected with retrovirus 
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expressing GFP and VH#576 differentiated into erythroid cells as oppose to 95% of 
uninfected MEL cells. This assay gave the same results for ALR3 (anti LMO2 scFv). A 
negative control of anti-RAS VH#6 was used to show that a VH antibody that does not bind 
to LMO2 cannot inhibit haemoglobinisation. This assay shows that erythroid cells 
expressing VH#576 do not undergo haemoglobinisation. This is a result of the interaction 
between VH#576 and LMO2. LMO2 is essential for haematopoietic development (Warren 
et al., 1994) and therefore the inhibition of LMO2 in MEL cell blocks their development. 
 
Inhibition of LMO2 dependent leukaemia in a mouse T-cell tumorigenesis transplantation 
assay has been demonstrated for ALR3. Rag1 null mice were injected with Thymoma T 
cells, which had been prepared from Lck-Lmo2 transgenic mice and infected with retrovirus 
expressing ALR3 and GFP. After 3 to 4 weeks neoplastic T cells were removed from the 
spleen for FACS analysis. Expression of the GFP after transplantation had decreased by 
approximately 70%, reflecting the inhibition of malignant mouse tumour growth by ALR3 
(Nam et al., 2008). An equivalent transplantation assay replacing ALR3 for VH#576 could 
potentially demonstrate its ability to inhibit malignant mouse tumour growth. 
 
The VH#576/LMO2ΔN7ΔC11 crystal structure described shows the binding of VH#576 
locks LMO2 in a specific conformation. A possible mechanism for the inhibition of LMO2 
activity by VH#576, as shown by the erythroid differentiation assay, is one of 
conformational change. It may be that the conformation of LMO2 when bound to VH#576 
is changed to such a degree that the protein can no longer interact with its natural partners 
such as LDB1 and TAL1. Therefore design of a small molecule that could perfectly mimic 
VH#576 and stabilise LMO2 in this new conformation could potentially inhibit its protein 
interactions within the DNA binding protein complex (LMO2, LDB1, TAL1, and E47/E12), 
blocking its activity as a transcription factor.  
 
5.6 Conclusion 
In conclusion, the crystal structure of VH#576/LMO2ΔN7ΔC11 has been solved to a 
medium resolution of 3.3Å and concurs well with both the LMO2 and VH#576 mutagenesis 
data. Differences in the structure of LMO2 when bound to Ldb1_LID or VH#576 have been 
revealed upon comparison. This is most likely explained by the intrinsic flexibility of LIM 
domains mediating associations with the appropriate protein partners. The favourable 
interactions between VH#576 and LMO2 drive and stabilise LMO2 conformational 
changes. Thus, interaction with VH#576 changes the conformation of LMO2, particularly in 
the LIM2 region. Development of a small molecule, which could perfectly mimic VH#576 
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by altering and stabilising the conformation of LMO2 in the same way, could have potential 
as a therapeutic by blocking its activity within the cell. However, the resolution of the 
solved crystal structure is not optimal for structure-based drug design. Further refinement of 
the structure or collection of diffraction data at an improved resolution, will eventually lead 
to a superior structure, more suited for drug design. Furthermore, the structural information 
of the macro complex, i.e. LMO2, LDB1, TAL1, and E47/E12, is not yet available. Having 
this information would greatly aid the design of small molecule inhibitors, providing 
information on which area of LMO2 to target and the potential to design a dual therapy to 
target more than one interaction within the complex. 
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6.1 General discussion 
Work detailed within this thesis has led to the crystal structure of LMO2 in complex with an 
intracellular antibody single domain, termed VH#576. It is the first time LMO2 has been 
crystallised in complex with a macrodrug. The crystal structure of the complex formed by 
LMO2 and VH#576 provides precise information about the nature of the interaction 
interface and this will be fundamental for structure based drug design. The structure was 
solved to a resolution of 3.3Å and reveals VH#576 binds across the two LIM domains of 
LMO2. 
 
Comparison of the VH#576/LMO2ΔN7ΔC11 structure with FLINC2 (chapter five) 
demonstrates the high degree of flexibility between the two LIM domains represented by 
the differences in relative positioning and angle between the two domains. This 
demonstrates the flexibility of the loops between the defined secondary structure of LMO2 
and may reflect a mechanism of allosteric control mediating associations with a broad range 
of proteins. 
 
The VH#576/LMO2ΔN7ΔC11 crystal structure was analysed with regards to the crystal 
packing and an interaction was identified between the long N-terminal tail (residues 7 to 26) 
of LMO2 and LIM1 of a second LMO2 molecule. This interaction is intriguingly similar to 
the one seen between the LID domain of LDB1 and LMO2 in the FLINC2 structure (Omari 
et al., 2010, manuscript in preparation); the N-terminal tail of LIM1 appears to mimic the 
LID domain of LDB1. There is evidence to suggest that LMO2 can form a weak homodimer 
(Nam et al., 2008, Sanchezgarcia et al., 1995). Still, VH#576/LMO2ΔN7ΔC11 is certainly a 
monomeric complex prior to crystallography as shown by the size exclusion 
chromatography and mass spectrometry data presented in chapter three. The interaction seen 
between LMO2 molecules may be an artifact of crystal packing or it may reflect a true 
dimerisation pathway. 
6.1.1 Medium resolution X-ray structure of VH#576/LMO2ΔN7ΔC11  
The crystal structure of VH#576/LMO2ΔN7ΔC11 was solved to a resolution of 3.3Å due to 
the low resolution of the diffraction data collected and this is reflected in the electron 
density map. At a resolution of 3.3Å, the α-helices, β-sheets and main chain can clearly be 
identified. Most aromatic side-chains are clearly visible however, density for some of the 
smaller side chains is missing and the rotamers of some side chains are not clear. At this 
resolution, ordered water molecules cannot be placed. The crystals tested for diffraction had 
a high solvent content and this partly attributes to the low resolution data as the high level of 
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disordered solvent leads to a decrease in X-ray intensities with increasing diffraction angle. 
There are two proteins presents in the VH#576/LMO2ΔN7ΔC11 complex and this may 
confer a degree of flexibility and as such large atomic motilities may contribute to the low 
resolution diffraction data. High atomic motilities not only limit the resolution of the data 
that can be collected but also decrease the peak densities in the Fourier maps to such an 
degree that some regions of the map are difficult to fit (Jensen, 1997). Therefore diffraction 
data of a higher resolution may or may not be possible to collect but would decrease the 
errors in atom position and hence increase the accuracy and figure of merit of the model; an 
aspect which is critical for structure-based drug design.  
 
Options for improving the crystal packing and hence diffraction capacity include 
optimisation of crystallisation conditions, which were bypassed in the initial stages. 
Alternatively, the kinetics of evaporation and hence crystallisation can be influenced by the 
use of an oil barrier over the vapour diffusion reservoir to slow down the rate of evaporation 
and potentially improve the order of the crystals grown (Chayen, 1997). Then again, 
perhaps the most likely solution, would be to examine the crystal contacts and packing of 
the molecules in the current crystal and design a construct with a higher chance of being 
more ordered and thus improve the X-ray diffraction properties (MacElrevey et al., 2007). 
Interestingly, upon initial inspection of the crystal contacts it appears residues 140 to 147 of 
LMO2, LIM finger four (right side) have very few intermolecular contacts and this may 
highlight flexibility within this region. The B-factors for residues within this region are also 
high again suggesting a high degree of mobility, which could have a negative impact on the 
crystal packing. Creating a construct with further C-terminal truncations would almost 
certainly interfere with the ability of LIM finger four to bind zinc. However, for the purpose 
of structure based drug design we are solely interested in the protein-protein interface 
between LMO2 and VH#576 and aim for an atomic resolution of 2.7Å or better.  
6.1.2 The LMO2 DNA binding protein complex 
Lmo2 is part of a DNA binding complex, originally identified in erythroid cells, comprising 
Tal1, Ldb1, E2a and Gata1 (Wadman et al., 1997). A distinct complex, which lacks Gata1, 
has been identified in T-cells from Lmo2 transgenic mice (Grutz et al., 1998b). Ectopic 
expression of LMO2 has been observed in T-cell tumour cells from patients with T-cell 
acute lymphoblastic leukaemia (T-ALL) due to specific chromosomal translocations 
(Boehm et al., 1991). In this section, theories of possible mechanisms for the onset of T-
ALL, as a result of the aberrant expression of LMO2, will be discussed. The prospects of 
designing a small molecule, which has the capacity to disrupt this LMO2 complex, will also 
be considered.  
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The increase in levels of LMO2 in T-cells, by enforced expression, may result in aberrant 
complex formation, which acts to sequester one or more proteins in the complex preventing 
their normal function, one such candidate is LMO4. There is no requirement for LMO2 in 
T-cells (McCormack et al., 2003), however LMO4 is highly expressed in T-cell precursors. 
Correspondingly, the displacement of LMO4, from LDB1, by LMO2 may contribute to the 
development of T-ALL although, LMO4 null mice have apparently normal populations of 
T-cells (Grutz et al., 1998a). The affinity of LMO2 for LDB1 has been shown to be lower 
than the affinity of LMO4 therefore an excess of LMO2 would be required to force binding 
equilibria to favour the formation of LMO2:LDB1 (Ryan et al., 2006). LIM1 of LMO2 has 
been shown to be more important than LIM2 for interaction with LDB1_LID. Based on 
point mutations analysed by yeast two-hybrid analysis, Ryan et al. demonstrate that residue 
I322 of LDB1 is an important residue for the interaction with LMO2-LIM1 and LMO4-
LIM1 but is only critical for the interaction with LMO2-LIM1. Analysis of the NMR 
solution structure of LMO2-LIM1:LDB1_LID shows the side chain of this residue is buried 
in a hydrophobic pocket between the two LIM fingers of LIM1 and this can also be seen 
from the FLINC2 structure (Omari et al., 2010, manuscript in preparation). Thus, a small 
molecule, which has the ability to mimic I322, and surrounding residues, would have 
potential to specifically inhibit the interaction between LDB1 and LMO2 but not LMO4.  
 
Aberrant expression, of LMO2, may play a role in the disruption of normal E2A function, 
contributing to the molecular pathway of T-ALL (Larson et al., 1996). Multiple competing 
equilibria experiments were used to characterise the assembly of the five component 
complex containing TAL1, LMO2, LDB1, E2A (E12 or E47) and DNA (Ryan et al., 2008). 
Due to a problem of protein solubility, TAL1bHLH and E12bHLH domains were purified as 
appose to full length proteins and LMO2 was purified as a chimera with the LID domain of 
LDB1. The main findings of Ryan et al. can be summarised in three points. Firstly,      
TAL1bHLH and E12bHLH preferentially form heterodimers rather than homodimers. Secondly, 
LMO2 has the capacity to interact with Tal1bHLH however, preferentially binds TAL1bHLH 
/E12bHLH heterodimer. Finally, E12bHLH is required for the complex to bind DNA. These 
results suggest the aberrant expression of TAL1, in T-cells, is likely to sequester E2A 
(E12/E47) protein and negatively affect E2A mediated gene expression and thus 
lymphocyte development as E2A activity is critical for this process (Bain et al., 1997). This 
is likely to be favoured in cells expressing both TAL1 and LMO2 as LMO2 has a higher 
affinity for the TAL1/E12 heterodimer. Hence, LMO2 promotes the formation of 
TAL1/E12 heterodimers (Ryan et al., 2008). As a result of these findings, Ryan et al 
proposed that development of a small molecule to inhibit a single interaction, for example 
between LMO2 and TAL1 would have a limited effect on restoring E2A activity and that 
General discussion and future work 
 
 200 
two inhibitors (targeting LMO2-TAL1 and TAL1-E2A interactions) would be required as 
an effective treatment for T-ALL. However, there are likely to be additional LMO2-only 
effects contributing to T-ALL progression.  
 
It is likely that LMO2 can interact with different sets of proteins to regulate the 
haematopoietic pathway (Yamada et al., 1998) and therefore, it is also likely that analogous 
interactions may ensue after ectopic LMO2 expression in T-cells. As LMO2 is not normally 
expressed in T-cells it may have affinity for proteins it does not normally interact with. 
These LMO2 interactions lead to the positive or negative regulation of gene transcription, 
which ultimately leads to a block in T-cell differentiation. 
6.1.3 VH#576 has the potential to inhibit the activity of LMO2 
As discussed previously (chapter five), the results of a recent erythroid differentiation assay 
demonstrated the ability of VH#576 to inhibit Lmo2, within the cell (T. Tanaka, personal 
communication). The VH#576/LMO2ΔN7ΔC11 crystal structure shows LMO2 in a 
conformation, which is different to that of LMO2 when bound to LID_LDB1 (FLINC2 
PDB). This distinct LMO2 conformation may represent a biological mechanism for the 
inhibition of its downstream regulation of gene transcription. According to data, from a 
mammalian two-hybrid competition assay, VH#576 cannot compete with LDB1 for LMO2 
binding, however LDB1 can compete with VH#576 (S. Waters, personal communication). 
Therefore inhibition of LMO2, as shown by the erythroid differentiation assay, must take 
place prior to formation of the complex.  
 
The small size of LMO proteins suggests they should be capable of freely moving between 
the cytoplasm and the nucleus however they are found predominantly in the nucleus. The 
mechanism for nuclear retention is unclear as LMO proteins lack a nuclear localisation 
signal. LDB1, on the other hand, is a nuclear protein and contains a nuclear localisation 
sequence. Experimental evidence has suggested that one function of LDB1 is to maintain 
LMO proteins in the nucleus (Kenny et al., 1998). The interaction between VH#576 and 
LMO2 may occur in the cytoplasm post protein synthesis at the ribosome. This would 
prevent the interaction between LMO2 and LDB1 and as such LMO2 would remain in the 
cytoplasm, blocking its activity as a nuclear transcription factor.   
 
TAL1 (36.5 KDa) is also predominantly a nuclear protein (Bernard et al., 1995). The 
interaction between Lmo2 and Tal1 seems to have a synergistic effect on tumour formation 
as well as on T-cell differentiation (Larson et al., 1996). Therefore, in terms of therapeutic 
design, this is an important interaction to target. Mammalian two-hybrid data suggests 
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TAL1 cannot compete with VH#576 for LMO2 binding and vice versa (S. Waters, personal 
communication) suggesting TAL1 and VH#576 interact with different regions of LMO2. 
Determination of the exact effect of the interaction between VH#576 and LMO2, upon 
formation of the DNA binding complex, requires further investigation using methods such 
as Electromobility shift assays. This would also provide information on the effect of 
VH#576 interaction on protein-nucleic acid interactions such as the interaction between 
E2A/TAL1 and DNA (E box motif). The pathogenic role of LMO2 is likely to be dependent 
on its ability to mediate protein interactions with DNA and this further highlights the 
importance of this experiment.  
 
Previous data suggests other macrodrugs (e.g. anti-Lmo2 scFv termed ALR3), identified by 
intracellular antibody capture, bind to the same region of LMO2 as VH#576; the mid region 
composed of an α-helix from LIM1 followed by a loop and then a pair of β-sheets from 
LIM2. Therefore, one conclusion is that this region of LMO2 is particularly efficient at 
binding proteins, macrodrugs and perhaps even small molecules. Furthermore, this may be 
the only structured region of free LMO2, the loops either side of this interaction site may 
display intrinsic disorder until interaction with another protein. Moreover, ALR3 has been 
shown to inhibit Lmo2 in a mouse T-cell tumour transplantation assay by preventing Lmo2-
dependent T-cell nepolasia (Appert et al., 2009, Nam et al., 2008). Therefore an experiment 
to test if VH#576 has the capacity to inhibit LMO2 dependent leukaemia in a mouse T-cell 
tumorigenesis transplantation assay would be key to determining its potential as a 
macrodrug. 
6.1.4 VH#576 and small molecule mimetics 
Monoclonal antibodies have interchain disulfide bonds which means they are almost always 
restricted to extracellular target antigens. VH#576 is a single domain intracellular antibody 
(iDab). iDabs were developed based on their ability to fold and interact with antigen in the 
reducing environment of the cell (Tanaka et al., 2003). In addition, VH#576 specifically 
binds LMO2 with nanomolar affinity and therefore has potential as a T-ALL therapeutic. 
The challenge associated with the use of antibody domains as therapeutics is delivery; the 
internalisation or expression inside the target cells. Options for delivery of VH#576 include 
protein transduction or virally mediated induction of antibody fragments into bone marrow 
cells ex vivo in association with transplantation in leukaemia patients (Lobato and Rabbitts, 
2003). Nevertheless, further advances in delivery methods are required before clinical use is 
a possibility. Small molecules have several advantages over antibody single domains such 
as cell permeability, relative ease of manufacture, higher metabolic stability, lower cost and 
oral delivery (Lipinski et al., 1997).  
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The structure based drug design approach detailed within this thesis can be described in four 
stages of which progress has been made for the first three. Following identification of an 
anti-LMO2 antibody single domain, VH#576, the crystal structure of 
VH#576/LMO2ΔN7ΔC11 was solved. This allowed identification of a target region for 
LMO2 and the VH#576/LMO2 interface to be characterised. This was followed by 
identification of a VH#576 hotspot (a group of residues which make a significant energetic 
contribution to the interaction) thus reducing the target area for small molecule drug design. 
All this information can be utilised in stage four; design of a pharmacophore template to 
screen libraries of small molecules in silico.  
 
The key VH#576 binding residues identified are mainly within CDR3 making it the most 
interactive of the hyper-variable loops. The crystal structure supports the mutagenesis data 
and shows the CDR3 residues interact with residues 82 to 135 located across LIM finger 
two (LIM1), three and four (LIM2) of LMO2 (Figure 6.1). The crystal structure and 
VH#576 mutagenesis data also demonstrate a critical interaction between VH#576 CDR2 
residues (Ser 52 and Asn 54) and residues of LIM finger two (Cys 60, Asp 53). A full 
alanine/glycine scan of VH#576 residues 37 to 50, the former VH/VL interface, would 
identify precise residues that are critical for the high affinity binding. If residues in this 
region are also vital, the surface area of VH#576 required for the interaction with LMO2 
would be 512Å2, which relates to a compound of molecular weight 850 Da (Cheng et al., 
2007) (Figure 6.1). This is larger than the typical 500 Da Lipinski limit (Lipinski et al., 
1997). However, there are examples of larger compounds that have entered clinical trials 
such as ABT-263, a 974 Da small molecule inhibitor of anti-apoptotic proteins Bcl-2, Bcl-
XL and Bcl-w. The small molecule acts to enhance the effect of cell death signals as shown 
by analysis of tumour regression in mice; a significant increase in the number of caspase 
three positive tumour cells was noted 24 hours post treatment (Shoemaker et al., 2008). The 
molecule (ABT-263) has successfully entered phase I/II clinical trials with acceptable oral 
bioavailability despite its large molecular weight (Park et al., 2008).  
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Figure 6.1: Key interaction region between LMO2 and VH#576 
VH#576 is represented in red with the side chains of critical interaction residues represented 
in ball-and-stick. LMO2 is shown in yellow with zinc atoms represented as spheres. The 
critical VH#576 binding site lays across LIM finger two (LIM1), three and four (LIM2). 
CDR1 is not involved in the reaction, two residues from CDR2 and seven from CDR3 are 
vital for the interaction. The former VH-VL interface spans residues Val 37 to Tyr 50 and 
amino acids within this region form hydrophobic interactions with LMO2 that are 
potentially critical and therefore included in the surface area calculation. The buried surface 
area of VH#576, critical for interaction with LMO2, is 512Å2. 
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As previously discussed, stage four of the strategy requires the production of a 
pharmacophore template and this forms the basis for the future work for this project. That is 
development of a small molecule lead structure (an initial starting point for medicinal 
chemistry efforts) based on the VH interaction with the target protein. An initial three-
dimensional pharmacophore model can be derived from a protein structure based on the 
steric and electronic features of the ligand (VH#576) that are necessary to ensure optimal 
interactions with a target protein (LMO2) and in this case, block its biological activity 
(Pellecchia et al., 2008). General chemical features of hotspot regions, such as lipophilic 
groups, H-bond interactions and charge transfer are important to describe the binding mode 
(Wolber and Langer, 2005). The pharmacophore model must have a high degree of 
selectivity. Such a pharmacophore can then be used to search a database; molecules are 
screened on their ability to satisfy a certain number of pharmacophore features. This will 
produce a smaller subset of compounds for focused screens (Rella et al., 2006) such as 
docking.  
 
Further in silico small molecule screens can reduce the chances of generating false positives 
and increase the probability of discovering genuine hits. In cases such as this, where the 
target protein structure is known, docking algorithms are commonly employed to further 
analyse the binding mode and interactions (Rella et al., 2006). SLIDE (Schnecke and Kuhn, 
2000) and DOCK (Oshiro et al., 1995) are computer programs commonly used for this 
approach. DOCK software flexibly aligns the ligand molecule into a rigid macromolecule 
environment and then estimates the tightness of the interaction by different scoring 
functions. SLIDE produces many different conformers of one compound, which are docked 
individually. These programs are used to identify a set of compounds, which can be tested 
in vitro. One approach, which has been employed by the THR laboratory, is Surface 
plasmon resonance; the target protein (e.g. His-NusA-LMO2) is immobilised on the chip 
through interaction with anti-His antibody and a solution phase analyte (the compound) 
passed over the top (Appert et al., 2009). The changes in refractive index, caused by 
changes in the mass at the surface, are a measure of binding affinity. A set of lead 
compounds are then compiled based on how amenable they are for chemical optimisation 
considering factors such as good ADME (adsorption, distribution, metabolism and 
excretion) and membership to an established SAR series (structure activity relationship) 
(Oprea et al., 2001).  
 
Recently a database of small molecules has been compiled, which have the potential to 
inhibit protein-protein interactions (Higueruelo et al., 2009) based on information from 
relevant scientific papers. The library, termed TIMBAL, has been analysed along side other 
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libraries and this highlighted significant differences; the molecules tend to form 
hydrophobic interactions and tend to be lipophilic and larger than the classical 500 Da 
Lipinski limit. Calculations shown in this chapter predict a small molecule with molecular 
weight 850 Da would be required to mimic VH#576 and this represents a common problem 
when targeting protein-protein interactions; the molecular weight of the compound required 
tends to be well above the classical Lipinski limit (Lipinski et al., 1997). Drug criteria for 
these types of targets may well have to vary from the Lipinski rules. The molecules in the 
TIMBAL database are not classical drug like molecules and may not be specific binders but 
they provide a platform for therapeutic development of protein-protein interaction 
inhibition. 
6.1.5 LMO2 as a drug target 
Lmo2 has a normal obligatory role in definitive haematopoiesis in mice (Yamada et al., 
1998) implying that non-cell specific targeting of the protein complex may produce side 
effects such as anaemia, and possibly other haematopoietic defects. For this reason, it may 
be necessary to target an anti-LMO2 small molecule to T-cells. One idea, which has been 
the focus of a considerable amount of research over the past decade, is to direct liposomes to 
specific cancer cells. An approach considered was to attach an antibody to the liposome 
membrane, which binds cancer cell surface receptors so that the liposome is delivered along 
with the drug into the cell (Nielsen et al., 2002).   
 
Further research into this problem has resulted in the development of Antibody-drug 
conjugates, which are designed to deliver a cytotoxic drug to tumour cells and release it 
after internalisation thereby activating the drug and thus restricting its toxicity to the 
diseased cells (Junutula et al., 2008). For this purpose, monoclonal antibodies have been 
designed to recognise antigens on the surface of tumour cells. Anti-CD33 conjugated to 
calicheamicin is one example of a successful application of this technology for the treatment 
of acute myeloid leukaemia. Cell surface markers on T-cells include CD44 and CD25, both 
of which are potential targets for development of antibody drug conjugates for the delivery 
of an anti-LMO2 small molecule.  
 
6.2 Conclusion 
In conclusion, the technologies described in this thesis offer an alternative strategy for the 
rational development of small molecule therapeutics. In this case, the strategy has been 
implemented with the aim of developing a new treatment for patients with T-ALL, 
associated with specific chromosomal translocations. The strategy of evolving a macrodrug, 
such as VH#576, into a small molecule is challenging. On the other hand it has the potential 
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to advance drug development for a wide variety of targets. Upon collection of higher 
resolution X-ray diffraction data the structure of VH#576/LMO2 will form the basis for 
the development of an anti-LMO2 small molecule inhibitor. 
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Size exclusion chromatography 
 
 
 
Figure 1: Calibration of Superdex 200 10/300 GL 
A low molecular weight gel filtration kit (Amersham) was used to calibrate the Superdex 
200 10/300 GL. A calibration curve was prepared by measuring the elution volumes of 
several protein standards, calculating their corresponding gel phase distribution co-efficient 
(Kav) and plotting the Kav values versus the logarithm of their molecular weight. The Kav was 
calculated for the protein of interest and the corresponding molecular weight extrapolated 
from the logarithmic scale.  
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Mass spectrometry 
A: 
 
B: 
 
 
Figure 2: NusA-LMO2 MALDI-MS peptide mass fingerprinting 
A: At least 100 laser shots were accumulated and combined to produce a raw spectrum 
(bottom). Spectra were processed (background subtraction, smoothing and peak centroiding) 
and calibrated externally using a tryptic digest of alcohol dehydrogenase. 
B: Peptide peaks matched between predicted (Peptide Mass program) and the actual 
spectrum are shown in bold and underlined; they cover 49% of the sequence thus 
confirming the identity of NusA-LMO2. 
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A: 
 
B: 
 
 
Figure 3: MBP-LMO2 MALDI-MS peptide mass fingerprinting  
A: Raw and processed spectra. 
B: Peptide peaks matched between predicted (Peptide Mass program) and the actual 
spectrum are shown in bold and underlined; they cover 60% of the sequence and thus 
confirm the identity of MBP-LMO2. 
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Figure 4: MBP-LMO2 rigid linker MALDI-MS fingerprinting  
Identity of the MBP-LMO2 rigid linker constructs was confirmed by MALSI-MS 
fingerprinting. Peptide peaks matched between predicted (Peptide Mass program) and 
spectrum are shown in colour and the sequence coverage indicated in bold. 
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A: 
 
B: 
 
Figure 5: Positive electrospray mass spectrometry analysis of lysine methylated 
VH#576/LMO2ΔN7 
Mass spectrometry was used to analyse methylated VH#576/LMO2ΔN7 under denaturing 
(A) and native (B) conditions. For each lysine methylated the molecular mass is increased 
by 28 Da therefore calculations indicated VH#576 had four lysines methylated and LMO2 
had ten. This indicated that all lysine residues in the complex had been methylated plus the 
N-terminal amine of both proteins. 
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A: 
 
B: 
 
C:  
 
Figure 6: Positive electrospray mass spectrometry analysis of lysine methylated 
VH#576/LMO2ΔN7ΔC11 under denaturing (A) and native (B and C) conditions. 
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Circular Dichroism spectropolarimetry 
 
A: 
 
B: 
 
Figure 7: Circular Dichroism spectropolarimetry analysis of NusA-LMO2 and MBP-LMO2 
NusA-LMO2 is represented by the top spectrum and MBP-LMO2 the bottom spectrum. 
Spectra were analysed by CDSSTR (Johnson, 1999) obtained from DICHROWEB 
(Whitmore and Wallace, 2004). Experimental data is shown in green and analysis by 
CDSSTR method is shown in blue. The characteristic minimum at around 215nm was found 
for both recombinant proteins, which is typical for a structure with considerable beta sheet 
content. From this data, we can confirm that both proteins are folded as the spectra of both 
are negative at more than 208 nm. 
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Figure 8:  Circular Dichroism spectropolarimetry of VH/LMO2ΔN7ΔC11 complex  
The spectrum was analysed by CDSSTR obtained from DICHROWEB. Experimental data 
is shown in green and analysis by CDSSTR method is shown in blue. The 
VH#576/LMO2ΔN7ΔC11 spectrum shows the characteristic minimum at around 215nm, 
which is typical for a structure with considerable beta sheet content. From this data, we can 
confirm that the protein complex is folded as the spectrum is negative at more than 208 nm. 
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Crystallisation reagents optimised 
Table 1: Optimisation of crystallisation conditions 
Plate Number Well Stars 
1=good 
3=excellent 
H11 ** 298955 MPD no. A2 
3 row dilution 
Original condition: MPD 10%, 100mM Na acetate 
pH 5.0 
H12 ** 
298962 Index no. 56 
3 row pH 
Nothing interesting 
A8 * 
F2 **  
H4 ** 
H7 *** 
H8 *** 
H9 * 
298948 Ammonium sulphate A3 
additive screen 
Original condition: 0.8M Ammonium sulphate, MES 
pH 6 
H10 ** 
298979 Natrix no. 38 
3 row dilution 
Original condition: PEG 4000 5%, 200mM 
Ammonium acetate, 150mM Mg acetate, 50mM 
HEPES-Na pH 7.0 
Rod cluster (perform 
additive screen) 
H9 ** 298986 Natrix no. 3 
3 row dilution 
Original condition: MPD 20% v/v, 100mM Mg 
acetate tetrahydrate, 50mM MES monohydrate pH 
5.6 (acts as cryo-protectant) 
H10 ***        
B9 * 
C10 * 
E6 ** 
F4 ** 
G3 ** 
298917 Natrix no.5 
additive screen 
Original condition: PEG 8000 5% w/v, 10mM MgCl 
hexahydrate, 
200mM KCl, 50mM MES monohydrate pH 5.6 
H4 **                              
298023 Natrix no.5 Original screen 
Original condition as above 
A5 ***                      
298931 Natrix no.5 
3 row pH Original condition as above 
Nothing interesting 
298924 Natrix no.5 
3 row dilution 
Original condition as above 
Nothing interesting 
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Alignment of VH#576 with anti-Ras antibody single domain, VH#6 
 
1       10        20        30        40                     
EVQLLESGGGLVQPGGSLRLSCAASGFSFSHSPMNWVRQAPGKGLEWV 
         
EVQLLESGGGLVQPGGSLRLSCAASGFTFSTFSMNWVRQAPGKGLEWV 
 
50        60        70        80        90 
SYISYNSSSIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC 
 
SYISRTSKTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC 
 
 100       110       120 
ARGLTESLELTADWFDYWGQGTLVTVS 
 
ARGRFFDY*********WGQGTLVTVS 
Figure 1: Alignment of anti-Ras VH#6 and anti-LMO2 VH#576 
The amino acid sequence (in single letter code) of anti-Ras, Y#6 (top), and anti-LMO2, 
VH#576 (bottom). The CDRs are coloured in yellow and differences in the amino acid 
sequences are highlighted in red. 
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LMO2 mutagenesis 
 
Figure 2: LMO2 protein sequences and relevant mutations 
The amino acid sequences (in single letter code) of LMO2, LMO1, LMO4 and LMO2 
mutant proteins. The residues involved in the LIM finger motif are shown in red. Amino 
acids, which are identical to the top sequence, are represented by a dot. The protein 
sequences of all LMO2 mutants used for the mammalian two-hybrid assay are shown. 
Appendix B 
 
 241 
Western blots  
CDR1; round one VH#576 mutations 
 
 
CDR2; round two VH#576 mutations 
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CDR3; round three VH#576 mutations 
 
 
 
CDR1 and 2; round four VH#576 mutations 
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CDR3; round five VH#576 mutations 
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Expression vector maps 
 
Figure 1: Map of E. coli expression vector pGEX-His-Tev-LMO2 
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Figure 2: Map of E. coli expression vector pET43a-LMO2 
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Figure 3: Map of E. coli expression vector pOPIN_M-LMO2 
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Figure 4: Map of E. coli expression vector pRK-His-Tev-VH#576-LMO2 
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Figure 5: Map of mammalian expression vector PM3-LMO2ΔN24 
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Figure 6: Map of mammalian expression vector pEF-VH#576-VP16 
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List of primers 
Chapter three 
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pOPIN_M NotI mutagenesis 
Forward (5’ to 3’) ACG CGC AGA CTA GCG CGG CCG CCT GGA ACT 
Reverse (5’ to 3’) CAG AAC TTC CAG GCG GCC GCG CTA GTC TGC 
Assembly PCR primers for the previous construct 
Forward (5’ to 3’) GAG ATA CCA TGG CAC ACC ATC 
Reverse (5’ to 3’) CCA GTC ACG ACG TTG TAA AAC 
MBP-AAA-LMO2 
Forward (5’ to 3’) GCG GCC GCC ATG TCC TCG GCC ATC 
MBP-AAAAA-LMO2 
Forward (5’ to 3’) GCG GCC GCC GCC GCC ATG TCC TCG GCC ATC 
MBP-AAAEF-LMO2 
Forward (5’ to 3’) GCG GCC GCC GAA TTT ATG TCC TCG GCC ATC 
pRK-His-Tev-VH#576-LMO2-7N mutagenesis 
Forward (5’ to 3’) GGA GAT ATA CAT ATG AGC CTG GAC CCT TCA 
Reverse (5’ to 3’) TGA AGG GTC CAG GCT CAT ATG TAT ATC TCC 
pRK-His-Tev-VH#576-LMO2-11N mutagenesis 
Forward (5’ to 3’) GGA GAT ATA CAT ATG TCA GAG GAA CCA GTG 
Reverse (5’ to 3’) CAC TGG TTC CTC TGA CAT ATG TAT ATC TCC 
pRK-His-Tev-VH#576-LMO2-13N mutagenesis 
Forward (5’ to 3’) GGA GAT ATA CAT ATG GAA CCA GTG GAT GAG 
Reverse (5’ to 3’) CTC ATC CAC TGG TTC CAT ATG TAT ATC TCC 
pRK-His-Tev-VH#576-LMO2-16N mutagenesis 
Forward (5’ to 3’) GGA GAT ATA CAT ATG GAT GAG GTC CTG CAG 
Reverse (5’ to 3’) CTG CAG GAC CTC ATC CAT ATG TAT ATC TCC 
pRK-His-Tev-VH#576-LMO2-20N mutagenesis 
Forward (5’ to 3’) GGA GAT ATA CAT ATG CTG CAG ATC CCC CCA TCC 
CTG CTG ACA TGC GGC GGC TGC CAG 
Reverse (5’ to 3’) CTG GCA GCC GCC GCA TGT CAG CAG GGA TGG GGG 
GAT CTG CAG CAT ATG TAT ATC TCC 
pRK-His-Tev-VH#576-LMO2-25N mutagenesis 
Forward (5’ to 3’) GGA GAT ATA CAT ATG TCC CTG CTG ACA TGC GGC 
GGC TGC CAG 
Reverse (5’ to 3’) CTG GCA GCC GCC GCA TGT CAG CAG GGA CAT ATG 
TAT ATC TCC 
pRK-His-Tev-VH#576-LMO2-29N mutagenesis 
Appendix C 
 
 253 
Forward (5’ to 3’) ATA CAT ATG TGC GGC GGC TGC CAG CAG AAC ATT 
Reverse (5’ to 3’) CGC GTG GTA CCA AGC TTA C 
Assembly PCR primers for the previous constructs 
Forward (5’ to 3’) CAT ATG AGA GGA TCG CAT CAC CA 
Reverse (5’ to 3’) GCG CGC ACG CGT GGT A 
pRK-His-Tev-VH#576-LMO2-7N-2C mutagenesis 
Forward (5’ to 3’) ACT AAG ATC AAT GGG TAG ATA TAG TGT ACA GGA 
Reverse (5’ to 3’) TCC TGT ACA CTA TAT CTA CCC ATT GAT CTT AGT 
pRK-His-Tev-VH#576-LMO2-7N-7C mutagenesis 
Forward (5’ to 3’) GAC ATT TAC GAG TGG TAG AAG ATC AAT GGG ATG 
Reverse (5’ to 3’) CAT CCC ATT GAT CTT CTA CCA CTC GTA AAT GTC 
pRK-His-Tev-VH#576-LMO2-7N-8C mutagenesis 
Forward (5’ to 3’) CAG GAC ATT TAC GAG TAG ACT AAG ATC AAT GGG 
Reverse (5’ to 3’) CCC ATT GAT CTT AGT CTA CTC GTA AAT GTC CTG 
pRK-His-Tev-VH#576-LMO2-7N-11C mutagenesis 
Forward (5’ to 3’) GTG TGC GAA CAG GAC TAG TAC GAG TGG ACT AAG 
Reverse (5’ to 3’) CTTAGTCCACTCGTACTAGTCCTGTTCGCACAC 
Assembly PCR primers for the previous constructs 
Forward (5’ to 3’) CCG TCA TCA CCG AAA CG 
Reverse (5’ to 3’) TCC TTT CGG GCT TTG TTA GA 
 
Chapter four 
NusA-LMO2 expression vector 
 
pET43a-LMO2 
Forward 
CGCGACTAGTGGGTCTGAAAACCTGTATTTCC 
pET43a-LMO2 
Reverse 
CGCGCCTAGGGAATTCCTAGATGATCCCATTGA 
 
Chapter five 
Primer Sequence (5’to3’) 
CDR1 
pEF-VP16-VH#576 Mutagenesis  
S28G Forward GCAGCCTCTGGATTCGGCTTCAGTCATAGT 
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S28G Reverse ACTATGACTGAAGCCGAATCCAGAGGCTGC 
H31G Forward TCTGGATTCAGCTTCAGTGGTAGTCCTATGAAT 
H31G Reverse ATTCATAGGACTACCACTGAAGCTGAATCCAGA 
S32G Forward TTCAGCTTCAGTCATGGTCCTATGAATTGGGTC 
S32G Reverse GACCCAATTCATAGGACCATGACTGAAGCTGAA 
N35G Forward AGTCATAGTCCTATGGGTTGGGTCCGCCAGGCT 
N35G Reverse AGCCTGGCGGACCCAACCCATAGGACTATGACT 
CDR2 
pEF-VP16-VH#576 Mutagenesis 
Y53G Forward GTTTCATACATTAGTGGTAATTCTTCGAGTATA 
Y53G Reverse TATACTCGAAGAATTACCACTAATGTATGAAAC 
N54G Forward TCATACATTAGTTATGGTTCTTCGAGTATATAC 
N54G Reverse GCATATACTCGAAGAACCATAACTAATGTATGA 
S55A Forward TACATTAGTTATAATGCTTCGAGTATATACTAT 
S55A Reverse ATAGTATATACTCGAAGCATTATAACTAATGTA 
S56A Forward ATTAGTTATAATTCTGCGAGTATATACTATGCA 
S56A Reverse TGCATAGTATATACTCGCAGAATTATAACGAAT 
S57G Forward AGTTATAATTCTTCGGGTATATACTATGCAGAC 
S57G Reverse GCTTGCATAGTATATACCCGAAGAATTATAACT 
Assembly PCR primers for the previous constructs 
VH#576 Forward TGAACACGTGGCCCA 
VH#576 Reverse AGCTTCATTGCGGCC 
CDR3 
pEF-VP16-VH#576 Mutagenesis 
E102A Forward GCGAGAGGGTTGACGGCGTCTCTTGAGTTGACG 
E102A Reverse CGTCAACTCAAGAGACGCCGTCAACCCTCTCGC 
S103G Forward AGAGGGTTGACGGAGGCTCTTGAGTTGACGGCG 
S103G Reverse CGCCGTCAACTCAAGAGCCTCCGTCAACCCTCT 
L104G Forward GGGTTGACGGAGTCTGGTGAGTTGACGGCGGAT 
L104G Reverse ATCCGCCGTCAACTCACCAGACTCCGTCAACCC 
E105G Forward TTGACGGAGTCTCTTGGGTGGACGGCGGATTGG 
E105G Reverse CCAATCCGCCGTCAACCCAAGAGACTCCGTCAA 
L106G Forward ACGGAGTCTCTTGAGGGGACGGCGGATTGGTTT 
L106G Reverse AAACCAATCCGCCGTCCCCTCAAGAGACTCCGT 
T107A Forward GAGTCTCTTGAGTTGGCGGCGGATTGGTTTGAT 
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T107A Reverse ATCAAACCAATCCGCCGCCAACTCAAGAGACTC 
D109G Forward CTTGAGTTGACGGCGGGTTGGTTTGATTACTGG 
D109G Reverse CCAGTAATCAAACCAACCCGCCGTCAACTCAAG 
Y113A Forward GCGGATTGGTTTGATGCCTGGGGCCAGGGAACC 
Y113A Reverse GGTTCCCTGGCCCCAGGCATCAAACCAATCCGC 
Assembly PCR primers for the previous constructs 
VH#576 Forward TGAACACGTGGCCCA 
VH#576 Reverse CGAGGCTGATCAGCGA 
pEF-VP16-VH#576 Mutagenesis 
CDR1 and CDR2 Second round 
S30G Forward TCTGGATTCAGCTTCGGTCATAGTCCTATGAAT 
S30G Reverse ATTCATAGGACTATGACCGAAGCTGAATCCAGA 
S32A Forward TTCAGCTTCAGTCATGCTCCTATGAATTGGGTC 
S32A Reverse GACCCAATTCATAGGAGCATGACTGAAGCTGAA 
N35A Forward AGTCATAGTCCTATGGCTTGGGTCCGCCAGGCT 
N35A Reverse AGCCTGGCGGACCCAAGCCATAGGACTATGACT 
Y50A Forward CTGGAGTGGGTTTCAGCCATTAGTTATAATTCT 
Y50A Reverse AGAATTATAACTAATGGCTGAAACCCACTCCAG 
S52G Forward TGGGTTTCATACATTGGTTATAATTCTTCGAGT 
S52G Reverse ACTCGAAGAATTATAACCAATGTATGAAACCCA 
N54A Forward TCATACATTAGTTATGCTTCTTCGAGTATATAC 
N54A Reverse GTATATACTCGAAGAAGCATAACTAATGTATGA 
S57A Forward AGTTATAATTCTTCGGCTATATACTATGCAGAC 
S57A Reverse GTCTGCATAGTATATAGCCGAAGAATTATAACT 
Assembly PCR primers for the previous constructs 
VH#576 Forward TTTCCAGGGCGGATCC 
VH#576 Reverse GCCGCACATATGTATATCTCCTTCTTAAAGTTAA 
ACAAAA 
pEF-VP16-VH#576 Mutagenesis  
CDR3 Second round 
E102G Forward GCGAGAGGGTTGACGGGGTCTCTTGAGTTGACG 
E102G Reverse CGTCAACTCAAGAGACCCCGTCAACCCTCTCGC 
S103G Forward AGAGGGTTGACGGAGGGTCTTGAGTTGACGGCG 
S103G Reverse CGCCGTCAACTCAAGACCCTCCGTCAACCCTCT 
L104A Forward GGGTTGACGGAGTCTGCTGAGTTGACGGCGGAT 
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L104A Reverse ATCCGCCGTCAACTCAGCAGACTCCGTCAACCC 
E105A Forward TTGACGGAGTCTCTTGCGTTGACGGCGGATTGG 
E105A Reverse CCAATCCGCCGTCAACGCAAGAGACTCCGTCAA 
L106A Forward ACGGAGTCTCTTGAGGCGACGGCGGATTGG 
L106A Reverse CCAATCCGCCGTCGCCTCAAGAGACTCCGT 
T107G Forward GAGTCTCTTGAGTTGGGGGCGGATTGGTTTGAT 
T107G Reverse ATCAAACCAATCCGCCCCCAACTCAAGAGACTC 
D109A Forward CTTGAGTTGACGGCGGCTTGGTTTGATTACTGG 
D109A Reverse CCAGTAATCAAACCAAGCCGCCGTCAACTCAAG 
Y113G Forward GCGGATTGGTTTGATGGCTGGGGCCAGGGAACC 
Y113G Reverse GGTTCCCTGGCCCCAGCCATCAAACCAATGCGC 
pEF-VH#576 Framework mutations 
Forward TGA ACA CGT GGC CCA 
Reverse CGA GGC TGA TCA GCG A 
Assembly PCR primers for the previous constructs 
Forward TTTCCAGGGCGGATCC 
Reverse GCCGCACATATGTATATCTCCTTCTTAAAGTTAA 
ACAAAA 
pRK-VH#576 Framework mutations 
Forward TCC AGG GAA GAG AGG GAG ATA GTT TCA TAC ATT AGT 
Reverse ACT AAT GTA TGA AAC TAT CTC CCT CTC TTC CCT GGA 
Assembly PCR primers for the previous constructs 
Forward ATA GTT AAG CCA GTA TAC ACT CCG CT 
Reverse CGC GCG AAG CTT GCG AAT TCT CAG CTC GAG AC 
 
 
Appendix D 
 
 257 
 
Appendix D 
 
 
